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ABSTRACT 
 
Renal disease is a major global public health issue that affects 10% of the general population 
with premature morbidity and mortality related to cardiovascular disease and infection. 
Interstitial fibrosis is a common hallmark of progressive kidney dysfunction. There remains a 
stubborn discrepancy in identifying which patients suffer adverse events because of their 
disease or resulting treatment. Investigation in patient genome variation may explain this 
discrepancy. 
Caveolin-1 is the essential structural protein for caveolae that are ubiquitously distributed in 
fibroblasts, endothelial and epithelial cells. They act as molecular chaperones for 
transcellular signalling such as degradation of the activated TGFβ-1 receptor. In this thesis, 
caveolin-1 single nucleotide polymorphism rs4730751 CC genotype is shown to be 
associated with a better outcome in renal patients for arterial stiffness, and reduced 
mortality from cardiovascular disease, infection, malignancy in ANCA associated vasculitis. 
By inducing renal models of fibrosis in caveolin-1 knockout mice, deletion of caveolin-1 leads 
to increased fibrosis. 
In conclusion, this polymorphism could be used as a marker of disease risk either in isolation 
or as part of a clinical risk score to counsel patients on the likely prognosis of their condition. 
Manipulation of caveolin-1 expression may be a therapeutic strategy in reducing renal 
fibrosis. 
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1.1 Introduction 
1.1.1 Chronic Kidney Disease Burden 
Renal disease is a major global public health issue that affects estimates of 10-16% of the 
general population in developed countries leading to premature morbidity and mortality (1). 
In 2009-2010, the economic burden of chronic kidney disease (CKD) on the English National 
Health Service (NHS) was an estimated £1.45 billion (equivalent to 1.3% of all NHS spending 
that year), with over half of the costs related to the 2% of the CKD population with end-stage 
renal disease (ESRD) requiring renal replacement therapy (RRT) (2). The resultant effect of 
the CKD burden is an excess in length of stay in hospitals, hospital associated infections as 
well as an excess of 7000 cerebral vascular events and 12000 myocardial infarctions 
compared to age/gender matched controls (2). Thus, it remains paramount to identify 
individuals with CKD at the earliest time-point in order to instigate therapy to prevent the 
progression to ESRD. 
In 2004, the UK adoption of the 4 variable (age, sex, race and serum creatinine) Modification 
of Diet in Renal Disease equation (3) to estimate a person’s glomerular filtration rate based 
on two readings three months apart, led to a marked increase in the number of previously 
undiagnosed patients with CKD especially in primary care. This equation was later updated in 
2008 following standardisation of serum creatinine laboratory measurements (Figure 1-1). 
 
Figure 1-1 Modification of Diet in Renal Disease Equation (4)  
Estimated Glomerular Filtration Rate = 30849× standardized serum creatinine (micromol/l) 
−1.154 × age−0.203 × 1.212 (if black race) × 0.742 (if female); units mL/min/1.73 m2 
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The 5 stage estimated glomerular filtration rate (eGFR) has further been refined to highlight 
those with proteinuria (Figure 1-2) and thus those who are at particular risk of progression 
to more advanced stages of renal disease and its complications, especially cardiovascular 
disease (5, 6). In a cross-sectional single point eGFR measurement study using the 2009 and 
2010 Health Survey for England data, the prevalence for eGFR <60mls/min per 1.73m2 
(stages 3-5) was estimated at 5.2% (7). However, compared to 2003, the prevalence of CKD 
stages 3-5 is on the decline except in men aged 65-74 years old (8). Risk stratification has 
allowed better patient counselling and targeted therapy  to reduce kidney disease 
progression and associated complications, with examples such as proteinuria reduction with 
angiotensin converting enzyme inhibitors (ACE I), angiotensin receptor blockers (ARBs), renin 
and aldosterone inhibitors that not only control blood pressure (5, 6, 9), but reduce the 
blood pressure in glomeruli by targeting the renin-aldosterone-angiotensin system and 
vasodilation of the glomerulus efferent arteriole thus reducing the intra-glomerular blood 
pressure (Figure 1-3). Further risk stratification is still required due to increasing prevalence 
of factors that adversely associate with CKD such as an aging population, ethnic diversity 
(especially South-Asians) and prevalence of diseases such as diabetes mellitus. 
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Figure 1-2 Heatmap of chronic kidney disease progression risk (10) 
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Figure 1-3 Schematic coronal section of a kidney (A), nephron (B) and its glomerulus (C) (11) 
 
 
Abbreviations: AA, afferent arteriole; BS, Bowman’s space; CD, collecting duct; DT, distal tubule; 
EA, efferent arteriole; GEC, glomerular endothelial cell; LOH, loop of Henle; MC, mesangial cell; 
Pod, podocyte; PT, proximal tubule 
 
 
1.1.2 Adverse outcomes in renal disease 
As described above, age, ethnicity, proteinuria, poorly controlled diabetes and hypertension 
are well described risk factors for progression of renal decline in CKD. In addition to these 
risk factors, renal tubulointerstitial fibrosis has been the key common pathological finding in 
patient’s accelerated CKD irrespective of the underlying cause (12). However, patients with 
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CKD also have an increased morbidity and mortality due to multifactorial reasons such as 
accelerated cardiovascular disease, sepsis, acute kidney injury episodes, increased 
hospitalisations, lower socioeconomic status, frailty, depression and fracture risk (13, 14). 
Patients with CKD stage 3-5 also have a median three co-existing disease processes with 
their CKD, such as hypertension, diabetes, atrial fibrillation, heart failure or pulmonary 
disease in an epidemiology study of over half a million patients in Canada (14). To compound 
the management of patients with CKD, their underlying renal pathology and renal 
replacement strategies such as transplantation, mean they may suffer further complications 
from potential therapies used in these scenarios such as immunosuppressive regimens. 
Despite the relative therapeutic success in reducing the prevalence in CKD in the UK, and 
understanding the associated risk factors that affect patients with CKD, there remains a 
stubborn discrepancy in identifying which patients would benefit the most and which suffer 
adverse events because of their disease or treatment. Investigation into patient genome 
variation may explain this discrepancy. 
 
1.1.3  Genetic variation in kidney disease 
Since the 1980s, there have been more than 3000 research papers published on the genetics 
of CKD (15). Initially, these had concentrated on Mendelian patterns of inheritance to 
understand the pathophysiology of inherited diseases such as adult polycystic kidney 
disease. The mutations in genes PKD1 and PKD2 have led to more informed genetic 
counselling regarding the progression of their disease as well as the pathways leading to this 
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disease (16). These techniques have been also been applied to inheritable congenital kidney 
resulting from single gene disorders especially in children. 
Over the last decade, single gene studies have focused on biological plausible candidate 
gene association with kidney disease. These studies were often underpowered with inclusion 
of multiple ethnicities in cohort studies, with little attempt at replication and correction for 
multiple confounders. However, as the 1000 genome project has recently confirmed, there 
is a large genomic discrepancy depending on your ethnicity and ancestry (17). One method 
of counter-acting these issues is genome-wide linkage studies that combine the above two 
strategies, by examining large genomic regions in family-based collections of DNA to 
associate transmission of genetic variants to the development of CKD. Conditions such as 
CKD are likely to be more complex with many potential pathways and environmental 
changes leading to its development and progression. The ability to find enough numbers of 
related individuals with an underlying condition to track genetic change across multiple 
generations remains a barrier to success for this method. 
The most common type of genomic variation is single nucleotide polymorphism (SNP) that 
must occur in over 1% of the population to be called a SNP and has the possibility of two 
alleles at a given site (biallelic) (18). Other types of polymorphisms include insertion/deletion 
or copy number variation of the number of nucleotides. This has led to genome-wide 
association studies (GWAS) into CKD with the advantage of examining millions of SNPs in 
unrelated affected individuals to controls. A GWAS typically involves using tag SNPs that are 
SNPs that have been ‘aggregated’ from haplotypes of nearby SNPs or SNPs that have been 
inherited together. GWAS will allow the identification of common SNPs that associate with 
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disease, however may miss less common SNPs that may relate to important changes in CKD 
and especially in a subset of this large population. In all genomic investigations, it is 
paramount that the correct control group is identified and that patients are phenotyped 
correctly. SNPs identified may infer changes to RNA thus affecting the protein function upon 
translation (non-synonymous) but may have small effect size to the overall condition being 
investigated such as CKD. To validate SNPs found by GWAS, replication studies should be 
performed of the single gene variant identified as well as performing functional analyses 
using transcripts of tissue or other samples from patients by performing an expression as a 
quantitative trait locus analysis (eQTL). This could either be a transcript encoded by a nearby 
to SNP gene (cis-QTL) or transcript away from that SNP with alteration of its abundance or 
function, either on the same or a different chromosome (trans-eQTL) (19). A functional 
context of the SNP effect can be elucidated using tissue specific transcripts such as a renal 
biopsy sample and possible pathways to the phenotype being studied. To further examine a 
functional context to the associated SNP, animal models using knockouts of gene and 
inducing the phenotype desired can further elucidate possible pathways and therapeutic 
interventions. Another high-output genomic advance is the use of next generation 
sequencing that allows investigation of a person’s whole exome that contains the protein-
coding part of the genome, 1-2% of the human genome, or whole genome sequencing (20). 
This technique is utilised especially when examining tissue or a subgroup of cells from tissue. 
The advantage of this technique is the allowance to find novel mutations with phenotype 
association, however also proposes the challenge of interpreting large volumes of data. The 
phenotypes studied in GWASs in CKD have tended to focus on estimated glomerular 
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filtration rate (eGFR), CKD progression, proteinuria and renal disease prevalence, rather than 
measures of cardiovascular disease or mortality. 
Examples of success in GWAS association with renal disease, using the above strategies 
comes from the CKDGen study group who performed a meta-analysis of 20 GWASs. This 
included over 67000 patients studied of European ancestry who had biopsies of either their 
native or transplant kidney. The analysis was from population-based studies rather than 
case-control and examined the glomerular and tubulointerstitial gene expression in relation 
to declining eGFR. They had not only found 13 new loci related to kidney function and serum 
creatinine secretion but also found vascular endothelial growth factor A gene expression in 
both renal compartments with strong enrichment for the hypoxia signalling pathway (21). 
GWASs have also been able to confirm laboratory findings even in small populations of 
disease such as in membranous nephropathy. In a French cohort of just 75 cases, the 
phospholipase A2 receptor (PLA2R) 1 gene was found to significantly associate with 
membranous nephropathy (22), after previous confirmation of serological M-type PLA2R 
autoantibody could be found in 70% of cases to differentiate between primary and 
secondary membranous nephropathy which in turn, has marked therapeutic implications 
(23). Subsequent investigation has revealed an odds-ratio (OR) of 2.00 with the presence of 
the at risk SNP genotype for PLA2R1 despite being located within the first intron (non-coding) 
part of the gene (24). GWASs have also been able to confirm that the pathogenesis of 
disease states such as antineutrophil cytoplasmic antibody associated vasculitis (AAV) has a 
genetic component and the subsets of this condition (granulomatosis with polyangiitis (GPA) 
and microscopic polyangiitis (MPA)) show genetic distinctions and thus are distinct 
autoimmune syndromes (25). 
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As well as inherited genetic influence on outcomes and prevalence in CKD, epigenetics is a 
field that is helping researchers to understand the influence that environmental factors have 
on the human genome and thus disease presentation and variance amongst individuals. This 
has been observed even in phenotypic discordant monozygotic twins (with identical DNA 
sequence) to explain their differences (26). There are 3 main epigenetic changes that occur, 
namely chromatin modification, RNA interference and DNA methylation. However, these can 
occur at the same time, thus unravelling their effects upon gene regulation is challenging. To 
add to this complexity, different cell types will express different epigenetic changes or 
epigenomes, thus performing epigenome-wide association studies in CKD are fraught with 
difficulty to understand their meaning, even if they are from the same tissue such as from 
kidney biopsies, due to the many cell types in this organ. Chromatin modification is thought 
to effect gene expression by changing DNA availability to transcriptional machinery that can 
result in chromatin states of transcription inactivity or activity (termed euchromatin) by 
histone acetylation, methylation, phosphorylation and ubiquitination. RNA interference 
results in impedance of translation efficiency of mRNA to protein. RNA interference can 
occur in short non-coding RNA (microRNAs) or long noncoding RNA and has been shown to 
skew the female X-chromosome in renal transplantation that is associated with a reduced 
allograft survival if donor female X-chromosome is skewed (27). DNA methylation occurs at 
sites where a methyl group is enzymatically added to the phosphate that links cytosine to 
guanine (CpG site). This can alter the function of the gene by more frequently silencing the 
gene, but also by activation via inhibiting co-factors or microRNA that repress transcription 
(15). 
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The following prose is based on ‘Genetic polymorphisms and kidney transplant outcomes’ 
with myself as first author (28). 
Genetic polymorphism studies have been an area of great interest in renal transplantation 
recently, with the aim to improve short and long term outcomes such as acute rejection, 
allograft survival and patient survival respectively. The studies reflect the investigative 
strategies outlined above and highlight how they can be used to inform clinical practice, but 
also conflicting results that can be found. 
 
1.1.3.1 T cells, innate immunity and inflammation based genetic studies in renal 
transplantation 
One of the largest multi-centre genomic trials in renal transplantation originated from the 
Deterioration in Kidney Allograft Function (DeKAF) genomic study from 2010 (29). It 
consisted of 990 patients from North America, testing over 2700 candidate SNPs, but 
suffered from being multi-ethnic, consisting of kidney and simultaneous kidney-pancreas 
transplantation, having large centre-centre variation and end-points such as acute rejection 
(AR) rather than graft or patient survival. After attempted correction for this variation and 
ethnic diversity, 15 SNPs were identified with AR and tubulitis severity, with the two 
strongest associations pointing to T cell activation via protein phosphorylation and cell cycle 
progression (rs2227931 in ATR, rs2267130 in CHEK2, and rs3088142 in DUSP13) and 
inflammation (rs811925 in PRDM1 (interferon-β) and rs2228059 in IL15RA). 
The first GWAS in renal transplantation of medium-term allograft function was reported last 
year in 326 White patients. Although there was a high initial genotyping failure rate (>18%), 
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263 patients had a functioning graft and assessment of 5-year function by creatinine only, 
with 511,662 SNPs analysed. After linkage disequilibrium pattern assessment and 
multivariate analysis including 15 clinical variables, two SNPs rs3811321 (TCRA encoding for 
T cell receptor alpha chain conferring antigen specificity) and rs6565887 (ZNF516 intronic for 
zinc finger protein (integral for DNA transcript processing) expressed mainly in the kidney, 
spleen and lung) were significant and explained 17.4% of 5 year-creatinine variance, with 
survival analysis showing AA genotype of both being significantly protective against time to 
transplant failure and for ZNF516 time to patient death (30).  
A meta-analysis in HLA-G-14-base pair insertion/deletion of 907 patients from 5 case-control 
studies showed no association with kidney allograft rejection (31), however an Italian study 
of 418 patients found that the homozygous deletion genotype was at risk for advancing 
allograft failure and subsequent loss (32). A further genomic analysis of 979 recipients 
enrolled in the 2010 DeKAF study was performed last year, and investigated chronic allograft 
dysfunction (defined as a clinical diagnosis as a ≥25% rise in serum creatinine from baseline), 
and assessment of severity of tubular atrophy and interstitial fibrosis on indication biopsy. 
However, this study had the same issues of varying centre practices e.g. 
immunosuppression, steroid withdrawal, dialysis post immediate transplantation, 
combination of kidney and simultaneous kidney pancreas recipients and ethnic diversity. 
None of the top 15 SNPs were significant after correction for multiple testing (false discovery 
rate set at 20%) for biopsy severity, though the top SNPs prior to correction were for the 
leptin receptor (LEPR – encodes for a pro-inflammatory cytokine receptor gene and leptin 
plays a role for regulatory T cell proliferation) and CYP4F12 (encoding for metabolic enzyme 
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in the cytochrome P450 system for drug metabolism). Two further drug metabolism related 
SNPs in FM03 and FM06 were associated with chronic allograft dysfunction (33). 
An interesting recent report within the last 12 months highlights the emerging importance of 
gene copy number variation in determining graft outcome, and represents one of the few 
recent single-centre studies to address graft failure as an outcome (34). Bay reported 
superior medium-term graft outcome when patients displayed less than four total copies of 
the gene encoding complement factor 4 (C4), although this held only in the subgroup 
receiving deceased donor kidneys (as opposed to live donation) raising the issue of 
gene:environment interactions (in this case the “environmental influence of ischaemia) in 
determining outcome. 
Although such studies set the scene for further investigation, drawing robust conclusions will 
require further replication and validation in independent cohorts. This is clearly also the case 
for the multiple single-centre studies, which have directed attention to other candidate gene 
variants, and have investigated outcomes in populations of varied ethnicities. These studies 
may be of relevance in light of their biological plausibility, and may serve to guide future 
efforts. An interesting report described 599 Dutch de novo transplant recipients who 
underwent testing of the promoter region of FOXP3 gene for the short (<16) or long (>16) 
number of dinucleotide (GT) repeats. The short repeat genotype was associated with 
improved allograft survival (HR=0.67, 95% CI 0.48-0.94, p=0.02). Of functional relevance, the 
short repeat has an enhanced promoter gene activity compared to the long repeat genotype 
(35).  
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Other studies reported over the last 12 months include investigation of topical Th17 pattern 
related genes (IL-17, IL-21, IL-23R) in relation to AR risk (36, 37). TNF-α 2/2 genotype was 
also a risk for AR (38), as was UGT1A variation, possibly mediated by its effects on bilirubin 
levels and concomitant anti-oxidative properties (39). TLR9, COX-2, AIF1, and MBL2 gene 
variants have also shown associations with AR (40-42). Interferon gamma regulates 
macrophage production of human allograft inflammatory factor-1 with a recent meta-
analysis of IFNy 874 T/A in 1650 patients revealing AA genotype to be protective amongst 
White deceased donor allograft recipients (43). In contrast, 2 single centre non-replicated 
studies that found no such association (44, 45). 
Endothelial cell-leucocyte crosstalk is another pathway for potential modulation of the post-
transplant immune response with a study of 269 Polish White patients showing a significant 
multivariate association with early and long-term (up to 5 years) allograft dysfunction as 
measured by serum creatinine. Gene variation in ICAM1 (rs5498) and VCAM1 (rs1041163) 
were significantly associated with graft loss, with some evidence for association with 
mortality (p=0.06) (46). Co-stimulatory molecular CD28 rs3116496 TT genotype was 
associated for AR, but not CAN or delayed graft function (47).  
The field of transplant genetics is clearly not immune to the problem of publication bias, 
with “positive” findings far more likely to be submitted and accepted to the literature. 
Recent “negative” studies include investigations showing no relationship between AR and IL-
1, IL-2, IL-6 (also no relationship with chronic allograft nephropathy [CAN]), IL-10, IL-21, 
TGFβ-1 (also no effect on graft function (48)), TNF-α, TLR4, CD14 (also no effect on CAN or 
graft survival), and CTLA4 or PTNPN 22 (also no association with graft function, survival or 
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patient mortality) (36, 44, 45, 48-52). Despite negative findings for inflammatory and 
apoptotic genes IL-6, TGFβ-1 and Fas individually, La Manna did find that a combination of 
high producing genotype IL-6 and low Fas production was protective for graft function (Odds 
Ratio [OR]: 0.79) over a 2.5 year follow-up period in 376 Italian deceased donor transplant 
patients (48).  
These “negative” studies may be better considered “null” studies – i.e. they are 
underpowered to exclude a relevant clinical effect, and the last example highlights issues 
where secondary, multiple or post-hoc outcomes are evaluated, which in this case are 
clearly stated, but in other scenarios may be less transparent and lead to a type II error 
dominating the findings. As a result, these studies do not directly aid a clinician with which 
SNP requires investigation for their individual patients, but more aid in hypothesis 
generating which pathways may be responsible in determining patient outcome variability.  
1.1.3.2 Pharmacogenetics 
Most studies of transplant pharmacogenomics over the last 12 months have investigated the 
cytochrome P450 system with outcomes based on tacrolimus trough levels and clearance. 
CYP3A5 3*3 genotype results in far lower CYP3A enzyme activity than 1*1 genotype (53), 
and recent reports confirm that transplant recipients displaying the 1*1 or 1*3 genotype 
require higher doses of tacrolimus to reach target levels; it has also been suggested that 
lower drug variability ensues from administration of once-daily tacrolimus preparations (54-
57). However, upon independently testing the previously developed CYP3A5 genotype-based 
tacrolimus dosing DeKAF algorithm (58), it was shown to be a poorly predictive model for 
tacrolimus clearance when using tacrolimus doses used in routine clinical practice (59). 
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Shuker et al also showed in a randomised control trial, that tacrolimus dose dependent 
change based on CYP3A5 genotype had no effect on clinical outcome or the number of 
patients reaching therapeutic tacrolimus levels early post live donor kidney transplant (60). 
It has also been suggested that the high intravariability of tacrolimus is a risk factor for CAN 
and graft loss, although CYP3A5 genotype was not associated with intrapatient tacrolimus 
variability (61).  
This has led to research in other drug metabolism gene variants that could be combined with 
the carrier status of CYP3A5 to improve identification of patients with altered tacrolimus 
metabolism and potential toxicity/under-dosing. Most have combined CYP3A4 genotypes to 
CYP3A5 and shown CYP3A4 1*1 and CYP3A5 3*3 genotypes require a lower tacrolimus dose 
to reach a desired level (62-64). CYP3A4*22 and CYP3A5*3 alleles might explain 
interindividual difference in pharmacokinetic parameters of tacrolimus (65). Variation in 
Multidrug-resistance-1 gene (MDR-1), also known as ABCB1 (which encodes the efflux 
transporter p-glycoprotein involved in calcineurin-inhibitor disposition), has also been 
studied. Almost all studies suggest ABCB1 C3435T SNP does not impact tacrolimus 
pharmacokinetics (56, 66-68). However, there may be an effect on calcineurin-inhibitor 
pharmacodynamics resulting in altered T cell IL-2 production (69), perhaps explaining why 
the C3435T genotype is associated with increased risk of AR, chronic rejection and graft loss 
as well as more severe periodontal disease with cyclosporine use (66, 70). Also relevant to 
pharmacodynamics, but this time in relation to donor genetics and donor:recipient 
interaction, is an instructive case report describing consistently low tacrolimus levels but 
severe biopsy proven tacrolimus-induced nephropathy where the donor and recipient 
displayed CYP3A5 3*3 and 1*3 genotypes respectively (71). 
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1.1.3.3 Post-transplant hyperglycaemia 
Another area of focus in transplant outcome has been the development of impaired glucose 
tolerance (IGT) and new onset diabetes after transplantation (NODAT), which are associated 
with patient mortality and poorer allograft survival (72). A GWAS of candidate SNPs in 
NODAT was performed in 26 NODAT patients (and 230 controls) with subsequent de novo 
SNP genotyping in 57 NODAT patients (and 383 controls), discovered 8 SNPs associated with 
pancreatic β-cell apoptosis (73). This Belfast cohort was limited to White, adult recipients 
with NODAT defined as requirement for oral hypoglycaemics or insulin after transplantation. 
Other recent studies have shown Mitochondrial DNA haplotype H is associated with 
increased risk of NODAT (74). Low adiponectin levels have been associated with the 
development of NODAT and in an adjusted model of 270 White Brazilian patients, rs1501299 
TT genotype was associated with increased risk for NODAT (75). The renal-angiotensin 
system can modulate adiponectin levels, and a study of 372 Polish patients found an 
association between ACE I/D genotype and higher adiponectin levels in women with a lower 
BMI but not increased insulin resistance (76). 
 
1.1.3.4 The importance of donor gene variation in graft failure 
As discussed above, studies of donor gene variation are scarcer than those of the transplant 
recipient, yet may be highly informative. A study from Reeves-Daniel has shown the 
association between donor APOL1 variation and graft survival. This North American study 
suggested, in fact, that this may account for the differences in graft outcome ascribed to 
donor race (specifically the worse outcomes in for kidneys donated by African American 
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individuals), rather than race per se (77). A recent European case report represents a 
cautionary tale whereby accelerated graft failure of the recipient, and also the development 
of renal dysfunction and proteinuria in the donor was seen following live donation from the 
monozygotic twin of an African Caribbean patient. Both donor and patient displayed the at-
risk APOL1 gene variant, highlighting not only the increased risk of graft failure in this 
setting, but also having implications for the safety of certain donors, particularly those of 
African origin (78).  
As may be the case described for drug metabolism genes described above, the combination 
of donor and recipient gene variation may be relevant. A non-replicated Korean study 
showed an association between graft survival and the summed number of A alleles from 
donor and recipient in MMP-7 and MMP-20 (79). A report of 100 patients from Saudi Arabia 
described donor IL-10 (-1082) GA genotype as a risk for transplant rejection, but not graft 
failure (44). A study involving 2985 genotyped donors from the Collaborative Transplant 
Study (CTS) has described an association between graft failure and donor ABCB1 genotype in 
2011 (80). This extends data from a study published in 2009 demonstrating increased risk for 
graft failure when both donor and recipient were homozygous for the C3435T variant in 
ABCB1 (81).  
A cohort study from Birmingham and Belfast has also described a replicated association 
between death censored allograft graft loss and severity of interstitial fibrosis and donor 
CAV1 (caveolin-1) SNP rs4730751 (82). Interstitial fibrosis severity is a prognostic marker for 
progression of CKD. Caveolin-1 ubiquitous distribution and pleiotropic effects could relate to 
patients’ adverse outcomes as their renal disease progresses. 
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1.2 Caveolae and Caveolin-1 
1.2.1 History of Caveolae and Caveolin-1 
Caveolae are sub-class of non-clathrin coated lipid rafts that were morphologically first 
identified in 1953 via transmission electron microscopy and appear as little cave-like 
invaginations of the plasma membrane of 50-100 nanometres in size (83). In 1955, Yamada 
first described caveolae existing in the renal mouse glomerular capillary endothelium (84). 
Caveolae are ubiquitously distributed though predominately found in endothelial cells, 
epithelial cells, striated and smooth muscle cells, fibroblasts and type 1 pneumocytes, with 
almost twenty percent of the total plasma membrane of adipocytes being occupied by 
caveolae (85, 86). There are three main isoforms of the caveolin protein, with CAV1 being 
essential for the formation of caveolae. In 1989, the first monoclonal antiphosphotyrosine 
antibody was produced against a 22-kDa protein from Rous sarcoma virus-transformed chick 
embryo fibroblasts in the process of oncogene related protein phosphorylation. This protein 
was resistant to non-ionic detergent conditions with over 90% of the protein fractionated 
with the cytoskeleton and punctate staining in the margins of fibroblasts and in parallel 
arrays along actin stress fibres (87, 88). In 1992, Rothberg et al first ascribed the protein 
component of the caveolae membrane coat as caveolin (89). In 1999, caveolin-2 was 
described as 20-kDa protein that co-localises and is dependent on CAV1 to form hetero-
dimers (90) and caveolae membrane localisation to the basolateral surface of epithelial cells, 
whilst caveolae with CAV1 alone, are not seen on the apical surface (91). Caveolin-3 has a 
similar morphology to caveolin-1, and is mostly found in cardiac, smooth and skeletal 
myocytes (92). 
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1.2.2 Structure of caveolae and caveolin-1 
Caveolae are largely composed of cholesterol with concentrated glycosphingolipids and 
sphingomyelin relative to the plasma membrane distribution, with CAV1 required for its 
structural stability. As shown in Figure 1-4, caveolae can form either the classical omega or 
little cave, enlongated (for channel formation) or a direct vesicle formation mostly at the 
basolateral surface. This depends on the proteins called cavins whose abundance changes 
the mobility of CAV1 and thus structural integrity of the caveolar structure allowing the 
structure and its contents to be endocytosed. If the ratio of cavin-1 to cavin-2 is higher, then 
the caveolae omega shape is favoured; if cavin-2 expressed levels higher than cavin-1, then 
the elongated shape is formed whilst cavin-3 expression directs vesicle formation (93). 
Depletion of cholesterol results in decreased CAV1 expression that can also lead to 
destabilisation of the caveolae structure to become mobile from the plasma membrane. 
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Figure 1-4 Electron micrograph and schematic representation of caveolae structures 
 
Modified from Rothberg et al (89) and Chidlow et al (93). Cav-1, caveolin-1; Cav-2, caveolin-2. 
 
Caveolin-1 is a protein that remains intracellular, formed via the endoplasmic reticulum (ER) 
system and transported from the Golgi apparatus to the plasma membrane. CAV1 exit from 
the Golgi apparatus is accelerated by increasing cholesterol and inhibited after 
glycosphingolipid depletion (94). There are two isoforms of CAV1, alpha of 178 amino acid 
length and beta which is 31 amino acid lengths shorter, with the former isoform having a 
higher affinity for the plasma membrane. The N’ terminal and C’ termini face the cytoplasm, 
after tyrosine phosphorylation and palmitoylation respectively (Figure 1-5). Between the 
termini, there is a hairpin structure hydrophobic domain of 32 amino acids (residues 102-
134) that inserts to plasma membrane and is involved in hetero-oligomerization of CAV1 
with caveolin-2 (95). Residues 82-101 and 135-150 flank this region, with the latter termed 
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C’ membrane attachment domain that contains a cis-Golgi targeting sequence. The N’ 
membrane attachment domain or caveolin scaffolding domain (residue 82-101) is integral in 
membrane localisation and anchoring of various proteins within caveolae and regulation 
(both inhibition and enhancement) of their signalling activity (85). Another important site is 
the tyrosine-14 residue (Y14), which requires phosphorylation for caveolar endocytosis and 
is important in cell adhesion. 
 
Figure 1-5 Modified colour coded primary structure to the compartments of caveolin-1 in the 
plasma membrane with inclusion of the Y14 site (95) 
 
 
Y14 
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1.2.3 Caveolin-1 gene 
 
The human caveolin-1 gene is located on the long arm of chromosome 7, at genomic locus 
7q31.1 (7:116540796) as shown in Figure 1-6. It consists of 3 exons (30, 165 and 342 base 
pair in length respectively) and 2 introns (1.5 and 32 kilobases in length) spaced in-between. 
The first exons contain CpG islands that via methylation are thought to be the main part of 
CAV1 gene expression in cancer cell lines (96). The third exon harbours the functional 
oligomerisation, scaffolding, transmembrane and C’ membrane attachment domains that 
are highly conserved across species (97). 
Figure 1-6 The caveolin-1 human gene on chromosome 7 and its three exons below with size in 
base pairs (modified from (85)) 
 
 
The red rectangle shows the location of the caveolin-1 gene on chromosome 7 
 
 
1.2.4 Caveolin-1 signalling 
There are several roles of caveolae and CAV1 which are integral to cellular function. The 
most common involves vesicular transport of macromolecules (such as albumin) via 
transcytosis from the luminal side of the capillary endothelium to the interstitial space via 
membrane-bound vesicles. The accumulation of gold-labelled albumin in the interstitial 
space is not seen in the knockout CAV1 mouse by transmission electron microscopy as 
compared to the wild-type mouse (98). Endocytosis is the second example of vesicular 
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membrane trafficking by caveolae. Caveolae share similar vesicle docking and fusion 
molecules (soluble N-ethylmaleimide-sensitive factor attachment protein receptors (SNARE) 
and dynamin) as seen in the traditional clathrin-mediated endocytosis. Pathogens such as 
Simian virus 40 and the cholera toxin utilise collections of caveolae for internalisation into 
the cell, forming with a distinct endosomal compartment with a neutral pH called a 
caveosome, for delivery to the ER and Golgi apparatus with recycling of CAV1 to the plasma 
membrane (85, 99).  
CAV1 and caveolae are also integral to cellular signalling and signal transduction by 
compartmentalising receptors upon ligand binding, acting as a chaperone of signalling 
molecules and ligand bound receptors for delivery to the cell nucleus as well as 
concentrating such events in the confines of a specific subcellular environment (85). 
Receptors such as the epidermal growth factor receptor (EGFR) and transforming growth 
factor beta (TGFβ) receptor are internalised by caveolae upon ligand binding after 
phosphorylation of Y14 part of CAV1 (100). This internalisation is dependent on Src kinases 
and protein kinase C (101). Golgi derived CAV1 via SNARE protein syntaxin-6 is also essential 
for plasma membrane delivery of receptors angiotensin II type 1, insulin and the stretch 
activated channel short transient receptor potential channel-1 (94). 
In the majority, CAV1 effects are inhibitory upon cellular signalling, acting to degrade 
receptors except in the case of the insulin receptors. The main outcomes of CAV1 signal 
association are pro-apoptotic and anti-fibrotic. The most commonly described signalling 
CAV1 associations are with endothelial nitric oxide synthase (eNOS) and TGFβ pathways. 
CAV1 via its CSD binds eNOS resulting in its inactivity and can act as a reservoir of inactivated 
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eNOS. The influx of calcium leads to more calmodulin recruitment and binding to the eNOS 
enzyme leading to its release from bound CAV1 and thus restoration of electron flow from 
NADPH to its reductase domain flavins and then to the heme moiety of eNOS, generating the 
vasodilator nitric oxide (NO) from L-arginine. The generation of NO leads to a dissociation of 
CAV1 scaffold, leading to termination of signal transduction. However, if the substrate L-
arginine becomes limited, eNOS functions in an uncoupled mode, leading to the electron 
transfer to the heme moiety to react with oxygen to form reactive oxygen species (ROS) 
(102). 
ROS releases TGFβ-1 from its latency-associated peptide and latent TGFβ-binding protein to 
become activated (103). Upon this ligand binding, TGFβ type 1 receptor is phosphorylated 
after binding with TGFβ type II receptor to form a serine/threonine kinase heterotetrameric 
complex (Figure 1-7). If this complex is internalised by the early-endosome antigen 1 non-
lipid/clathrin raft pathway, this phosphorylates the SARA/Smad 2/3 complex downstream to 
induce a conformational change that results in heteromerization of Smad 4 and 
translocation to the nucleus to regulate transcription of pro-fibrotic target genes as well as 
the downregulation of CAV1 and Smad 7 (104). However, if the TGFβ receptor I/II complex is 
internalised by caveolae, then SMURF/Smad 7 is recruited and exerts a negative effect upon 
TGFβ signalling by proteasomal degradation and ubiquitination of the TGFβ receptor 
complex in CAV1 positive vesicles. In addition, CAV1 diminishes Smad 2 phosphorylation, 
disrupts its interaction with Smad 4, and prevents Smad 2 translocation to the nucleus, 
further reducing TGFβ signalling (104). 
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Other signalling events associated with caveolae endocytosis involve fibronectin degradation 
and integrin internalisation (105, 106). The detachment of fibroblasts triggers ganglioside 
GM1 internalisation via CAV1 and its Y14 phosphorylation; GM1 internalisation leads to Rac1 
loss from the plasma membrane and its reduced activation (94). Thus not only is CAV1 
important in compartmentalising signal transduction in caveolae by concentrating and 
localising signalling molecules by acting as docking points for numerous cell surface 
receptors after ligand binding, but also regulates cell adhesion, cell migration via β1-
integrins, extracellular matrix (ECM) interactions and acts as flow sensors in endothelial cells 
and regulates stretch-induced cell cycle progression (94, 106). CAV1 response to chronic 
shear stress is to increase its levels with redistribution from the Golgi complex to the plasma 
membrane and formation of caveolae (107). This leads to increased mechanosensitivity with 
activation of signalling pathways such as eNOS and mitogen-activated protein kinase 
(MAPK). In Cav1-/- mice, show defects in chronic flow-dependent remodelling of blood 
vessels (108). Upon stretch, cell cycle progression is inhibited with CAV1 downregulation or 
in Cav1-/- smooth muscle cells through pathways including PI3 kinase-AKT/protein kinase B, 
MAPK ERK, c-Src and integrins (109). 
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Figure 1-7 Schematic representation of TGFβ ligand (diamond yellow) receptor complex I and II 
internalisation via clathrin and caveolae rafts (modified from (110)) 
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1.2.5 Caveolin-1 in renal adverse outcomes 
 
1.2.5.1 Caveolin-1 in renal fibrosis 
 
CAV1 has been an attractive protein to investigate in the context of organ fibrosis as 
suggested with its effects described in the previous section and the following section 
summarises renal fibrotic CAV1 research. 
CAV1 interaction with TGFβ in fibrosis is a common pathway by which renal and non-renal 
chronic disease progresses and thus has been extensively investigated. Li et al used primary 
murine pulmonary endothelial cells that were capable of obtaining a myofibroblast 
phenotype after TGFβ-1 stimulation, inducing αSMA expression from wild-type cells. Cav1-/- 
cells produced very high spontaneous levels of αSMA that was corrected upon CAV1 
functional restoration using its CSD peptide; thus CAV1 regulates endothelial-to-
mesenchymal transition in tissue fibrosis (111). Ito et al (112) showed that adding 
hyaluronan with its receptor CD44 to immortalised renal proximal tubular epithelial cells 
(HK2) led to an increase of lipid raft internalisation of TGFβ via MAP kinase from the non-
lipid pathway predominance. The authors co-cultured HK2 cells with cells transfected with a 
Smad responsive promoter and blocked several components (e.g. CD44 and its interaction 
with hyaluronan) along this pathway to confirm their finding. As the authors state, this 
conflicts with previous work with metastatic breast tumour cells that suggest hyaluronan 
promoted the non-lipid pathway, and thus the finding may be dependent on specific tissue 
microenvironments. Whilst Zhang et al (113) have shown stimulation with IL-6 led to more 
non-lipid raft pathway dominance for the TGFβ receptor in HK2 cells and a decrease in the 
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association of the IL-6 receptor to CAV1 upon co-immunoprecipitation. This was after the 
observation that IL-6 is only expressed on proximal tubular epithelial cells at times of renal 
disease. However despite the affinity labelling findings, it was noted that stimulation with IL-
6 and TGFβ-1 did not lead to an increase in Smad 2 or 3 or 7 protein expression, but only the 
luciferase assay suggested more Smad activity. 
As well as TGF, there have been many other signalling events associated with CAV1 in renal 
fibrosis and are summarised in Table 1-1 and further described below. Peng et al (114) 
showed a Src dependent phosphorylation of the CAV1 Y14 site occurred with RhoA 
activation and formation of ROS when they mechanically stretched mesangial cells via a 
cyclic vacuum as a model of intraglomerular hypertension leading to glomerulosclerosis. In 
the Cav1 knockout mouse, there was no RhoA or ROS activation but this function was 
promptly restored upon restoration of Cav1 (115). 
30 | P a g e  
 
Table 1-1 Summary of cytokines, chemokines and receptors associated with caveolin-1 in renal 
fibrosis 
 
Cytokine/Chemokine/Receptor Effect of caveolin-1 interaction 
Angiotensin II In vascular smooth muscle cells, promotes 
angiotensin II type 1 receptor binding to 
caveolin-1. This promotes Rac1 into caveolae, 
increasing localised reactive oxygen species 
production and EGFR transactivation. 
 
Angiotensin II type 1 receptor CAV1 required for its renal expression in a basal 
state. This receptor is required to mediate 
angiotensin II induced ROS production by 
NAPDH oxidase. This oxidative stress is seen in 
spontaneously hypertensive rats. Treatment 
with losartan (angiotensin II type 1 receptor 
antagonist) to these rats results in increased 
CAV1 expression and co-localisation with heat 
shock protein 70 to the plasma membrane in 
proximal tubules and reduced Nox4 co-
immunoprecipitation with heat shock protein 
70 (116). 
 
β1 integrins Act as mechanosensors bound to CAV1 in 
human umbilical vein endothelial cells (117). 
 
CD40 CAV1 associated with CD40 in antigen 
presenting cells (B lymphocytes, macrophages, 
dendritic cells). Upon CD40 binding to its ligand 
(CD40L), c jun NH2-terminal kinase, p38, MAP 
kinases, Src related kinases dissociate from 
CAV1 and are mainly pro-inflammatory. 
Plasminogen activator inhibitor-1 is a powerful 
fibrotic mediator that is released after CD40 
cross-linking with tumour necrosis factor 
receptors which results in Lyn phosphorylation 
association with CAV1 (118). 
 
CXCR4 CXCR4 dimerization induced by stromal derived 
factor-1 occurs in caveolae, for homing of 
haematopoieitic stem cells and enodthelial 
progenitor cells (119). 
 
Endothelial-1 Example of regulatory activity of caveolin-1 that 
binds the endothelial receptor B in a basal 
state, but is released upon ligand binding with 
endothelial-1 to promote downstream 
signalling. However, endothelial-1 increases 
caveolin-1 to bind and internalise and degrade 
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its receptor B, thus reducing prolonged 
endothelial-1 effects (120). 
 
Endothelial nitric oxide synthase/nitric 
oxide release 
Unbinding of endothelial nitric oxide synthase 
from caveolin-1 is required for its activation 
and release of nitric oxide. This is achieved by 
increased cytosolic calcium or Akt activation, 
leading to nitric oxide induced endothelial 
relaxation. Paradoxically this could lead to an 
impaired renal arterial autoregulation. Reduced 
CAV1 leads to a reduced myogenic response to 
stretch. Excess eNOS activity leads to increased 
vascular permeability to serum albumin. Also 
with less caveolin-1 and more eNOS activity and 
nitric oxide release at a basal rate, there is an 
impaired nitric oxide induced relaxation upon 
stimulation. 
 
HO-1 Heme-oxygenase 1 is upregulated in periods of 
oxidative stress such as in ischaemic-
reperfusion injury. CAV1 directly inhibits its 
anti-apoptotic actions (121). 
 
Nephrin In a model of angiotensin II podocyte injury, 
nephrin dephosphorylation resulted in 
podocyte apoptosis. This dephosphorylation 
required caveolin-1 Y14 phosphorylation with 
interaction with Csk (negative regulation of Src 
kinases) (122). 
 
p42/44 MAP kinase Suppressed by caveolin-1 and thus mesangial 
cell proliferation induced by bFGF and PDGF 
(123). 
PDGFR Increased PDGF results in internalisation of its 
receptor and increased turnover of caveolin-1 
and renal cell proliferation (124). 
 
RhoA In primary mesangial rat cells, TGFβ-1 induced 
RhoA activation is prevented by caveolae 
disruption and downstream TGFβ-1 collagen-1 
accumulation. TGFβ-1 induced RhoA activation 
is dependent on Y14 CAV1 phosphorylation 
(114). 
 
Survivin CAV1 acts as a tumour suppressor through 
survivin suppression that is dependent on β-
catenin-Tcf/Lef pathway with E-cadherin. 
Survivin is a protein inhibitor of apoptosis and 
controls progression through the G2/M 
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checkpoint of the cell cycle. Cyclin-1, c-myc and 
VEGF gene expression are also reliant on this 
pathway (125). 
 
TGFβ CAV1 suppresses TGFβ-1 signalling after it has 
bound to its receptor by internalising and 
proteasomal degradation of the receptor 
through recruitment of the SMURF/SMAD7 
TGFβ-inhibitory complex, reduced SMAD 2 
signalling and reduced TGFβ type II gene 
expression. 
 
TNFα TNF receptor 1 and CD36 are co-localised to 
caveolae like domains in TNFα induced 
apoptosis (126). 
 
VEGF 
 
 
 
 
Increases caveolae number and caveolin-1 
related structures to form fenestrae in 
glomerular endothelial cells and thus 
permeability (1, 9). Causes a nearly 2.5 fold 
increase in VEGFR2/CAV1  association in vitro 
mesangial cells and this increase is seen in 
steptozotocin induced in vivo rat model of 
diabetic nephropathy via Src induced Y14 
phosphorylation (127). 
 
VEGFR2 Is negatively regulated by caveolin-1 as seen in 
tumour growth and permeability (128). ROS 
important for VEGFR2 autophosphorylation. 
 
 
As another model of hypertension, Bocanegra et al (116) investigated the protective profile 
of losartan upon proximal tubular cells from spontaneously hypertensive rats, whose CAV1 
expression was significantly reduced compared to control. Losartan (an angiotensin II type 1 
receptor antagonist) was noted to reduce ROS through Nox4 downregulation and NADPH 
inactivation, through increased levels of CAV1 and co-localisation with Heat shock protein 
70. However two questions remain: was this just a by-product of the blood pressure 
lowering ability of losartan and why none of these effects were seen in the control group? 
The editorial comment focussed on the mechanisms behind hypertension and ROS 
production causing reduced renal function and structural damage; this was mainly to 
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inappropriate activation of intrarenal angiotensin II within the proximal tubules due to its 
translocation of angiotensin II type 1 receptor (AT1) from the plasma membrane to CAV1 
rich domains. Here, CAV1 acts as a molecular chaperone to AT1, providing a platform for 
redox signalling events through NADPH oxidase dependent production of ROS via Nox4 
(129). 
Genetically obese Zucker rats on a casein diet have also been shown to have reduced eNOS 
and raised CAV1 in renal structural damaged kidneys as compared to those on a soy diet, but 
again, CAV1 is known to fluctuate with cholesterol levels making it difficult to interpret the 
findings (130). From Valles et al (131), ureteric obstruction leads to an early rapid intrarenal 
angiotensin II rise that leads to an increase in extracellular matrix protein production and 
oxidative stress damage causing fibrosis. Nitric oxide can ameliorate interstitial fibrosis and 
in loss of eNOS leads to marked tubulointerstitial fibrosis in the inducible NOS knockout 
mouse. CAV1 is expressed in vascular endothelium, smooth muscle and epithelial cells of the 
proximal, distal and convoluted tubules and ducts. CAV1 also leads to apoptosis via 
inhibition of p42/44 MAP kinase signalling. Thus the authors wished to look at the role of 
CAV1 expression in congenital unilateral ureteropelvic junction obstruction with grade IV 
hydronephrosis on imaging requiring surgical intervention after vesico-ureteral reflux was 
excluded. The 19 children had ‘normal renal function for their age’, were on no medication 
and were normotensive. The scorers of interstitial volume and CAV1 staining were blinded. 
There were two groups with group 1 split into subset A with obstruction <1yr, subset B with 
obstruction >1yr, and group 2 had significant renal impairment compared to group 1 
(99mTc-DPTA renal scan expression of kidney filtration rate 28.8±2% to 39.7±2.1% 
respectively). The results showed group 2 CAV1 was present in the proximal tubule unlike 
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control and group 1, as well as co-localising with the AT1 receptor. Increased CAV1 
expression was confirmed on Western Blotting for protein transcription from group 2’s 
urine. eNOS was low in group2 (p<0.01). Unfortunately the control was based on children 
with renal cell carcinoma where it is known that CAV1 has expression can be altered and 
may thus not act as a true control. 
Further to the above human study suggesting increased CAV1 expression in the more 
chronic and fibrotic group in children, histological increased glomerular expression of CAV1 
in Japanese patients has been identified in diseases that target the glomerulus such as 
diabetic nephropathy, membranous nephropathy and focal segmental glomerulosclerosis 
(132). It was also noted that CAV1 expression was also reduced in glomerular endothelial 
cells with the use of steroids. In diabetic nephropathy, murine Cav1 knockout led to a worse 
glomerulosclerosis and albuminuria in the streptozotocin model of type 1 diabetic 
nephropathy, though there is limited tubulointerstitial fibrosis in this model (133). CAV1 
increased expression was also noted in a streptozotocin rat model of diabetic nephropathy 
with increased VEGF receptor 2 (VEGFR2)/CAV1 association in vivo (127). In vitro, primary rat 
mesangial cells after stimulation with VEGF, caused more CAV1/VEGFR2, CAV1/Src 
expression and fibronectin upregulation via RhoA activation. Transfection of mesangial cells 
with an overexpression of non-phosphorylatable CAV1 Y14 prevented VEGF-induced RhoA 
activation and fibronectin upregulation. Another model of nodular glomerulosclerosis 
utilises human urinary free light chains from patients suffering from light chain deposition 
disease injecting to wild-type and Cav1 knockout rats’ tail veins to induce nodular 
glomerulosclerosis. In the Cav1 knockout, there was increased nodular glomerulosclerosis 
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and increased mesangial matrix production, however there was a mix of gender used that 
may have influenced the results (134). 
Other human studies have focussed on CAV1 in renal transplantation. Yamamoto et al (135) 
have previously shown that de novo caveolae formation occurs in transplant glomerulopathy 
in glomerular endothelial cells and now investigate CAV1 in chronic active antibody 
mediated rejection and thus transplant capillaropathy, where they found CAV1 to be 
associated with peritubular capillary endothelia that is not normally present in healthy 
kidney. Pontrelli et al (118) also investigated chronic allograft nephropathy secondary to 
immune system activation where CD40 is upregulated in acute rejection in proximal tubular 
epithelial cells. This led to increased Lyn phosphorylation and thus NFҡB activation. Lyn 
phosphorylation is strictly associated with CAV1 and inhibiting Lyn blocked the profibrotic 
induction of PAI-1. 
Park et al (119) have used an unilateral ureteric obstruction (UUO) model in FVB/N mice to 
investigate the surge of stem cells that occurs upon 10 days after ligation of the left ureter. 
In the Cav1 knockout, the mesenchymal stem cell post obstructive surge was blunted 
significantly which led to no regeneration of the parenchyma and marked fibrosis as 
measured by Sirius red staining. Indeed some of the surge could be from the response of the 
resident kidney stem cells. In this model, the FVB/N wild-type mice are a different strain to 
the Cav1 knockout mice and the control kidney was the contralateral kidney of each mouse. 
These factors could affect the interpretation of their findings as different mouse strains have 
varying susceptibility to fibrosis and the contralateral compensation after ligation of the 
ureter could be different. 
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In summary, there appears to be negative effect of CAV1 expression leading to a worse renal 
phenotype especially in glomerular disease. However, this is in opposition to the non-renal 
literature where the CAV1 reduction in patient samples or knockout of caveolin-1 in vitro has 
been found to lead to a more fibrotic phenotype. This may be due to the organ and 
microenvironment studied such as in bleomycin induced lung fibrosis (136), idiopathic 
pulmonary fibrosis (137), scleroderma/systemic sclerosis (138), cardiac fibrosis (139) and 
keloid scars (140) which involve more TGFβ dependent processes that are reliant on the 
expression of CAV1 in fibroblasts. 
 
1.2.5.2 Pleiotropic effects of caveolin-1 in adverse renal outcomes 
As well as tubulointerstitial fibrosis, there are common adverse outcomes experienced by 
patients as their renal disease progresses as described in section 1.1.2. Due its ubiquitous 
nature of distribution, CAV1 has been associated with many of these outcomes. 
Infection: In patients suffering from scleroderma associated lung disease, their 
bronchoalveolar lavage revealed activated monocytes and polymorphonuclear cells; these 
patients’ monocytes, neutrophils and T cells had a reduced expression of CAV1 (136).  In 
mice exposed to lipopolysaccharide challenge, the deletion of Cav1 led to a decreased 
expression of CD14 and CD36 during macrophage differentiation and suppressed phagocytic 
ability and impaired bacterial clearance (141).  Cav1 knockout mice also had an increased 
mortality with induced Pseudomonas aeruginosa and Klebsiella pneumoniae sepsis (142, 
143).  In cystic fibrosis, effective internalisation of pathogens such as Pseudomonas 
aeruginosa is required for an appropriate immune response for its clearance; its 
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internalisation is reliant on CAV1 in type 1 pneumocytes and bladder epithelium (144). CAV1 
interaction with protein kinase Cα upon activation and calcium release is essential for its 
translocation to caveolae in order for production of infectious enveloped human 
cytomegalovirus particles in fibroblasts (145). Infection with polyomavirus viraemia can 
cause BK nephropathy in renal transplant recipients. Moriyama et al in vitro data shows this 
viral entry in human proximal tubular epithelial cells requires co-localisation with CAV1 for 
caveolae entry into the cells (146). 
Cardiovascular disease: CAV1 has been associated with an inflammatory macrophage 
phenotype that promotes atherosclerosis by the production of foam cells (147). Schwencke 
et al have found reduced CAV1 expression in VSMC of human atheroma (148). CAV1 also 
binds eNOS in an inactive state and with an influx of calcium, its release thus affecting 
vascular function (149). In the Cav1 knockout mouse, cardiac hypertrophy occurs despite the 
high presence of caveolin-3, in which the latter is thought to be the predominant isoform of 
caveolin in the heart (150).  
Malignancy: CAV1 may have a tumour suppressive role depending on the cancer type. CAV1 
has been shown to promote apoptosis and in Cav1 knockout mice, hyperactivation of the 
p42/44 MAP kinase cascade and cyclin D1 upregulation in breast cancer models lead to 
cancer progression and metastases (151). CAV1 has been considered as a prognostic marker 
in several cancers (152). However, in prostate cancer, CAV1 upregulation has been 
associated with progression of the malignancy (153), highlighting CAV1 altered function 
depending on the organ microenvironment studied. 
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Diabetes: CAV1 scaffolding domain binds to the insulin receptor and lack of CAV1 in 
adipocytes results in reduced phosphorylation and lack of translocation of GLUT-4 to the 
plasma membrane, leading to reduced glucose uptake and insulin sensitivity especially 
amongst patients with hypertension (154, 155). Metformin has also been shown not to 
reduce hyperglycaemia in Cav1 knockout mice that are naturally hyperglycaemic compared 
to their wild-type counterparts (155). The Cav1 knockout mouse adipocytes have chronically 
elevated hepatic gluconeogenesis and also show defects in insulin secretion and 
mitochondrial function (155, 156). In a lipotoxic environment, pancreatic β cells are 
protected against apoptosis by SREBP-1c/CAV1 signalling involved in PPARβ/δ-regulated 
GLP-1R expression (157). 
1.3 Thesis Hypothesis 
Identification of patients with relative positive or maladaptive phenotypes is necessary for 
the concept of personalised medicine to design treatment protocols for the individual rather 
than the traditional population based strategy. Thus the approach of candidate SNP 
association has been used in this thesis to identify patients at risk of adverse outcomes in 
renal disease. 
HYPOTHESIS: Can the pleiotropic effects of caveolin-1 differentiate patients' phenotype in 
chronic kidney disease? 
AIM 1: To differentiate patients' phenotype in kidney disease by CAV1 and related candidate 
gene SNPs. 
AIM 2: To investigate if the lack of Cav1 leads to an increased fibrotic phenotype in 
experimental renal fibrosis. 
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1.3.1 Thesis Chapters 
In renal transplantation, donor CAV1 SNP rs4730751 has been associated with renal 
transplant organ survival, function and fibrosis (82, 158). In haemodialysis dependent 
patients, this SNP has been associated with carotid intima medial thickness (159). Thus the 
SNP has been used in this thesis, using a series of candidate SNP association studies to 
clinical phenotypes in CKD, to demonstrate if the pleiotropic effects of CAV1 can 
differentiate patients with a worse phenotype. Renal tubulointerstitial fibrosis is the 
cornerstone of progression of CKD irrespective of the underlying cause (160); by using 
animal models the effects on fibrosis by the knockout of Cav1 can be explored in this thesis. 
The following scenarios are used to explore the thesis hypothesis and aims: 
a) Cardiovascular disease in CKD can be attributed to 2 distinct pathological processes – 
atherosclerosis and arteriosclerosis (161, 162). While the risk of athero-thrombotic events 
such as myocardial infarction is elevated, arteriosclerosis leading to vascular and myocardial 
damage (in particular left ventricular disease) is the predominant process resulting in a 
higher risk of sudden cardiac death from arrhythmias and congestive heart failure.  Left 
ventricular disease and arterial remodelling is further exacerbated by patients undergoing 
haemodialysis due to recurrent fluid excess requiring removal over short haemodialysis 
sessions, myocardial ischaemia and myocardial stunning (159, 163, 164). The determinants 
of the severity of myocardial disease are poorly characterised though hypertension, 
oxidative stress and activation of the renal angiotensin system are all thought to be relevant.  
Genetic predisposition research to the development of heart failure in CKD has been limited 
(165). In the general population, there has been interest in the association between the 
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Glu298Asp rs1799983 polymorphism within eNOS and heart failure (166, 167). Although this 
polymorphism has been associated with endothelial dysfunction and progression of CKD 
(168), it is not known if this polymorphism is associated with early cardiac structural changes 
that occur in non-dialysis CKD.  
Testa et al found that there was a significant independent and interaction association 
between CAV1 rs4730751 and eNOS rs1799983 genotype and increased carotid arterial 
intima thickness (vascular hypertrophy) and cross-sectional area across the common carotid 
artery (arterial remodelling) (159). It is not clear if these associations occur in non-dialysis 
CKD or just a phenomenon seen in haemodialysis patients. eNOS is bound to CAV1 requiring 
a calcium influx for its release from CAV1 in order to become activated. 
In light of this, I investigated if these gene variants are associated with pulse wave velocity 
(as a cardiovascular mortality prognostic marker of arterial stiffness (169)) changes in non-
dialysis CKD. These gene variants were also investigated for associated changes in systolic 
and diastolic left ventricular (LV) function, based on detailed cardiac magnetic resonance 
imaging (CMR) in non-dialysis CKD patients with no known history of heart failure. 
b) Anti-neutrophil cytoplasmic antibody associated vasculitis is a multisystem disorder that 
affects the kidneys and lungs predominately. Despite recent therapeutic success in 
improving the first year survival rate over the last 2 decades, there remains up to 28% 5 year 
mortality rate and significant morbidity associated with the complications and treatment of 
the disease, such as infection, cardiovascular disease, malignancy and progression of renal 
disease that mirrors the pleiotropic effects of CAV1 described in section 1.2.5.2 (170). 
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c) Emerging paradigms of new onset diabetes after transplantation (NODAT) have focussed 
on understanding risk factors (e.g. post-transplant hyperglycaemia and immunosuppressive 
agents) involved in its pathogenesis with the aim of identifying those at risk and 
development of potential prevention and treatment strategies (171). Genetic risk of NODAT 
and identification of potential associated single nucleotide polymorphisms (SNPs) have 
increased our knowledge base of pathways involved in NODAT (172, 173). 
d) The trigger in fibrosis is initiated by the sterile inflammation response to danger 
associated molecular pattern signals that are released from damaged tissue from almost any 
insult. This leads to two main patterns of response, namely immune activating and non-
activating apoptotic pathways (174). This response of the resident stroma of the kidney via 
chemokines and cytokines supports the infiltration of leukocytes. The combination effect of 
this crosstalk appears to influence fibrotic development (175). CAV1 is reported to be found 
in leukocytes and stroma and is a potential link to understanding this crosstalk (136, 176). 
However, as mentioned in section 1.2.5.1, the effects of CAV1 in renal fibrosis remain 
unclear. Hence, the aim is to investigate if Cav1 knockout leads to more fibrosis. Two mouse 
fibrotic models are used to investigate tubulointerstitial fibrosis. UUO and ciclosporin-A 
(CsA) nephrotoxicity are two mouse models of renal fibrosis that reflect clinically significant 
entities in humans of obstructive uropathy, and in renal transplant patients CsA induced 
nephropathy. The nephropathy profile consists of tubulointerstitial fibrosis, tubular atrophy, 
glomerulosclerosis, loss of glomerular and peritubular capillaries, characterised by 
macrophage influx. The UUO model has the advantage of being a reliably reproducible and 
quick model with marked destruction of the renal architecture by day 14 after the ureter is 
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tied. It is also advantageous as the contralateral kidney undergoes hyperfiltration 
compensation that means the overall kidney function is not curtailed. However, the CsA 
model allows a less destructive patchy fibrosis to develop over a longer duration (28 days) 
with resulting bilateral renal disease and chronic kidney function impairment. 
A search in Pubmed of ‘caveolin-1 knockout mouse’ (24th February 2016) reveals nearly 500 
associated publications since 1998. It has mainly been utilised to highlight signalling events 
associated with CAV1 as discussed above as well as mirror human diseases such as 
scleroderma associated lung fibrosis. The Cav1 knockout mouse (CKO) is surprisingly viable 
and initially fertile considering the inability to form caveolae and CAV1’s ubiquitous 
distribution. However, the CKO does have a lower lifespan than its wild-type counterpart. In 
a 2 year study it was noted that the CKO lifespan was about half its wild-type, between 7-16 
months of age, displaying marked pulmonary fibrosis, pulmonary hypertension and cardiac 
hypertrophy (177).  Table 1-2 reflects some of the most important phenotypic changes seen 
in the CKO mouse. 
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Table 1-2 Phenotypes of caveolin-1 knockout mouse (Modified from (178)) 
 
Organ system and phenotype Proposed mechanism 
Cancer 
Increased sensitivity to carcinogens Increased cyclin D1 and ERK 1/2 levels 
    
Cardiac 
Cardiac hypertrophy p42/44 MAP kinase hyperactivation 
Dilated cardiomyopathy Unknown, increased fibrosis at 12months 
    
Central nervous system 
Reduced brain weight; multiple motor and 
behavioural abnormalities 
Altered maintenance of cortico-striato-pallido-
thalamo-pontine pathways involved in motor 
control 
At age 3-6months develop Alzheimer’s disease 
characteristics 
Increased beta and tau deposits 
    
Endocrine-metabolic 
Adipocyte abnormalities with impaired 
lipolytic activity and altered lipid droplet 
architecture 
Altered lipid homeostasis; altered perilipin 
phosphorylation 
Accelerated mammary gland development Hyperactivation of prolactin signalling 
Decreased glucose uptake 
Insulin resistance and altered glucose 
transporter localization. Over 2-fold reduction 
in plasma leptin levels 
    
Gastrointestinal   
Hyperproliferation of intestinal crypt cells Upregulation of Wnt/β-catenin signalling 
Reduced nitric oxide-mediated intestinal 
smooth muscle relaxation 
Abnormalities in interstitial cells of Cajal and 
smooth muscle 
Decreased liver regeneration post-
hepatectomy 
Impaired coordination of lipid metabolism and 
cell proliferation 
    
Immune system  
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Increased susceptibility to bacterial infection 
Macrophages exhibit increased nitric oxide 
and inflammatory response with increased 
chemokines to CCL3, IL-6, IFNy TNF-α and 
CXCL10 3 days post Salmonella infection and 
reduced survival from 13 days to 7 days 
compared to wild-type with reduced 
neutrophil recruitment.  
  
Lymphoreticular 
Reduced response to thymus-independent 
antigens 
Unknown 
    
Pulmonary 
Constricted alveolar spaces Thickened alveolar wall 
Pulmonary hypertension with reduced 
exercise tolerance after 10mins of swimming 
Multiple causes 
    
Transport 
Disruption of glycosylphosphatidyl inositol-
anchored protein transport 
Altered Golgi protein processing 
    
Urogenital 
Impaired renal calcium absorption 
Abnormal function of plasma membrane 
calcium ATPase 
Enlarged seminal vesicles Engorgement of seminal fluid 
Bladder hypertrophy Smooth muscle hyperplasia 
    
Vascular 
Reduced aortic contractile tone Increase in endothelial nitric oxide activity 
Impaired angiogenic response Altered VEGF protein interactions 
Neointimal hyperplasia Increased cyclin D1 and ERK 1/2 levels 
Microvascular permeability Altered clefts and tight junctions 
Abnormal arterial remodelling during changes 
in flow 
Altered mechanotransduction 
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CHAPTER 2:  
MATERIALS AND METHODS 
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2.1 Material and Methods 
2.1.1 Methods for Human Studies 
2.1.1.1 Genotyping 
2.1.1.1.1 PAXgene DNA extraction from whole blood for genotyping 
In all genotyping studies in the thesis, whole blood was collected in PAXgene Blood DNA 
tubes (Qiagen, Manchester, UK), frozen at -20°C for 24 hours in a wire rack (to prevent tubes 
from cracking) and then stored at -80°C. Samples were defrosted at room temperature for 2 
hours and inverted 10 times to homogenise the sample as plasma and red cells had 
separated, before starting the DNA extraction process. DNA extraction was undertaken using 
the PAXgene Blood DNA Kit (Qiagen Manchester, UK).  Firstly, 8.5ml of whole blood was 
poured from PAXgene Blood DNA Tubes into a 50ml falcon tube and then 25ml of PAXgene 
cell lysis buffer was added. The solution was briefly mixed by inversion to lyse the red and 
white blood cells. Cell nuclei and mitochondria were pelleted by centrifugation at 2500 x g 
for 5 minutes.  The excess solution was then poured into a disposable jar (containing 1% 
virkon solution) without disturbing the cell pellet.  The cell pellet was washed by adding 5ml 
of PAXgene wash buffer and vortexed vigorously for 5s before discarding the supernatant. 
The pellet was then resuspended using 5ml of PAXGene digestion buffer/protease and 
vortexed for 20s. Protein contaminants were removed by incubation with 5ml of PAXgene 
digestion buffer/protease enzyme at 65oC in a water bath for 10 minutes. To enable DNA to 
be precipitated from solution, 5ml isopropanol was then added and the solution inverted 20 
times until visible white strands of DNA clumped together.  The sample was then centrifuged 
for 3 min at 2500 x g to pellet the DNA. The supernatant was discarded and the tube 
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inverted on a clean piece of dry absorbent paper for 1 minute. The pellet was then washed 
in 5ml of 70% ethanol and vortexed for 1s before a further centrifugation step at 2500 x g 
for 3 minutes.   The supernatant was then discarded and the samples was left to dry by 
inverting the tube on a clean piece of absorbent paper for 5 minutes, dabbed to remove any 
ethanol on the rim, before being left inverted for a further 5 minutes. The DNA pellet was 
then resuspended by adding 1ml PAXgene resuspension buffer and incubating for 1h at 65°C 
in a water bath.   The DNA was then stored at -20oC until DNA quantification. 
 
2.1.1.1.2 PicoGreen DNA Quantification 
DNA was then quantified using PicoGreen DNA quantification. Calf thymus DNA (1mg/ml) 
(Sigma Aldrich, St Louis, USA) was resuspended in 1ml T.E. buffer [T.E. Buffer is made from 
10ml of Tris-EDTA 100x concentrate (Sigma Aldrich, St Louis, USA) added to 990ml of Baxter 
H2O (Baxter, Compton, UK)] and left overnight. Using the resuspended calf thymus DNA and 
T.E. Buffer, a serial dilution was created, to be used as standards, with the following known 
concentrations produced: 800ng/ml, 400ng/ml, 200ng/ml, 100ng/ml, 50ng/ml, 25ng/ml, 
12.5ng/ml and 6.25ng/ml. The DNA samples were then diluted: 2ul of neat DNA sample in 
198ul T.E. Buffer. Both the serial dilutions from the calf thymus DNA and the samples were 
left to resuspend overnight at 4oC. Standards and DNA samples were mixed with PicoGreen 
reagent (Invitrogen, Carlsbad, USA) in a 96 Flat-well Microplate (Alpha Laboratories, 
Eastleigh, UK). Duplicates of 50µl of each standard were mixed with 50µl of a PicoGreen 
solution A (made up from a stock of 1194μl of T.E buffer and 6μl of PicoGreen reagent). 5ul 
of the each diluted DNA samples in duplicate were mixed with 95ul of PicoGreen solution B 
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(made up of 7580μl of T.E. buffer and 20μl of PicoGreen reagent). Once the PicoGreen 
reagent had been applied, the plate was covered in foil and left for 10 minutes to let the 
picogreen integrate into the DNA.  The plate was then read using the cytofluor multi-well 
plate reader series 4000 (Perseptive Biosystems, Framingham, USA) with excitation set at a 
wavelength of 485nm and emission set at a wavelength of 530nm. From this the 
concentration of DNA for each sample could be calculated by comparing to the known 
concentration of the standards (Figure 2-1). 
 
Figure 2-1 PicoGreen standard curve using known concentrations of calf thymus 
 
 
 
2.1.1.1.3 Genotyping of Single Nucleotide Polymorphisms using Taqman 
All DNA samples were then all diluted to a working stock of 4ng/µl. To enable genotyping, 
2.25µl of DNA was added to a 384-well plate along with 2.75µl of assay master mix 
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[consisting of 2.50µl of ABI Genotyping Master Mix (Applied Biosystems, Foster City, USA), 
0.09µl of SNP Assay on Demand genotyping assay (Applied Biosystems, Foster City, USA) and 
0.16µl Millq H2O/ DNA sample]. The SNPs assayed were for CAV1 rs4730751 and eNOS 
rs1799983. Polymerase chain reaction (PCR) amplification as performed on a M J Research 
PTC-225 Peltier Thermal cycler (Genetic Research Instrumentation, UK) under standard 
Taqman genotyping conditions with 50 PCR cycles were undertaken. Plates were read using 
a 7900HT Fast Real-Time PCR System (Applied Biosystems, Foster City, USA) which reads the 
fluorescence release from each allelic-specific Taqman probe allowing the genotype of each 
sample to be deduced. 
 
2.1.1.1.4 SNP genotyping using the Sequenom MassARRAY iPLEX platform 
Sequenom genotyping (Sequenom Inc., Hamburg, Germany) allows the detection of 
polymorphisms at multiple SNPs simultaneously (iPLEX Gold technology). Initially, PCR 
primers were designed to amplify all regions containing the SNPs of interest using 
MassARRAY Assay Designer v4.0; primers were sourced from Metabion (Martinsried, 
Germany). Following PCR amplification in TF-0384 PCR plates (Thermo Scientific, UK), shrimp 
alkaline phosphatase dephosphorylates unbound nucleotides to eliminate them from further 
reactions. Extension primers were designed which were specific for the DNA sequence 
adjacent to each SNP. These anneal to the PCR-amplified DNA in the presence of a high 
fidelity polymerase enzyme. Adenine, cytosine, guanine and thymine nucleotides which have 
been modified by the removal of the hydroxyl group at the 3′ end (ddNTPs) are added to this 
reaction so that one modified base is added to each extension primer. The removal of the 
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hydroxyl group prevents subsequent base extension causing termination of the DNA 
sequence once these modified bases are incorporated at the SNP locus.  
The determination of each individual’s genotype relies upon the ability of Matrix Assisted 
Laser Desorption Ionization Time of Flight technology to detect the differences in mass 
between the incorporated bases at the SNP loci. The DNA samples are ionised by a laser and 
accelerate through the mass spectrometer to the detector. The allele is determined by the 
rapidity with which the ion is detected with heavier bases detected last (179). SNP analysis 
was undertaken using the MassARRAY Compact instrument with Typer version 4.0 software 
(Sequenom) as shown in Figure 2-2. This technology was used in Chapter NODAT studies. 
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Figure 2-2 Genotyping using Sequenom technology highlighting rs2265919 
 
 
 
2.1.1.2 Laboratory testing 
Routine laboratory testing included haematological (Beckan Coulter Haematology Analyser) 
and biochemical profiles and urinary albumin:creatinine measurements (Roche Hitachi 702 
Analyser); performed by Queen Elizabeth Hospital Birmingham laboratory. 
 
2.1.1.3 CAV1 in aortic pulse wave velocity 
Two independent cohorts were investigated as part of this study. Baseline data including 
aortic pulse wave velocity (aPWV) was collected by original study investigators. Subsequent 
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ethical approval and genetic testing consenting was performed by me. The first included 
patients with early CKD enrolled into 2 randomised controlled trials as part of the larger 
“CRIB” studies (Chronic Renal Impairment in Birmingham). Baseline data was analysed in 
these patients who were participating in these two completed, single centre RCTs (CRIB-II 
(180) and CRIB-PHOS (181)) based at the Queen Elizabeth Hospital Birmingham, United 
Kingdom between 2005-2011. Both these studies were interventional in design, but baseline 
data was collected prior to the institution of any change in therapy.  Inclusion criteria for 
these studies were: baseline aortic pulse wave velocity investigations, age 18-80 with eGFR 
30-89ml/min/1.73m2, total cholesterol <5.5mmol/L, resting blood pressure controlled to 
<140/90 for at least 6 months. Exclusion criteria were: diabetes mellitus, peripheral vascular 
disease, symptomatic cardiovascular disease (previous myocardial infarction, known heart 
failure, valvular heart disease) and atrial fibrillation. 
The second (“replication”) cohort consisted of patients enrolled in the “RIISC” (Renal 
Impairment In Secondary Care) study (182). Baseline data was collected upon entry into the 
“RIISC” study. This is a prospective, on-going, observational investigation of patients with 
later stage chronic kidney disease with inclusion criteria of at least one of a) CKD 4 and 5, or 
b) CKD 3 with either accelerated progression (as defined as an eGFR declined of 
≥5mls/min/year or ≥10mls/min/5years) or proteinuria (as defined as a urinary 
albumin:creatinine ≥70mg/mmol on three occasions); exclusion criteria specific to “RIISC” 
included those on renal replacement therapy or immunosuppression (182). For the purposes 
of this genetic investigation, the exclusion criteria were extended to include those described 
above in the “CRIB” cohort. 
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To limit the confounding effect of population stratification only patients of white (self-
reported) ethnicity were included in these genetic substudies. In the “CRIB” cohort, the high 
sensitive C-reactive protein was measured by Tina-quant CRP (Latex) ultrasensitive assay 
(Roche Diagnostics, United Kingdom). In the “RIISC” cohort, this was measured using the 
SpaPlus assay (Binding Site, United Kingdom). The studies (“CRIB” and “RIISC” and their 
genetic components) were approved by East Midlands Nottingham 1 Research Ethics 
Committee and South Birmingham Research Ethics Committee respectively and adhered to 
the Declaration of Helsinki. Study participants provided written informed consent. 
 
2.1.1.3.1 Aortic Pulse Wave Velocity Measurements 
In the ”CRIB” cohort, aPWV was calculated by measuring the distance (with a standard tape 
measure) in metres between the carotid and femoral arteries, subtracting for the distance of 
the carotid artery to the sternal notch.  This was then divided by the transit time (time delay 
between the start of each waveform in seconds), sequentially recording ECG-gated carotid 
and femoral waveforms using an applanation tonometer in triplicate, and the SphygmoCor 
system (AtCor Medical, Sydney, Australia). The transit time determines the time difference 
between the onset of the pulse wave between the carotid and femoral artery. 
In the RIISC cohort, the Vicorder system (Skidmore Medical, Bristol, UK) was used to 
measure aPWV by measuring simultaneous pressure waveforms by a volume displacement 
technique, using blood pressure cuffs placed around a patient’s neck (carotid artery) and top 
of their leg (femoral artery), in triplicate. The aortic path length between the carotid and 
femoral arteries were measured from the mid-clavicle (measured at the shoulder level to 
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avoid variation with patient anatomy (breast, abdomen etc)) to the mid-point of the thigh 
cuff. 
2.1.1.3.2 Outcome measure 
The primary aim was to evaluate the association between aPWV and with CAV1 SNP 
rs4730751 genotype. 
2.1.1.3.3 Statistical Analysis 
Data are presented as median (interquartile range [IQR]) unless stated otherwise. 
Continuously distributed data were compared using Student’s t-test, categorical data by 
means of χ2 testing and non-parametric data by Mann-Whitney U. A type 1 error rate less 
than 5% (p≤0.05) was considered statistically significant. Genotype distributions were 
assessed for concordance with Hardy-Weinberg equilibrium using a χ2 goodness-of-fit test 
with a type 1 error rate set at 5%. Hardy-Weinberg equilibrium is an efficient way to test that 
the expected frequency of a study population does not differ grossly from an expected 
frequency and detects potential error in genotyping or a skewed population of SNP genotype 
due to factors such as inbreeding (183). CAV1 gene variation at rs4730751 and other 
relevant clinical and demographic characteristics were initially examined in a series of 
univariate analyses. Known clinical variables that influence aPWV as well as genotype were 
included in multivariate analysis (i.e. no selection process was used to remove these 
variables). Based on previous data, the analysis investigated differences between patients 
demonstrating and not demonstrating CC genotype at the studied locus (i.e. CC versus non-
CC (82, 159)). A type 1 error rate of 5% (p≤0.05) was associated with statistical significance. 
SPSS software, version 21 (SPSS Inc., Chicago, Illinois) was used for analysis. 
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2.1.1.4 eNOS SNP in left ventricular function in CKD 
The “CRIB” patient cohort with the inclusion and exclusion criteria mention above 
underwent cardiac magnetic resonance imaging (CMR) and tissue doppler imaging (TDI) 
were included in this chapter. Baseline data and imaging data was collected prior to this 
project. Ethical approval, patient consent and whole blood collection for genotyping was 
performed by me. To limit the confounding effect of population stratification only patients 
of white (self-reported) ethnicity were included. 
The study was approved by East Midlands Nottingham 1 Research Ethics Committee and 
adhered to the Declaration of Helsinki. Study participants provided written informed 
consent. 
 
2.1.1.4.1 Cardiovascular Magnetic Resonance Imaging 
CMR was performed on a 1.5-T scanner (Sonata Symphony, Siemens, Erlangen, Germany). 
Serial contiguous short axis cines were piloted from the vertical long axis and horizontal long 
axis of the right and left ventricle (electrocardiogram gated, steady-state free precession 
imaging [True-Fisp]; temporal resolution 40-50ms, repetition time 3.2ms, echo time 1.6ms, 
flip angle 60°, slice thickness 7mm) in accordance with previously validated methodologies 
(184). Analysis was performed off-line (Argus Software, Siemens) by two blinded observers 
for the assessment of ventricular volumes (end-diastole, end-systole, stoke volume) and 
ejection fraction. Heart rate and baseline brachial arterial blood pressure were measured at 
the time of CMR. 
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2.1.1.4.2 Echocardiography 
Transthoracic echocardiography (Vivid 7; GE Vingmed Ultrasound, Horten, Norway) was 
performed by an experienced echocardiographer. All parameters were measured in 
triplicate according to American Society of Echocardiography recommendations (185) and 
analysed offline (EchoPAC; GE Vingmed Ultrasound, Horten, Norway) by two blinded 
observers. Resting left ventricular (LV) diastolic function was assessed using standard 
techniques (186).  
 
2.1.1.4.3 Arterial Stiffness and Distensibility 
Pulse wave velocity, augmentation index and ascending aortic distensibility were common 
measures of arterial stiffness and distensibility in the two randomised control trials, they 
have been included here. Pulse wave analysis was performed on the radial artery using a 
high-fidelity micromanometer (SPC-301; Miller Instruments, Houston, TX). The peripheral 
arterial waveform was used to generate a central arterial waveform using a validated 
transfer function (SphygmoCor; AtCor Medical, Sydney, Australia). The same system was 
used to determine aortic pulse wave velocity by sequentially recording ECG-gated carotid 
and femoral waveforms as previously described. CMR data was used for the ascending aortic 
distensibility measurement data. 
 
2.1.1.4.4 Outcome Measures 
The primary aim was to evaluate the association between LV ejection fraction (LVEF) with 
eNOS (G894T) SNP rs1799983 genotype. Secondary outcomes included: LV end-diastolic 
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volume indexed to body surface area (LVEDVI), LV end-systolic volume indexed to body 
surface area (LVESVI) and S’ lat (systolic velocity of the basal anterolateral LV wall). As there 
is much debate over which parameters of diastolic function should be measured as well as 
their variability in assessment (187), six diastolic parameters were assessed in a cluster 
analysis (see section 2.1.1.4.5) to separate the cohort into two risk categories of diastolic 
dysfunction; these were then assessed by eNOS genotype. The “diastolic” parameters 
included: e' lat (early diastolic velocity of the basal anterolateral LV wall on tissue doppler), 
E/e' lat (maximum velocity of the E-wave of mitral valve inflow by the maximal anterolateral 
LV wall velocity of e’), mitral valve E/A (ratio of early to late mitral inflow velocities), LVMI 
(left ventricular mass index), mitral valve propagation velocity (MV VP) and LAVI (left atrial 
volume index). 
 
2.1.1.4.5 Statistical Analysis 
Baseline demographics and cardiac investigations were compared across the genotype 
groups, using Kruskal-Wallis (continuous data) and Fisher’s Exact tests (categorical data) as 
appropriate. The relationship between these was then investigated using regression analysis. 
Initially, univariate linear regression models were produced, with variables being log-
transformed where there was evidence of a non-linearity. Multivariate regression models 
were used (including all factors simultaneously) in order to adjust for potentially 
confounding and clinically relevant factors. Genotype distributions were assessed for 
concordance with Hardy-Weinberg equilibrium using a χ2 goodness-of-fit test with a type 1 
error rate set at 5%.  
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A cluster analysis was then performed, to divide patients into groups based on the values of 
a range of diastolic parameters. The Two-Step cluster analysis in IBM SPSS 19 was used, with 
the number of clusters determined automatically (in this study, two main clusters). 
Demographic factors were then compared between the resulting clusters, using t -tests or 
Fisher’s Exact test, as applicable. All analyses were performed using IBM SPSS 19 (IBM Corp. 
Armonk, NY), with p≤0.05 deemed to be indicative of statistical significance. 
 
2.1.1.5 CAV1 in antineutrophil cytoplasmic antibody associated vasculitis 
Two independent cohorts were investigated as part of this study that had banked genomic 
DNA genotyped by Taqman assay for CAV1 SNP rs4730751. To limit the confounding effect 
of population stratification only patients of white (self-reported) ethnicity were included. 
Patients were diagnosed as antineutrophil cytoplasmic antibody (ANCA) associated vasculitis 
(AAV) according to the European Medicines Agency algorithm (clinical diagnosis of either 
granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA), supported by 
either a positive ANCA assay or a diagnostic biopsy, and the absence of an alternative 
explanation (25), after I reviewed patients’ data in the UK.  In the United Kingdom, patients 
with AAV presenting to the nephrology service at Queen Elizabeth Hospital Birmingham 
between 1979 and 2009, in who genomic DNA had also been isolated as part of the clinical 
research program at the centre, were included. The replication Northern European cohort 
included patients from the Vasculitis Centre Lübeck/Bad Bramstedt, Germany and the 
Maastricht University Medical Centre+, the Netherlands who presented with GPA or MPA 
between 1982 and 2009 to the rheumatology services of the respective centres.  
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ANCA testing was performed by indirect immunofluorescence (United Kingdom) and ELISA 
methods (Germany and the Netherlands) depending on how the data was collected 
historically. 
The study was performed in accordance with the principles expressed in the Declaration of 
Helsinki. Respective separate National Ethics Committee approval was sought from: South 
Birmingham Regional Ethics Committee 0723 by me, Ethics Committee of the University of 
Lübeck AZ-06-087 and the Maastricht Local Ethics Committee 05-158. Study participants 
provided written informed consent and the data were analysed anonymously. 
 
2.1.1.5.1 Outcome measures 
The primary outcome measure was a composite of time to all-cause mortality or time to 
renal replacement therapy (RRT – either dialysis or kidney transplantation beyond 3 months 
from initial presentation). Secondary outcomes included time to: all-cause mortality, RRT, 
death from infection, death from a vascular cause (ischaemic heart disease, heart failure, 
abdominal aortic aneurysm or cerebral vascular accident), and time to cancer development 
from AAV diagnosis. Cancer onset dates were not available from the replication cohort, only 
if cancer developed post diagnosis. Non-melanoma skin cancers were excluded. Data was 
retrieved from prospectively maintained institutional database, updated by me and 
corroborated by my requesting and reviewing death certificate records. The independent 
effect of CAV1 genotype was adjusted for: age at diagnosis, gender, type of ANCA, and 
serum creatinine level at presentation. 
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2.1.1.5.2 Statistical Analysis 
Data are shown as median (1st and 3rd quartiles) unless otherwise indicated. Group 
comparisons were assessed using Mann-Whitney U and χ2 testing as appropriate. 
Cumulative events were analysed with Kaplan-Meier estimates, with the log-rank test used 
for intergroup comparison. Time-to-event analyses were performed using a Cox proportional 
hazards model. Categorical outcome data was analysed by logistic regression. Genotype 
distributions were assessed for concordance with Hardy-Weinberg equilibrium using a χ2 
goodness-of-fit test with a type 1 error rate set at 5%. CAV1 gene variation at rs4730751 and 
other relevant clinical and demographic characteristics were initially examined in a series of 
univariate analyses. Known variables that influence AAV outcomes as well as genotype were 
included in multivariate analysis (i.e. no selection process was used to remove these 
variables). In addition, an interaction term “CAV1 genotype x diagnosis” was analysed to 
examine a differential effect of genotype depending on clinical diagnosis. A type 1 error rate 
of 5% (p≤0.05) was associated with statistical significance. SPSS software, version 18 (SPSS 
Inc., Chicago, Illinois) was used for analysis. 
 
2.1.1.6 New onset diabetes after transplantation – can genetics identify pathways 
to its development? 
From 2009 to 2012, live and deceased donor renal transplant recipients were prospectively 
followed-up over a 12 month period in a single-centre adult tertiary centre at Queen 
Elizabeth Hospital Birmingham, United Kingdom. To exclude pre-existing diabetes, patients 
underwent glucose testing (after a minimum of eight hours fasting) immediately prior to 
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transplantation and excluded if ≥6.1mmol/l or HbA1c ≥6.5% (48mmol/mol). In addition, live 
donor recipients underwent oral glucose tolerance testing (OGTT) with a standard 75g 
glucose load within a week prior to transplantation. Following transplantation, OGTTs were 
then performed at 7 days, and then 3 months and 12 months in all patients except those 
who developed clinically manifest hyperglycaemia requiring treatment. NODAT was 
diagnosed if a] fasting glucose ≥7mmol/l or 2-hour OGTT was ≥11.1mmol/l from day 7 
onwards and persisted at the 3 month time-point, b] HbA1c ≥6.5% (48mmol/mol) from 3 
months onwards, or c] requirement for institution of therapy for NODAT in which case OGTT 
was not undertaken (fasting clinic glucose was ≥7mmol/l in all such patients). Exclusion 
criteria of pre-transplant diabetes and the requirement for exclusion of non-white patients 
to avoid population stratification were essential in a genetic investigation such as this.  
All patients received an identical immunosuppression regimen consisting of anti- CD25 
monoclonal antibody induction followed by maintenance tacrolimus (target per-dose trough 
levels 5-8ng/ml by liquid chromatography with tandem mass spectrometry), mycophenolate 
mofetil (2g daily dose) and prednisolone (20mg/day initially weaning to 5mg/day by 3 
months, and then continued). Literature review to identify candidate gene variants was 
undertaken as described previously (73) with the inclusion of CAV1 SNP rs4730751. 
Genotyping were performed using Sequenom iPLEX technology. The study received approval 
from the local research ethics committee (NRES West Midlands Black Country 
08/H1204/103) prior to commencement, and was conducted in accordance with the 
Declarations of Helsinki and Istanbul with patient written consent. 
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2.1.1.6.1 Outcome measure 
SNP genotype association with development of NODAT was the primary outcome. 
 
2.1.1.6.2 Statistical Analysis 
Data are shown as median (1st and 3rd quartiles) if not normally distributed or mean 
(±standard deviation) if normally distributed.  Baseline demographics were assessed using 
Mann-Whitney U (non-parametric data) or Student’s t test if normally distributed for 
continuous data, and Fisher’s exact testing for categorical data as appropriate using  SPSS 
software, version 20 (SPSS Inc., Chicago, Illinois) for analysis. Genotype distributions were 
assessed for concordance with Hardy-Weinberg equilibrium using a χ2 goodness-of-fit test 
with a type 1 error rate set at 5% analysed using PLINK (188). Genotype to phenotype 
associations and event analyses were conducted using logistic regression with the 
development of NODAT at any time during the first 12 months post-transplantation as the 
end measure of interest (time to event analysis was not undertaken due to only 2 post-
transplant time-points). Univariate genotype:phenotype relationships and then the 
relationship in a multivariate model fully adjusted for age, sex, baseline body mass index 
(BMI) and change in BMI over 12 months from transplantation (no selection process) were 
calculated using PLINK. 
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2.1.2 Materials and Methods for Murine Studies 
The following was performed by me. Mice were commercially bought with their genetic 
alterations. 
 
2.1.2.1 Mice 
The Cav1-/- (CKO) mouse (JAX, the Jackson Laboratory, United States) was created by Michael 
Lisanti by replacement of a 2.2 kb region of the caveolin-1 gene including exons 1 and 2 and 
part of the promoter region, with a neo resistance cassette via homologous recombination, 
named Cav1tm1Mls. This mouse was originally crossed on C57BL/6J (C57 Black6 substrain J) 
mice for five generations, but was later noted this backcross had a diminished reproductive 
performance. Therefore, it was backcrossed on to the 129S6/SvEv background for one 
generation to improve reproductivity. The mice bought from JAX via Charles River (UK), are 
primarily a mix of 129 and C57BL/6 with a minor contribution from the originating mutant 
embryonic stem cell linage of the Swiss Jim Lambert (SJL). The control caveolin-1 wild-type 
strain for CKO mouse experiments was therefore based on the same strain as the CKO, due 
to known differing propensities to develop renal fibrosis between mouse strains. These were 
also brought from JAX via Charles River. Both wild-type and CKO were inbred at purchase, 
with a colony established at the Biomedical Sciences Unit. For all experiments, males were 
used only at age 6-8 weeks. Mice were maintained in 12 hour light/12 hour dark cycles with 
free access to food and water. 
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2.1.2.2 Genotyping of mice 
Genomic DNA was isolated from newborn mice ear clippings. DNA was then extracted using 
the DNAeasy Tissue Kit (Qiagen) using the manufacturer’s instructions with DNA 
concentration and DNA wavelengths analysed using Nanodrop 2000 (ThermoScientific, 
Figure 2-3). Mice were then genotyped for caveolin-1 wild-type (WT) or knockout (KO) using 
primers (AltaBioscience, Table 2-1) and protocols as stated on the JAX website. The mix used 
for polymerase chain reactions (PCR) is shown in Table 2-2. The programme used for PCR is 
shown in Table 2-3. Samples were run on a 1.5% agarose gel (0.75g agarose, 50ml x1 TBE 
buffer) with 5µl of GelRed (Biotium) x10000 stock, ran at 85 volts and visualised using the 
ChemiDoc (Biorad). Caveolin-1 wild-type band is noted at 690bp, knockout band at 410bp 
and heterozygote double band at 410bp and 690bp (Figure 2-4). 
 
Table 2-1 Primers used for mouse genotyping for caveolin-1 
 
Primer Sequence 5' --> 3' Primer Type 
oIMR1972 GTG TAT GAC GCG CAC ACC AAG  Wild type 
oIMR1973 CTA GTG AGA CGT GCT ACT TCC  Mutant 
oIMR1974 CTT GAG TTC TGT TAG CCC AG Common 
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Table 2-2 Polymerase chain reaction mix 
 
 
Volume (µl) 
ddH20 3.2 
oIMR1972 20µM 0.6 
oIMR1973 20µM 0.6 
oIMR1974 20µM 0.6 
DNA 1 
REDtaq ReadyMix (Sigma R2523) 6 
  Total volume 12 
 
 
Table 2-3 Techne TC Plus thermocycler programme for polymerase chain reaction 
 
Step # Temp °C Time Note 
1 105 ‘Prelid’  
2 94 3 mins Stage 1, x1 cycle 
3 94 30 seconds Stage 2 
4 65 1 min Stage 2 
5 72 1 min Stage 2 
   Repeat stage 2 (steps 3-5) for 35 cycles 
6 72 2 min Stage 3, x1 cycle 
7 10  hold 
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Figure 2-3 Example of DNA concentrations and wavelengths using Nanodrop 2000 
(ThermoScientific) 
 
 
Figure 2-4 Genotyping fragment sizes shown far right, with caveolin-1 wild-type 690bp, knockout 
410bp, and ladder fragment sizes shown far left. Negative control in the far right non-ladder lane 
 
 
 
 
 
690bp 
410bp 
1000bp 
500bp 
Ladder 
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2.1.2.3 Small animal models of renal fibrosis 
Two small murine models of renal fibrosis previously described in the literature, were 
performed at University of Birmingham. A successful application was made to the United 
Kingdom Home Office for a personal licence for murine experiments to be carried out at the 
Biomedical Sciences Unit at the University of Birmingham (PIL 30/9343, replaced by 
electronic PIL IB5C52417, project licence 40/3352). 
 
2.1.2.3.1 Ciclosporin-A nephrotoxicity pilot model (189) 
A pilot model was performed as this model of patchy interstitial renal fibrosis (as seen in 
human prolonged use in renal transplants) had not been performed in Birmingham before. 
C57/BL6 male mice from Charles River, aged 6-8 weeks, weight 20-24g were given a low 
<0.025% salt diet (Special Diet Services, UK) for a week prior to either daily ciclosporin-A 
(CsA) or control vehicle subcutaneous injections for 28 days. At the end of the model, mice 
were placed in metabolic cages for 24 hours for urinary collection, prior to cardiac puncture 
for whole blood under general anaesthesia. After cervical dislocation to induce death, their 
kidneys were harvested.  
CsA powder was kindly donated by Novartis. As per their protocol for animal subcutaneous 
injections, a CsA (Sandimmun) microemulsion is required by stirring 50mg of CsA powder in 
a mixture of Cremophor EL (Sigma C5135) – a polyethoxylated castor oil – made to a volume 
of 1ml with 94% ethanol. This microemulsion was too thick to draw up into a 1ml syringe 
which was required for subcutaneous (s/c) injection, thus was further diluted adding 2/3rds 
94% ethanol to 1/3rd Cremophor EL. In total 200mg CsA powder dissolved overnight in 
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8.9mls Cremophor EL and 17.7mls 94% ethanol (final concentration 7.5mg/ml) with 30mg/Kg 
being injected daily and 4mls/Kg daily of vehicle in control mice after aliquoting 30mls of 
vehicle (9.75mls Cremophor EL and 20.25mls 94% ethanol). The microemulsion was 
protected from light. 
 
2.1.2.3.2 Unilateral ureteric model of obstruction 
Kidneys were harvested at day 3 and day 14 after unilateral ureteric obstruction (UUO). 
Using inhalational anaesthesia (4% Isofluorane, 3L/min oxygen), mice underwent a midline 
laparotomy at day 0 with a heating mat underneath after receiving 0.05mg/Kg Temgesic 
(opiate based analgesia) subcutaneously. Their bowel was lifted and covered with sterile 
saline soaked gauze to prevent dehydration.  The left ureter was identified and ligated using 
two 5.0 non-absorbable sutures. After bowel replacement using cotton buds, the midline 
peritoneal membrane incision was closed using absorbable 5.0 sutures, and the abdomen 
with clips (Figure 2-5). The mouse was then placed in a warming box to recover for 24 hours. 
Sham-operated mice underwent the same procedure, except the left ureter was mobilised 
instead of ligated. 
Before kidneys were harvested after cervical dislocation, mice were placed for a 24 hour 
urine collection in metabolic cages (for protein estimation). The following day via cardiac 
puncture under inhalational anaesthesia, blood sampling was performed for urea and 
creatinine. 
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Figure 2-5 Representative images of unilateral ureteric obstruction model. A) abdomen shaved and 
cleaned with chlorhexidine. B) Midline laparotomy and retractors. C) Bowel displaced on to saline 
soaked gauze. D) Left ureter identified. E) Ureter ligated. F) Clips applied to close abdomen 
 
 
2.1.2.4 Kidney harvesting and sectioning 
Mice were weighed pre models of fibrosis and prior to blood sampling and cervical 
dislocation, weighed again. Kidneys were then removed and the kidney capsule removed. 
The kidneys were weighed using the same scales, then cut in half to reveal the coronal 
section of the kidney (Figure 1-3) with a scalpel and blotted to remove any remaining blood. 
There are wide variations in collagen content depending on the area of kidney investigated, 
thus areas of pre injury high collagen concentrations (renal capsule and renal pelvis) were 
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removed (190). Also, the same pole was used for analysis in all subsequent experiments via 
quarters of kidney sectioned as shown in Figure 2-6 (cutting the coronal section in half 
again). 
Figure 2-6 Sectioning of kidneys. The left upper quarter was used for polymerase chain reactions 
(PCR), lower left quarter for Western blotting (WB), upper right quarter for confocal microscopy 
and the lower right quarter for histology. The ‘hashed’ area representing the renal pelvis, was 
removed before sectioning into quarters 
 
 
 
2.1.2.5 Blood sampling 
A 1ml syringe was used to collect whole blood after cardiac puncture under inhalational 
anaesthesia prior to cervical dislocation. The blood was mixed with 75µl of EDTA 0.02% 
solution (Sigma), in a sterile 1.5ml eppendorf and kept on ice for 1 hour prior to being frozen 
at -20°C and sent to MRC Harwell (Oxford) for analysis. 
 
2.1.2.6 Real time quantitative polymerase chain reaction 
The left upper quarters of sectioned kidney were weighed prior to be being snap frozen in a 
cryovial in liquid nitrogen and kept frozen at -80°C until analysis. The whole quarter was 
homogenised using the gentleMac dissociator and M tubes (Miltenyi Biotec) and an 
PCR 
WB Histology 
Confocal 
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equivalent volume to a maximum of 30mg of tissue homogenised (to avoid overloading the 
spin columns) in RLT lysis buffer was used to  extract RNA using the RNEasy Mini Kit (Qiagen) 
using the manufacturer’s instructions.  RNA was analysed for concentration and A260/A280 
quality using the Nanodrop 2000 (ThermoScientific). RNA was then diluted with RNAse free 
water so that 1µg was used in each reverse transcription reaction to cDNA using the Taqman 
Reverse Transcription (Applied Biosystems). The mix and programme used for RNA to cDNA 
is shown in Table 2-4 and Table 2-5 respectively. 
Table 2-4 Reverse Transcription Mix 
 
 
Volume (µl) 
X10 reverse transcription buffer 5 
Magnesium Chloride 25mM 11 
dNTPs mix 10mM 10 
Random hexamers 2.5 
RNAse inhibitor (20u/µl) 1 
Multiscribe ReverseTranscriptase 
(50u/µl) 1.25 
RNA 15 
Total volume 45.75 
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Table 2-5 Reverse transcription thermocycler programme 
 
Step # Temp °C Time Note 
1 105 ‘Prelid’  
2 94 5 mins Initial denaturisation 
3 25 10 mins Stage 1 
4 37 1 hour Stage 2 
5 48 30 mins Stage 3 
6 95 5 mins Stage 4 
7 10  hold 
 
 
cDNA concentration and wavelength quality was again analysed using the Nanodrop 2000 
(ThermoScientific). Quantitative PCR was performed on 384 well plates, single plex, using the 
following Taqman Gene Expression assays TGFβ-1 (Mm01178820_M1 FAM-MGB), collagen 
1α1 (Mm00801666_M1 FAM-MGB), collagen 3α1 (Mm01254476_M1 FAM-MGB), caveolin-1 
(Mm00483057_M1 FAM-MGB) and GAPDH (Mm99999915_g1 VIC-MGB) was used as a 
housekeeping gene. Assays were run using the Lightcycler 480 II (Roche) using the mix and 
programme shown in Table 2-6 and Table 2-7.  The cycle number (Ct) for the target gene was 
subtracted from the Ct for the control gene (ΔCt). This was then normalised to a calibration 
of the control sample mean of the ΔCt. Sham operated mice was used as control. The 
relative quantity was calculated as 2-ΔΔCt (delta-delta method). This relative quantity is 
known as the mRNA fold induction relative to control. Fold increase ratios were then 
expressed to demonstrate fold changes between groups. 
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Table 2-6 Quantitative polymerase chain reaction mix 
 
 
Volume (µl) 
Taqman Gene Assay x20 1 
Mastermix x2 10 
DNAse free water 7 
cDNA (20ng/µl) 2 
  Total volume 20 
 
 
Table 2-7 Lightcycler programme 
 
Step Temp °C Time Note 
Pre-incubation 95 10 mins x1 cycle 
Amplification a) 95 15 seconds a) b) c) for 45 cycles 
b) 60 1 min  
c) 72 1 second  
Cooling 40 30 seconds x1 cycle 
Melting Curve 20 10 minutes x1 cycle 
Hold 10   
 
 
 
2.1.2.7 Western Blotting for Caveolin-1 
2.1.2.7.1 Tissue lysate preparation 
Tissue lysates were prepared using the gentleMACs M tubes for homogenisation from the 
left lower quarters of sectioned kidneys. The tissue had been placed in cryovials and snap 
frozen in liquid nitrogen before being stored at -80°C. Each frozen tissue sample was placed 
in 890µl sterile phosphate buffered saline (PBS), 100µl of 10x RIPA lysis buffer (Sigma-
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Aldrich) and 10µl of protease cocktail inhibitor (Calbiochem) prior to homogenisation. The 
lysate protein concentration was then assayed using Pierce BCA protein assay 
(ThermoScientific). The equivalent volume of 300µg protein concentration was then placed 
in a new eppendorf. An equal volume of cold 20% trichloroacetic acid (TCA) was added, left 
on ice for 30 minutes and then centrifuged for 5 minutes at 4°C at 15000rpm with the 
resultant supernatant discarded. 500µl of cold acetone was added to the pellet, vortexed 
quickly and left on ice for 5 minutes before centrifuging for 5 mins at 4°C at 15000rpm with 
the resultant supernatant discarded; this process was repeated. The eppendorf was placed 
in a heat block at 100 with the lid open, to drive off the remaining acetone. 60µl of x2 
sodium dodecyl sulphate (SDS) sample buffer (4% SDS (Geneflow, UK); 0.1M dithiothreitol 
(Sigma-Aldrich); 20% glycol (BDH Limited, UK); 0.0625M Tris-HCL (pH 6.8); 0.004% 
bromophenol blue (Sigma-Aldrich)) was added and boiled for 5 minutes at 100°C. 
2.1.2.7.2 SDS-polyacrylamide gel electrophoresis and Western blotting 
Eppendorfs were spun for a few seconds so any debris was confined to the bottom. 20µl of 
equal protein concentration of lysates were then loaded onto a 12% SDS-polyacrylamide gel 
(see Table 2-8) and run for 1.5 hours at 100 volts with pre-stained markers (BioRad). Proteins 
were then wet transferred on to methanol-activated 0.2µm polyvinylidene difluoride 
membranes (Biorad). Following blotting, membranes were washed quickly with Tris buffered 
saline (TBS) containing 0.1% tween-20 (Sigma-Aldrich) (TBS-T), then incubated with 5% 
bovine serum albumin (BSA)/TBS-T at room temperature for a minimum of an hour. 
Overnight at 4°C, blots were probed with anti-mouse caveolin-1 antibody (Santa-Cruz 
Biotechnology), 1:500 dilution in 5% BSA/TBS-T on an orbital shaker. The antibody was then 
poured off and frozen for further use, and the membrane was washed 4 times with TBS-T 
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over an hour. The blot was then probed with an anti-rabbit HRP secondary antibody (Dako), 
1:5000 dilution in 5% BSA/TBS-T for 1 hour at room temperature. After 4 washes with TBS-T 
over 1 hour, proteins were visualised with enhanced chemiluminescence prime (Amersham 
Pharmacia Biotech) and proteins imaged using the Chemidoc (Biorad). After 4 washes with 
TBS-T the blot was probed with anti-mouse β-actin antibody (Sigma-Aldrich), 1:5000 dilution 
in 5% BSA/TBS-T for 1 hour at room temperature as a control; the same process of washes 
and secondary anti-rabbit HRP antibody incubation, enhanced chemiluminescene prime 
visualisation and imaging was performed to confirm equal protein loading. 
Table 2-8 SDS Gel recipes 
12% Resolving Gels    5% Stacking Gels 
 
Protogel (Geneflow EC-890) 4mL      1.3mL 
dH2O    3.5mL      6.1mL 
Tris HCl 1.5M pH 8.8 2.5 mL    0.5M pH 6.8 2.5mL 
20% SDS (Geneflow EC-874) 50µL      50µL 
10% APS   100µL      100µL 
Temed (Geneflow EC-503)  10µL      10µL 
Abbreviations: APS, ammonium persulfate; SDS, sodium dodecyl sulphate 
 
2.1.2.8 Confocal microscopy 
The right upper quarter kidney (Figure 2-6) was placed in 4% paraformaldehyde (PFA) for 2 
hours, and then kept in 18% sucrose overnight at 4°C. The tissue was then embedded in a 
cryomold (Tissue-Tek) containing optimum cutting temperature compound (OCT) and froze 
using the vapour of liquid nitrogen. 6µm sections were prepared using a cryostat and fixed 
by immersion in cold acetone for 20 minutes at 4°C, and allowed to air dry for 30 minutes. 
The slides were frozen at -80°C and allowed to equilibrate to room temperature prior to PBS 
washing for 5 minutes with gentle agitation. Primary and secondary fluorescent antibody 
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concentrations are shown in Table 2-9 and Table 2-10 respectively. Primary and secondary 
antibodies were diluted in PBS containing 1% BSA, 2% foetal calf serum. Primary antibodies 
were incubated overnight at 4°C, and then the antibody was tapped off and washed in PBS 
three 5 minute intervals with gentle agitation. The secondary antibody was added next for 1 
hour at room temperature before PBS x3 5minute washes. Nuclei staining was performed 
with DAPI (4',6-diamidino-2-Phenylindole, dihydrochloride from Invitrogen). The slide was 
then fixed in 1% PFA for 5 minutes at room temperature, washed x2 for 5 minutes in PBS, 
before a drop of VectaShield mounting medium (Vector Laboratories) was applied and a 
coverslip was mounted and clear nail vanish applied on the outer edges of the coverslip. The 
slide was then stored in the dark at -20°C until visualisation using the Zeiss confocal LSM 510 
microscope and processed using the LSM Image Examiner software (Zeiss, Germany). Images 
are presented with respect to the objective used of the microscope (x10, x40 or x63). 
Table 2-9 Primary anti-mouse antibodies for confocal microscopy (IF: immunofluorescence) and 
Western blotting (WB) 
 
Specificity Isotype Clone Supplier Working 
dilution 
Caveolin-1 (N20) polyclonal rabbit polyclonal Santa-Cruz WB 1:500 
IF 1:100 
SMA mouse IgG2a 1A4 Sigma 1:100 
CD31 rat IgG2a kappa 390 ebioscience 1:1000 
Synaptopodin mouse IgG1 G1D4 Progen neat 
E-cadherin rat IgG1 DECMA-1 ebioscience 1:100 
CD45 rat IgG2b  30-F11 ebioscience 1:100 
F4/80 rat IgG2a kappa BM8 ebioscience 1:100 
CD3 rat IgG2b kappa 17A2 ebioscience 1:100 
β-actin rabbit IgG 13E5 Cell signaling WB 1:1000 
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Table 2-10 Secondary antibodies for confocal microscopy and Western blotting 
 
Specificity Conjugate Host Supplier Working 
dilution 
Anti-rabbit IgG Alexa 488 goat Invitrogen 1:1000 
Anti-mouse IgG2a Alexa 568 goat Invitrogen 1:2000 
Anti-mouse IgG1 Alexa 680 goat Invitrogen 1:200 
Anti-rat IgG Cy5 goat Invitrogen 1:2000 
Anti-rabbit IgG Cy5 goat Invitrogen 1:1000 
Anti-rabbit IgG HRP goat Dako WB 1:5000 
 
 
2.1.2.9 Histology staining 
 
Sections were obtained as described above in ‘2.1.2.8 Confocal microscopy’ but from the 
right lower kidney quadrant. The Queen Elizabeth Hospital Birmingham pathology 
department kindly stained the frozen sections using haematoxylin and eosin and for collagen 
using Gomori trichrome staining. I then imaged the sections digitally using the Nikon Eclipse 
E400 microscope and NIS Elements Version 3.0 (Nikon). The kidney images were then 
analysed for percentage Gomori staining for collagen (as a surrogate for fibrosis scoring) in a 
blinded fashion by myself and a renal histopathologist, via a 5x3 grid-grid method. 
 
2.1.2.10 Statistical Analysis 
Results are presented as mean ± standard error of the mean (SEM). Statistical mean 
difference was assessed by a two-tail Student’s t test if normally distributed, otherwise 
Mann-Whitney U testing was used. One-way ANOVA was used to compare the difference 
between three groups and post-hoc analysis with Dunnett’s multiple comparison test. 
Analysis and graphical data were prepared by either GraphPad Prism 5 software or SPSS 
software, version 21 (SPSS Inc., Chicago, Illinois). 
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3.1 Genetic variation in cardiovascular disease in CKD 
3.1.1 CAV1 in aortic pulse wave velocity 
This section is based on my first author publication (191). 
3.1.1.1 Introduction 
Cardiovascular disease (CVD) is the leading cause of mortality in patients with CKD and is 
driven by two main pathological processes, atherosclerosis and arteriosclerosis. Traditional 
“atheromatous inducing” risk factors such as smoking and obesity do not fully account for 
this excess CVD risk (161). This is despite the increased presence of traditional cardiovascular 
risk factors such as diabetes mellitus, hypertension, and dyslipidaemia in CKD populations. 
Non-traditional risk factors include advancing renal dysfunction, proteinuria, 
homocysteinaemia and uraemic toxins (192). However, arteriosclerosis is a prominent 
component of the non-traditional risk for increased CVD mortality that arises from multiple 
factors. For example, there are alterations in the renin-angiotensin-aldosterone system in 
CKD, resulting in higher angiotensin II and thus, endothelial dysfunction from its stimulation 
of vascular smooth muscle cells that increase inflammation by these cells generation of 
intracellular superoxides, inflammatory cytokines and increased production collagen and 
matrix metalloproteinases (193, 194). Arteriosclerosis results in arterial stiffness due to 
medial arterial layer hypertrophy and fibrosis (195). This is exacerbated by altered calcium 
and phosphate handling (known as CKD-mineral bone disease), leading to increased vascular 
calcification and therefore, arterial stiffness. The normal aorta is elastic and acts as a 
reservoir to buffer the oscillatory changes in blood pressure during a cardiac cycle, by 
expanding in systole and recoiling in diastole. This process allows adequate coronary 
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perfusion that predominately occurs during diastole, as well as offering a dampened aortic 
pressure waveform and thus steady pressure flow to organs such as the kidney. However, 
with increased arterial stiffness, there is loss of this buffering resulting in greater fluctuations 
of systolic pressures, pulse pressures and greater shear stress. This leads to renal 
microvasculature damage and myocardial hypertrophy, fibrosis and reduced coronary 
perfusion due to reduced diastolic pressures. 
Aortic pulse wave velocity (aPWV) is the gold standard method for measuring arterial 
stiffness and has been consistently associated with all-cause and cardiovascular mortality in 
multiple conditions including CKD (169, 196). The purpose of this chapter was to assess the 
association of CAV1 rs4730751 SNP with arterial stiffness as measured by aPWV in an early 
CKD stage non-dialysis cohort (CRIB) and corroborate this relationship in an advanced CKD 
stage non-dialysis cohort (RIISC). 
 
3.1.1.2 Results 
Baseline data for the cohorts are shown in Table 3-1. In the Chronic Renal Impairment in 
Birmingham (“CRIB”) cohort, 235 patients were screened, with 24 patients excluded due to 
non-white ethnicity. 152 patients had consented for DNA to be collected and 144 of 152 
(>95%) tested patients were successfully genotyped. The median age was 57 years [IQR: 47-
65], estimated glomerular filtration rate (eGFR) 51 mls/min/1.73m2 [IQR: 41-58] and aPWV 
8.4 m/s ([IQR: 7.3-9.9]. Patient genotypes were 74 CC (51.4%), 64 AC (44.4%) and 6 AA 
(4.2%), which was within Hardy-Weinberg equilibrium (p>0.05). Patients with CC genotype 
demonstrated lower aPWV (8.1 m/s; IQR: 7.0-9.4) than patients with non-CC genotype 
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(aPWV 8.6 m/s; IQR: 7.5-10.8) (p=0.003). Patients with non-CC genotype were significantly 
older (p=0.02). In multivariate regression analysis, adjusted for age, gender, eGFR and mean 
arterial pressure (Table 3-2), CC was associated with a lower aPWV (coefficient -0.621 [-
1.218 to -0.24]; p=0.042; adjusted R squared 0.325). 
In the Renal Impairment in Secondary Care (RIISC) cohort, 639 patients were screened of 
which 202 met inclusion and exclusion criteria. 153 patients had consented for DNA to be 
collected and 147 of 153 tested patients were successfully genotyped (>96%). The median 
age was 58 years [IQR: 47-69], with eGFR 28 mls/min/1.73m2 [IQR: 21-37] and aPWV 8.8 
m/s [IQR: 8.0-10.3]. Patient genotypes were 92 CC (63%), 49 AC (33%) and 6 AA (4%), which 
was within Hardy-Weinberg equilibrium (p>0.05). As seen in the CRIB cohort, patients with 
CC genotype in the RIISC cohort demonstrated lower aPWV (8.7 m/s; IQR: 7.9-9.8) compared 
with 9.4 m/s (IQR: 8.0-10.8) (p=0.021) in patients with a non-CC genotype. In multivariate 
regression analysis, adjusted for age, gender, eGFR and mean arterial pressure (Table 3-2), 
CC was also associated with a lower aPWV (coefficient -0.984 [-1.523 to -0.445]; p<0.001; 
adjusted R squared 0.433). 
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Table 3-1 Baseline demographic and measurement data for the CRIB and RIISC cohorts by genotype 
 
p* (p value comparing CC and non CC genotype in CRIB); p** (p value comparing CC and non-CC genotype in RIISC); p*** (p value comparing across all patients in CRIB 
versus RIISC cohorts). p value by Student’s t-test for continuous variables and χ
2
for categorical variables unless stated. 
1
variables p value tested by Mann-Whitney U. 
 
 
 
  CRIB   RIISC   
Characteristic CC genotype Non-CC genotype p* value CC genotype Non-CC genotype p** value P*** value 
Number of patients (%) 74 (51) 70 (49)  92 (63) 55 (37)  0.05 
Age (years) 54 (45-63) 61 (49-67) 0.02 58 (49-69) 57 (39-70) 0.368 0.5 
Male (%) 41 (55) 38 (54) 0.9 49 (53) 36 (66) 0.147 0.6 
Current Smoker (%) 9 (12) 11 (16) 0.5 19 (21) 8 (15) 0.355 0.3 
Previous Smoker (%) 28 (38) 26 (37) 0.9 35 (38) 24 (44) 0.503 0.6 
        
Diagnoses        
Glomerular diseases (%) 44 (59) 28 (40) 0.02 25 (27) 14 (25) 0.819 <0.001 
Systemic Diseases (%) 11 (12) 13 (19) 0.6 11 (12) 8 (15) 0.651 0.2 
Tubulointerstitial diseases (%) 5 (7) 7 (10) 0.5 13 (14) 8 (15) 0.945 0.1 
Familial nephropathies (%) 10 (14) 8 (11) 0.7 17 (18) 5 (9) 0.123 0.5 
Miscellaneous (%) 6 (8) 14 (20) 0.04 26 (28) 20 (36) 0.305 <0.001 
 
Medication frequency 
       
Angiotensin conversion enzyme inhibitors (%) 52 (70) 39 (56) 0.07 35 (38) 14 (26) 0.117 <0.001 
Angiotensin II receptor blockers (%) 17 (23) 22 (31) 0.3 27 (29) 19 (35) 0.511 0.4 
β blockers (%) 10 (14) 16 (23) 0.1 28 (30) 12 (22) 0.256 0.06 
Calcium channel blockers (%) 16 (22) 19 (27) 0.4 42 (46) 21 (38) 0.376 0.001 
Alpha blockers (%) 9 (12) 7 (10) 0.7 15 (16) 14 (26) 0.177 0.04 
Diuretics (%) 24 (32) 19 (27) 0.5 28 (30) 19 (35) 0.605 0.7 
Statins (%) 31 (44) 32 (43) 0.9 45 (49) 24 (44) 0.535 0.6 
Active vitamin D (%) 6 (8) 6 (9) 0.9 26 (28) 17 (31) 0.733 <0.001 
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Measurement Data 
 
       
Body surface area (m
2
) 1.9 (1.8-2.1) 1.9 (1.8-2.0) 0.5 1.9 (1.7-2.1) 2.0 (1.8-2.1) 0.424 0.8 
Body mass index (Kg/m
2
) 27.9 (24.1-29.9) 27.6 (24.6-32.0) 0.6 27.9 (24.1-32.7) 28.2 (24.1-31.6) 0.687 0.4 
Mean arterial pressure (mmHg) 92 (85-98) 93 (85-102) 0.4 104 (97-114) 102 (97-112) 0.487 <0.001 
Systolic blood pressure (mmHg) 124 (115-135) 129 (119-143) 0.2 124 (114-136) 122 (113-137) 0.994 0.4 
Diastolic Blood Pressure (mmHg) 73 (68-80) 73 (66-82) 0.9 79 (71-86) 78 (74-84) 0.485 <0.001 
Haemoglobin (g/dl) 13.3 (12.5-14.3) 13.6 (12.5-14.3) 0.7 12.8 (11.5-14.0) 13.3 (12.2-14.0) 0.077 0.04 
Estimated glomerular filtration rate 
(mls/min/1.73m
2
) 
53 (40-59) 50 (42-57) 0.9 27 (20-37) 28 (21-38) 0.153 <0.001 
Albumin:creatinine (mg/mmol)
1 
5.1 (1-50) 12 (1-37) 0.7 28 (7-111) 18 (7-111) 0.702 <0.001 
High sensitive C-reactive protein (mg/l)
1
 1.4 (0.7-4.8) 2.1 (0.7-6.4) 0.4 2.3 (0.8-4.9) 2.1 (1.4-4.4) 0.431 0.3 
Fasting glucose (mmol/l) 4.9 (4.4-5.2) 4.9 (4.4-5.3) 0.995 4.9 (4.6-5.4) 4.9 (4.4-5.2) 0.678 0.3 
Total cholesterol (mmol/l) 4.8 (4.4-5.5) 4.6 (4.0-5.1) 0.024 4.9 (4.0-6.0) 4.8 (4.2-5.6) 0.604 0.07 
HDL cholesterol 
(mmol/l) 
1.47 (1.15-1.96) 1.33 (1.10-1.80) 0.244 1.31 (1.10-1.54) 1.35 (1.10-1.50) 0.470 0.01 
Triglycerides 
(mmol/l)
1
 
0.97 (0.68-1.75) 1.18 (0.85-1.87) 0.180 1.65 (1.01-2.55) 1.40 (1.10-2.19) 0.559 0.001 
Serum phosphate (mmol/l) 1.1 (0.9-1.2) 1.1 (1.0-1.2) 0.744 1.2 (1.0-1.3) 1.1 (0.9-1.2) 0.122 0.4 
Aortic pulse wave velocity (m/s) 8.1 (7.0-9.4) 8.6 (7.5-10.8) 0.003 8.7 (7.9-9.8) 9.4 (8.0-10.8) 0.021 0.07 
   
     
 
p* (p value comparing CC and non CC genotype in CRIB); p** (p value comparing CC and non-CC genotype in RIISC); p*** (p value comparing across all patients in CRIB 
versus RIISC cohorts). p value by Student’s t-test for continuous variables and χ
2
for categorical variables unless stated. 
1
variables p value tested by Mann-Whitney U. 
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Table 3-2 Multivariate analysis of aortic pulse wave velocity adjusted for age, gender, estimated 
glomerular filtration rate (eGFR) and mean arterial pressure (MAP) in the Chronic Renal 
Impairment in Birmingham and Renal Impairment in Secondary Care cohorts 
 
Variable Coefficient (95% Confidence 
Interval) 
p value 
Chronic Renal Impairment in Birmingham     
Age  0.094 (0.068, 0.119) <0.001  
Gender (Female) 0.452 (-0.161, 1.065) 0.1  
eGFR (mls/min/1.73m2) -0.014 (-0.036, 0.008) 0.2  
MAP (mmHg) -0.005 (-0.030, 0.021) 0.7  
Genotype (CC) -0.621 (-1.218, -0.024) 0.04  
  Renal Impairment In Secondary Care    
  Age 0.087 (0.067, 0.106) <0.001  
  Gender (Female) 0.116 (-0.423, 0.654) 0.7  
  eGFR (mls/min/1.73m2) 0.015 (-0.004, 0.034) 0.1  
  MAP (mmHg) 0.040 (0.019, 0.061) <0.001  
  Genotype (CC) -0.984 (-1.523, -0.445) <0.001  
 
 
 
3.1.1.3 Discussion 
Independent of other key risk factors, I found that CAV1 rs4730751 CC genotype is 
associated with lower arterial stiffness in patients with early and late stage non-dialysis CKD. 
Whilst CKD is major risk factor for CVD, the pathological basis for this relationship is 
uncertain, with inclusion of non-traditional risk factors as mentioned earlier that could 
include a genetic influence as shown in this study. Importantly, as CKD becomes more 
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advanced the dominant vascular lesion is arteriosclerosis and associated vascular stiffness, 
rather than atheromatous disease as seen in the general population (161). 
The robustness of this finding is strengthened by the investigation of two independent 
cohorts, with similar effect sizes seen in each cohort, and also the investigation of patients of 
white ethnicity to limit population stratification. The exclusion of patients of non-white 
ethnicity, and also those with previous myocardial infarction, peripheral vascular disease and 
diabetes mellitus (due to these exclusion criteria in the CRIB trials from which the first cohort 
were derived) may limit generalisability of the results. However, the differences in the 
severity of CKD between the 2 studied cohorts, and the use of different methods of aPWV 
measurement between cohorts, serve to increase potential generalizability of the results. 
aPWV was measured using the SphygmoCor system in CRIB and the Vicorder system in RIISC. 
Whilst the former has been used as a reference standard when comparing other aPWV 
measurement methodologies, the latter has the advantage of requiring less training to use 
and is less intrusive (197).  The Vicorder system has been shown to underestimate aPWV at 
higher values measured by the SphygmoCor system mainly due to measured transit times, 
however when directly compared, the systems are considered highly correlated (slope=0.64, 
r=0.85, p<0.001) in their aPWV recordings (197). This underestimation occurred with aPWV 
measures over 10m/s, yet the average aPWV for CRIB RCTs was 8.4 m/s and RIISC 8.8 m/s 
respectively, thus was unlikely to have had a significant bearing on the study findings. 
Despite the differing systems used, the investigated CAV1 polymorphism remained 
significantly associated with aPWV in multivariate analysis in both cohorts, with the potential 
of aPWV underestimation by the Vicorder system in RIISC with the cohort having more 
advanced CKD. 
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This study would be strengthened by longitudinal data on the CVD outcomes in the cohorts. 
It should also be noted no formal assessment of ischaemia was made with non-invasive 
(stress echocardiogram) or invasive investigations (coronary angiography) so its influence 
cannot be excluded. Data related to erythropoietin and intravenous iron use was not fully 
collected for both cohorts (no use of erythropoietin in “CRIB”) and thus I am unable to 
exclude if these therapies may have confounded the results. 
The finding of this association in a cohort of patient with early to moderate CKD which is 
replicated in a cohort with advanced CKD suggests that the pathological processes 
associated with CAV1 occur irrespective of the degree of renal impairment. CAV1 is 
ubiquitously distributed in cells pertinent to this current study. In vascular endothelium 
CAV1 interacts with eNOS such that reduced CAV1 increases eNOS activity which may have a 
deleterious effect on endothelial health and arterial stiffness, due to “uncoupling” of eNOS 
which leads to the generation of superoxide anion radicals (198) in oxidative stress 
characteristic of CKD (199). Similarly, caveolin-1 deficient aortic smooth muscle cells have 
been shown to be pro-arteriosclerotic with increased neointimal hyperplasia, cell 
proliferation and migration (200). These observations may underlie the findings of the 
current study. Conversely, lower levels of CAV1 in macrophages are associated with an anti-
inflammatory phenotype, reduced foam cell formation and therefore protection from 
atheroma (147). Interestingly, these contrasting functions of CAV1 in endothelium (“anti-
arteriosclerotic”) and macrophages (“pro-atheromatous”) may consolidate the findings of 
the current study whereby CC genotype associates with a reduced aPWV (“anti-
arteriosclerotic”) and the findings of Testa et al (159) who showed an association between 
CC genotype and increased carotid arterial intima media thickness (a measure of atheroma 
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rather than arteriosclerosis (201)). Patients included in the Testa et al non-replicated study 
were dialysis dependent (87 patients on haemodialysis, 47 on chronic ambulatory peritoneal 
dialysis) and had not excluded patients with diabetes or symptomatic heart disease which 
may account for their co-dominant model being associated with an adverse outcome. 
Further potential limitations of the study could be the lack of control for types of access used 
in the haemodialysis patients, or adequate control for electrolyte and fluid removal 
requirements that may have affected the left ventricular function of these patients and 
resultant arterial manifestations (202). Indeed, it has been suggested due to the complexity 
of patients in end stage renal disease, that controlling for potential confounders is difficult 
and thus may have affected the genotype:phenotype relationship found (203). For example, 
uraemic toxins such as high asymmetric dimethylarginine levels have been associated with, 
and shown to predict the progression of increased carotid arterial intima media thickness in 
dialysis dependent patients (204). 
In summary, CAV1 rs4730751 CC genotype is associated with lower aPWV in patients with 
non-dialysis CKD. This gene variant may represent a non-traditional risk factor for CVD 
associated with CKD. 
 
3.1.2 eNOS SNP in left ventricular function in early CKD 
This section is based on my first author publication (205). 
3.1.2.1 Introduction 
eNOS SNP rs1799983 for NOS3 is also known as Glu298Asp and G894T polymorphisms and 
has been associated with heart failure in the non-CKD population. This polymorphism is the 
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nucleotide guanine substitution of thiamine at position 894 of exon 7 on chromosome 7, 
resulting in glutamate or aspartate respectively at position of 298 on the protein. Thus, there 
is different cleavage of the eNOS enzyme depending on genotype and thus basal endothelial 
nitric oxide (NO) levels (206, 207).  The mutant Asp variant has been shown to have a lower 
NO production in vitro, pre and post shear stress, with lower (approximately 40%) 
NOS3/CAV1 association at basal levels and impaired NOS3/CAV1 dissociation after acute 
shear stress, in immunoprecipitation experiments (208). The same authors later used human 
umbilical endothelial cells to show that the Glu/Asp and the Asp/Asp variant also had 
significantly less NOS3/CAV1 association compared to Glu/Glu using immunoprecipitation 
(209). 
In the general population, there has been interest in the association between the Glu298Asp 
polymorphism within endothelial nitric oxide synthase (eNOS) and heart failure (166, 167). 
Although this polymorphism has been associated with endothelial dysfunction and 
progression of CKD through NO effects (168), it is not known if this polymorphism is 
associated with early, sub-clinical cardiac structural changes that occur in non-dialysis CKD as 
manifested by left ventricular dysfunction. In light of this, I investigated if this gene variant is 
associated with changes in systolic and diastolic function, based on detailed cardiac 
magnetic resonance imaging (CMR) in non-dialysis CKD patients with no known history of 
heart failure. 
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3.1.2.2 Results 
Genomic DNA was successfully genotyped in 132 (>94%) patients. The eNOS SNP rs1799983 
patient genotype frequency was GG in 47% (62/132), TG in 39% (51/132), and TT (Asp/Asp) 
in 14% (19/132). This distribution was within Hardy-Weinberg equilibrium bounds (p>0.05). 
Patient demographics are presented in Table 3-3 for the cohort as a whole and stratified by 
genotype (GG, TG and TT).There were no significant demographic differences across the 
three genotypes. Median age was 57 years, eGFR was 50.5 mls/min/1.73m2, with 85% of 
patients prescribed an angiotensin converting enzyme inhibitor or angiotensin II receptor 
blocker. The most common renal disease group was glomerular disease, with 16% of the 
cohort patients been diagnosed with IgA nephropathy on renal histology. 
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Table 3-3 Baseline demographics (p value across the three genotype groups) 
 
Characteristic GG genotype TG genotype TT genotype        All p value 
Number of patients (%) 62 (47) 51 (39) 19 (14) 132 
Age (years) 57 (46-63) 59 (47-66) 58 (42-69) 57 (46-65) 0.690
 
Estimated glomerular filtration 
rate (mls/min/1.73m
2
) 
50 (40-61) 51 (38-56) 45 (32-59) 51 (38-59) 0.686
 
Male (%) 30 (48) 28 (55) 15 (79) 73 (55) 0.063
 
High sensitive C-reactive 
protein (mg/l) 
1.59 (0.57-5.00) 1.75 (0.91-5.97) 2.79 (0.67-
9.87) 
1.87 (0.72-
5.62) 
0.550 
Total cholesterol (mmol/l) 4.7 (4.4-5.4) 4.5 (4.0-5.0) 4.8 (3.6-5.9) 4.6 (4.0-
5.2) 
0.374 
Mean arterial pressure (mmHg) 92 (85-101) 90 (85-100) 91 (85-99) 91 (85-
100) 
0.898
 
Systolic blood pressure (mmHg) 129 (117-139) 127 (114-135) 124 (111-
139) 
127 (115-
139) 
0.539
 
Diastolic Blood Pressure 
(mmHg) 
72 (66-81) 73 (67-81) 73 (66-79) 73 (66-80) 0.938
 
Body surface area (m
2
) 1.87 (1.77-2.02) 1.90 (1.73-2.03) 1.97 (1.92-
2.13) 
1.92 (1.79-
2.03) 
0.061
 
Body mass index (Kg/m
2
) 27.5 (24.1-31.4) 27.5 (24.2-31.1) 29.2 (25.7-
32.2) 
27.7 (24.2-
31.4) 
0.350 
Brain natriuretic peptide (ng/L) 86.6 (34.9-
176.2) 
84.3 (30.9-
205.7) 
70.0 (37.1-
160.9) 
84.4 (33.8-
193.0) 
0.989
 
Current Smoker (%) 8 (13) 5 (10) 2 (11) 15 (11) 0.930
 
Previous Smoker (%) 24 (39) 13 (25) 8 (42) 45 (34) 0.250
 
Diagnoses      
Glomerular diseases (%) 25 (40) 18 (35) 11 (58) 54 (40) 0.230
 
Systemic Diseases (%) 10 (16) 11 (22) 1 (5) 22 (17) 0.296
 
Tubulointerstitial diseases (%) 7 (11) 9 (18) 0 16 (12) 0.124
 
Familial nephropathies (%) 9 (15) 7 (14) 1 (5) 17 (13) 0.681
 
Miscellaneous (%) 11 (18) 6 (12) 6 (32) 23 (17) 0.147
 
Medication frequency      
Angiotensin conversion enzyme 
inhibitors (%) 
35 (56) 29 (57) 14 (74) 78 (60) 0.401
 
Angiotensin II receptor blockers 
(%) 
20 (32) 15 (29) 4 (21) 39 (30) 0.681
 
Β blockers (%) 13 (21) 10 (20) 3 (16) 26 (20) 0.956
 
Calcium channel blockers (%) 13 (21) 16 (31) 5 (26) 34 (26) 0.449
 
Alpha blockers (%) 7 (11) 6 (12) 2 (11) 15 (11) 0.999
 
Diuretics (%) 14 (23) 18 (35) 5 (26) 37 (28) 0.311
 
Statins (%) 28 (45) 20 (39) 9 (47) 57 (43) 0.765
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Univariate analysis revealed a significant difference across genotypes for LVEF and LVESVI 
(p=0.006 and p=0.024 respectively, Table 3-4). 
Table 3-4 Cardiac investigations relationship to genotype (p value across the three genotype 
groups) 
 
Cardiac Investigations GG genotype TG genotype TT genotype       All p value 
Cardiac Magnetic Resonance 
Imaging 
    
Left ventricular ejection 
fraction (%) 
71 (65-76) 76 (71-80) 73 (66-78) 74 (68-77) 0.006
 
Left ventricular end-diastolic 
volume index (mls/m
2
) 
61 (52-70) 57 (51-66) 59 (51-64) 59 (52-66) 0.344
 
Left ventricular end-systolic 
volume index (mls/m
2
) 
17 (13-23) 14 (12-17) 16 (12-20) 16 (12-21) 0.024
 
Left Ventricular Mass Index 
(g/m
2
) 
54.0 (45.0-67.0) 54.6 (45.0-67.1) 56.0 (47.0-
61.9) 
54.1 (45.3-
65.7) 
0.996 
Ascending Aortic Distensibility 
(x10
-3
 mmHg
-1
) 
2.53 (1.24-4.19) 2.15 (1.18-3.31) 2.11 (1.08-
3.41) 
2.35 (1.24-
3.68) 
0.692 
CMR Cardiac Output (l/min) 5.12 (4.37-6.17) 5.19 (4.64-5.94) 6.38 (4.37-
7.57) 
5.26 (4.57-
6.30) 
0.177
 
CMR Heart Rate (beats/min) 66 (60-77) 64 (58-77) 78 (62-87) 66 (60-78) 0.074
 
     
 
Tissue Doppler 
Echocardiography  
    
 
S’ lat, cm/s 8 (7-10) 9 (7-10) 9 (7-11) 8 (7-10) 0.688
 
e’ lat, cm/s 9 (7-12) 9 (8-12) 9 (8-11) 9 (8-12) 0.790
 
E/e’ lat 7.17 (5.73-8.96) 6.95 (6.08-8.40) 6.73 (6.13-
7.80) 
7.00 (6.00-
8.56) 
0.786
 
Mitral valve inflow E/A ratio 1.02 (0.87-1.23) 0.95 (0.81-1.20) 0.93 (0.70-
1.12) 
0.97 (0.81-
1.20) 
0.273
 
Mitral valve propagation 
velocity 
50.3 (41.9-66.7) 50.5 (43.6-65.1) 45 (37.7-
65.8) 
50.0 (41.0-
66.4) 
0.701
 
Left Atrial Volume Index 
(mls/m
2
) 
26.3 (21.8-32.9) 24.5 (20.6-32.3) 27.3 (22.5-
30.5) 
26.2 (21.6-
32.3) 
0.760
 
Pulse wave velocity (m/s) 8.3 (7.3-9.5) 8.3 (7.2-10.0) 9.5 (6.6-
10.7) 
8.3 (7.2-
10.0) 
0.808
 
Augmentation Index (%) 29.0 (22.8-35.1) 27.3 (20.0-35.3) 27.2 (13.3-
33.8) 
28.3 (20.7-
35.0) 
0.691 
   
  
 
Key: CMR (cardiac magnetic resonance); S’ lat (systolic velocity of the basal anterolateral LV wall); e’ lat (early 
diastolic velocity of the basal anterolateral LV wall on tissue doppler); E/e’ lat (maximum velocity of the E-wave 
of mitral valve inflow by the maximal anterolateral LV wall velocity of e’) 
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Post hoc Mann-Whitney U testing demonstrated significant differences between GG 
genotype and combined TG and TT genotypes (p=0.005, Figure 3-1). 
Figure 3-1 Left ventricular ejection fraction by genotypes (Mann-Whitney U, p=0.005 for GG vs non-
GG), and Kruskal-Wallis test between genotypes, p=0.006) 
G
G TG T
T
no
n 
G
G
0
20
40
60
80
p=0.006
p=0.005
eNOS Genotype
L
V
E
F
 (
%
)
 
 
Because of this, and to align with existing literature (209), further analysis compared the GG 
group with the non-GG (TG+TT) group, i.e. a “dominant” model. Linear regression analysis 
revealed an absolute 4% lower LVEF (p=0.005) and a 21% relative increased LV end-systolic 
volume index (p=0.011) in GG versus non-GG (TG+TT) genotyped patients as shown in Table 
3-5. 
In multivariate analysis, (adjusting for age, gender, estimated glomerular filtration rate 
(eGFR), CMR heart rate (HR), total cholesterol, high sensitive C-reactive protein (hsCRP), 
body mass index (BMI – if variables were indexed accounting for body surface area, BMI was 
excluded in the analysis) and brachial mean arterial pressure (BMAP)) the GG genotype and 
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male sex were associated with significantly lower LVEF (p=0.004 and p=0.017 respectively; 
Table 3-5). Male gender, GG genotype, eGFR, and heart rate were independently associated 
with a higher end systolic and diastolic volume index. A trend for GG genotype association 
with lower S’ lat was seen, but this failed to reach statistical significance (p=0.106).  
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Table 3-5 Univariate and multivariate analysis of systolic function as compared to GG vs non-GG 
 
Factor 
Univariate Multivariate 
Coefficient (95% CI) Sig. Coefficient (95% CI) Sig. 
LVEF 
Age 0.07 (-0.04, 0.18) 0.228 0.07 (-0.05, 0.19) 0.274 
eGFR 0.00 (-0.09, 0.08) 0.915 0.03 (-0.06, 0.11) 0.541 
BMAP -0.09 (-0.21, 0.03) 0.158 -0.06 (-0.19, 0.06) 0.318 
CMR HR 0.02 (-0.09, 0.12) 0.737 0.00 (-0.12, 0.12) 0.987 
Total Cholesterol -0.68 (-2.14, 0.77) 0.354 -0.70 (-2.32, 0.92) 0.394 
Log2 hsCRP
‡
 0.03 (-0.75, 0.81) 0.936 -0.22 (-1.02, 0.58) 0.586 
BMI 0.18 (-0.11, 0.47) 0.218 0.13 (-0.18, 0.45) 0.392 
Gender (Female) 3.10 (0.30, 5.90) 0.030 3.62 (0.66, 6.58) 0.017 
GG (Yes) -3.95 (-6.70, -1.21) 0.005 -4.24 (-7.12, -1.35) 0.004 
LVEDVI 
Age -0.01 (-0.20, 0.17) 0.878 0.03 (-0.16, 0.21) 0.782 
eGFR 0.16 (0.03, 0.30) 0.015 0.14 (0.01, 0.27) 0.033 
BMAP -0.14 (-0.34, 0.06) 0.169 -0.18 (-0.38, 0.01) 0.066 
CMR HR -0.20 (-0.37, -0.04) 0.018 -0.23 (-0.41, -0.04) 0.017 
Total Cholesterol -0.83 (-3.15, 1.49) 0.478 0.65 (-1.84, 3.15) 0.606 
Log2 hsCRP
‡
 -1.09 (-2.32, 0.15) 0.084 -1.20 (-2.40, 0.00) 0.050 
Gender (Female) -4.68 (-9.17, -0.18) 0.041 -5.02 (-9.56, -0.48) 0.031 
GG (Yes) 4.04 (-0.45, 8.53) 0.078 4.46 (0.02, 8.90) 0.049 
LVESVI
#
 
Age -0.40% (-1.00%, 0.20%) 0.195 -0.3% (-0.9%, 0.3%) 0.271 
eGFR 0.50% (0.10%, 0.90%) 0.021 0.4% (0.0%, 0.8%) 0.076 
BMAP -0.20% (-0.80%, 0.50%) 0.614 -0.3% (-0.9%, 0.3%) 0.336 
CMR HR -0.53% (-1.07%, 0.02%) 0.059 -0.6% (-1.2%, 0.0%) 0.057 
Total Cholesterol 0.3% (-7.0%, 8.2%) 0.936 3.5% (-4.7%, 12.3%) 0.413 
Log2 hsCRP
‡
 -1.9% (-5.8%, 2.2%) 0.357 -1.4% (-5.3%, 2.6%) 0.474 
Gender (Female) -16.6% (-28.0%, -3.5%) 0.015 -19.4% (-30.6%, -6.4%) 0.005 
GG (Yes) 21.0% (4.6%, 40.0%) 0.011 21.9% (5.3%, 41.1%) 0.009 
S’ Lat 
Age -0.03 (-0.07, 0.00) 0.040 -0.04 (-0.08, 0.00) 0.040 
eGFR 0.00 (-0.03, 0.02) 0.759 -0.01 (-0.03, 0.02) 0.606 
BMAP 0.02 (-0.02, 0.06) 0.294 0.02 (-0.02, 0.06) 0.248 
CMR HR -0.01 (-0.04, 0.02) 0.576 -0.02 (-0.06, 0.02) 0.347 
Total Cholesterol 0.13 (-0.28, 0.55) 0.529 0.15 (-0.36, 0.65) 0.571 
Log2 hsCRP
‡
 0.00 (-0.22, 0.22) 0.988 0.00 (-0.24, 0.25) 0.992 
BMI 0.03 (-0.06, 0.11) 0.543 0.05 (-0.04, 0.15) 0.278 
Gender (Female) 0.30 (-0.51, 1.11) 0.465 0.39 (-0.53, 1.30) 0.405 
GG (Yes) -0.45 (-1.26, 0.36) 0.270 -0.73 (-1.62, 0.16) 0.106 
p-Values from linear regression analysis 
#Outcome was log2-transformed prior to analysis to normalise the distribution. Quoted coefficients represent 
95 | P a g e  
 
the percentage increase in the outcome for an increase in one of the factors (or for the stated category relative 
to the reference). 
‡hsCRP was log2-transformed, hence the quoted coefficients relate to an increase of one unit in the log (i.e. a 
two-fold increase) 
Key: eGFR (estimated glomerular filtration rate; BMAP (brachial mean arterial pressure); CMR HR (cardiac 
magnetic resonance heart rate); hsCRP (high sensitive C-reactive protein; BMI (body mass index) 
 
A cluster analysis was performed with the assistance of Queen Elizabeth Hospital 
Birmingham statistician James Hodson, based on diastolic parameters in order to group 
patients based on their risk of diastolic function (Table 3-6). The most important factor in 
defining the clusters was found to be e’ lat, with mitral valve E/A (MV E/A) and E/e' lat being 
moderate contributors, and the remaining parameters being minimally discriminative. The 
first cluster had lower levels of e’ lat, MV E/A and MV VP and higher levels of E/e' lat and 
LAVI, hence represented those patients at most risk of diastolic dysfunction. 
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Table 3-6 Relative importance of diastolic parameters and their respective values for cluster 
separation 
 
Factor 
Relative 
Importance 
Cluster 1 Cluster 2 
Early diastolic velocity of the anterolateral 
left ventricular wall (e’ lat) 
1.00 
7.8 (7.4 - 8.3) 12.7 (11.9 - 13.5) 
Mitral valve inflow E/A ratio 0.73 0.87 (0.82 - 0.92) 1.27 (1.18 - 1.37) 
Peak E velocity to early diastolic velocity of 
the anterolateral left ventricular wall (E/e’ 
lat) 
0.62 
8.1 (7.6 - 8.6) 5.7 (5.4 - 6.1) 
Mitral valve velocity propagation 0.37 46.5 (43.3 - 49.9) 67.6 (58.8 - 77.7) 
Left Atrial Volume Index 0.12 27.0 (25.4 - 28.6) 23.8 (22.4 - 25.4) 
Left Ventricular Mass Index 0.00 54.5 (51.1 - 58.1) 54.1 (50.3 - 58.2) 
Data reported as: “Mean (95% CI)”. 
Key: e’ lat (early diastolic velocity of the basal anterolateral LV wall on tissue doppler); mitral valve E/A (ratio of 
early to late mitral inflow velocities); E/e’ lat (maximum velocity of the E-wave of mitral valve inflow by the 
maximal anterolateral LV wall velocity of e’) 
 
Comparisons between the clusters found that increased age (p<0.001) and reduced eGFR 
(p=0.014) were significantly associated with the risk of diastolic dysfunction clusters on 
univariate analysis (Table 3-7). 
Table 3-7 Univariate analysis of diastolic parameters clusters 
 
Factor Cluster 1 Cluster 2 p-Value 
Age 60.9 (1.1) 43.8 (1.7) <0.001 
Estimated Glomerular Filtration Rate 47.3 (1.8) 54.5 (2.3) 0.014 
Brachial Mean Arterial Pressure 92.2 (1.4) 91.4 (1.9) 0.700 
Gender (Male)   37 (56.1%)   19 (48.7%) 0.545 
Genotype (GG)   28 (42.4%)   22 (56.4%) 0.225 
Continuous factors are reported as: “Mean (SE)”, with p-values from independent sample t-tests. 
Dichotomous factors are reported as: “N (%)”, with p-values from Fisher’s Exact Test. 
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3.1.2.3 Discussion 
In this cohort of white patients with non-dialysis dependent CKD, and without heart failure, 
GG genotype for eNOS SNP rs1799983 was associated with a significant lower LVEF, greater 
LVESVI and greater LVEDVI than those found in non-GG genotypes. The burden of 
myocardial disease in CKD suggests the investigation of stratification by genetic risk in this 
setting to be a worthwhile endeavour, and this study represents the first such attempt with 
this eNOS polymorphism.  
Previous data from the general population suggest this gene variant represents an attractive 
candidate SNP, and support the findings of the current study. For instance Velloso et al 
studied a multi-ethnic Brazilian population and demonstrated increased frequency of GG 
genotype in patients with systolic heart failure compared with healthy controls (167). 
Another Brazilian study showed GG genotype was associated with a near 5% reduction in 
LVEF compared with TT genotype patients, findings very similar to those of the current study 
(210). Also noteworthy is the higher all-cause mortality associated with the GG genotype in 
hypertensive patients (211). An important aspect of the current study is the inclusion of 
white patients only, in an attempt to reduce confounding by population stratification. 
Indeed this is highlighted by the study of Velloso et al which did indeed show differences in 
genotype frequency at this locus between White and Afro-Brazilian individuals (167). It 
should be acknowledged, however, that further validation of these findings in diverse 
populations are required to confirm the robustness of my (and other’s) findings.  
The functional change associated with this gene variant also supports the clinical data as 
described earlier. The GG genotype of the studied SNP is associated with increased eNOS 
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activity and nitric oxide levels (212, 213) and experimental overexpression of eNOS (which is 
present within ventricular myocytes) results in reduced ventricular function (212, 214). This 
is particularly the case in conditions of oxidative stress such as CKD (199), since “uncoupling” 
of eNOS may lead to generation of superoxide anion radicals that further exacerbate cardiac 
dysfunction (198). 
The influence of genotype on cardiac function and outcome may be context-specific. Of 
note, McNamara et al suggested a beneficial effect of GG genotype outcome in patients with 
established, clinically evident heart failure (166). Whilst at first sight this data conflicts with 
the current study, and with that of other reports (167, 168), it should be noted that 84% of 
patients displayed an ejection fraction ≤35% (97.2% of participants were in NYHA stage II or 
greater, with >50% in stages III or IV). Furthermore there were differences in age and 
aetiology (ischaemic versus non-ischaemic) between genotype groups which may have 
influenced the results as well as variation in the technique used in measuring ejection 
fraction. Thus, it is certainly possible that this eNOS SNP influences outcome differentially 
depending on the stage of heart failure studied. Although the present study’s exclusion 
criteria (diabetes mellitus, peripheral vascular disease, myocardial infarction, known heart 
failure, valvular heart disease, atrial fibrillation, dialysis-dependence and uncontrolled 
hypertension) limits the generalizability of its findings, the exclusion criteria does allow 
removal of these potential external factors that affect both eNOS activity and left ventricular 
function, allowing a more ‘pure’ analysis of eNOS polymorphism association with LVEF in 
early CKD.  
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This study benefits from a uniform technique of detailed CMR assessment of cardiac 
volumes and systolic function, and very careful clinical phenotyping. Although no association 
with “diastolic dysfunction” parameters derived from echocardiography and genotype was 
evident, the size of the cohort means that such an effect cannot be excluded, and further 
study in larger cohorts is required.  
In summary, eNOS Glu298Asp polymorphism in non-dialysis CKD patients is associated with 
relevant sub-clinical cardiac remodelling as detected by CMR. 
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4.1 CAV1 in antineutrophil cytoplasmic antibody associated vasculitis 
This section is based on my first author publication (215). 
4.1.1 Introduction 
The vasculitidies represent an inflammatory group of disorders affecting small to large sized 
blood vessels. They can be secondary due to underlying connective tissues disorders, 
infection, malignancy and medication), and be localised or systemic. Anti-neutrophil 
cytoplasmic antibody (ANCA) associated vasculitis represent a group of primary autoimmune 
disorders that are systemic, mainly involving small to medium sized vessels and have a peak 
age affecting 60 to 70 year olds (216). ANCAs are directed against proteinase 3 (PR3) and 
myeloperoxidase (MPO) which are present in the primary granules of neutrophils and 
monocytes. The three main ANCA associated vasculitidies (AAV) are granulomatous 
polyangiitis (GPA), microscopic polyangiitis (MPA) and eosinophilic granulomatous 
polyangiitis (EGPA). There is now gathering evidence that these diseases are genetically 
distinct, with EGPA being often ANCA negative, much less common and thus treated in a 
different manner (25, 216, 217). The global incidence of GPA and MPA is increasing with an 
estimated 5-10 million people per year diagnosed (218). 
If left untreated AAV resulted in devastating multi-organ failure affecting organs such as the 
kidneys, lungs and skin resulting in high mortality of 90% at 2 years post diagnosis, prior to 
advent of potentially highly toxic treatment with cyclophosphamide and high-dose 
corticosteroids (219, 220).  Despite success in improving patient life expectancy, there 
remains high mortality at 5 years (up to 28%) and significant morbidity associated with 
complications of the disease and its treatment such as infection, cardiovascular disease, 
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malignancy and chronic kidney disease. These types of clinical outcomes have been 
associated with the pleiotropic effects of CAV1, thus the purpose of this study was to 
investigate whether the CAV1 gene variant rs4731751 was associated with these clinical 
outcomes in AAV. The primary outcome measure was chosen as a combined end-point of 
time to all-cause mortality and time to renal replacement therapy (RRT), as this 
encompassed the increased risk of death from the co-morbidities associated with AAV and 
the progression of kidney disease (and interstitial fibrosis). Following preliminary results in 
an AAV cohort from Birmingham, UK, a combined Northern European replication AAV cohort 
from Germany and the Netherlands was studied to validate the findings. 
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4.1.2 Results 
4.1.2.1 Birmingham Cohort 
In the Birmingham cohort, genomic DNA was successfully genotyped in 187 (>93%) patients. 
The CAV1 SNP was within Hardy-Weinberg equilibrium bounds (p>0.05). Demographics of 
this cohort are shown in Table 4-1. The genotype of the patients at the studied locus was AA 
in 12.3% (23/187), AC in 38.5% (72/187), and CC in 49.2% (92/187). During a median follow-
up of 110 months (interquartile range, 67-166 months), 58 patients died and 37 patients 
required RRT. There were 78 (41.7%) primary composite outcome events. 
 
Table 4-1 Demographics for Birmingham and Northern European cohorts are shown  
 
Characteristic Birmingham Northern Europe p value 
Number of patients 187     589 
Age, years 67 (56-77)   63 (52-71) <0.001 
Age at diagnosis, years 58 (46-68) 54 (42-63) 0.003 
Male (%) 104 (56) 302 (51) 0.314 
Genotype    
AA (%) 23 (12) 30 (5) 0.001 
AC (%) 72 (39) 231 (39) 0.93 
CC (%) 92 (49) 328 (56) 0.130 
Granulomatosis with polyangiitis (%) 110 (59) 531(90) <0.001 
Microscopic polyangiitis (%) 77 (41) 58 (10) <0.001 
Age at diagnosis, years 58 (46-68) 54 (42-63) 0.003 
Creatinine at presentation, µmol/L 182 (100-385) 90 (90-150) <0.001 
Cytoplasmic (c) ANCA (%) 109 (58) Not measured  
Perinuclear (p) ANCA (%) 71 (38) Not measured  
Proteinase 3 (PR3) (%) Not measured 438 (74)  
Myeloperoxidase (MPO) (%) Not measured 97 (17)  
Negative (%) 7 (4) 54 (9)  
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Kaplan-Meier estimate of the primary combined outcome of time to all-cause mortality/RRT 
revealed significant differences between genotypes at  rs4730751 (Figure 4-1; p=0.022), with 
inferior outcomes in patients with non-CC genotype. 
Figure 4-1 Kaplan-Meier analysis of time to all-cause mortality and renal replacement therapy in 
the Birmingham cohort by genotype of CAV1 SNP rs4730751. The number of patients at risk at 
separate time points is shown by year of follow-up. Graphic data shown to the last surviving 10% 
patients. p=0.022 
 
 
 
 
Year: 0 1 5 10       15 20 
AA 23 20 16 9       6 4 
AC 72 60 45 23       9 5 
CC 92 82 70 40       18 9 
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Overall primary outcomes rates were 60.9% (14/23) for patients with genotype AA, 48.6% 
(35/72) for AC, and 31.5% (29/92) for CC genotypes. The Cox model examined patient 
genotype as non-CC (i.e. AA and AC combined) genotype versus CC genotype. A univariate 
association was found between genotype and time to all-cause mortality/RRT (non-CC vs. CC 
hazard ratio [HR]: 1.90; 95% confidence interval [CI], 1.19-3.02; p=0.007). This effect 
persisted in the multivariate analysis, where a similar HR was observed (non-CC vs. CC HR, 
1.86; 95% CI, 1.14-3.08; p=0.013), adjusted for age at diagnosis, gender, type of ANCA and 
serum creatinine level at presentation. 
 
4.1.2.1.1 Secondary Analyses 
After adjusting for age at diagnosis, gender, creatinine at presentation and type of ANCA, 
non-CC genotyped patients were at significantly increased risk for time to all-cause 
mortality, time to death from infection, time to death from a cardiovascular cause and time 
to cancer development from AAV diagnosis. There was some evidence for an increased risk 
of RRT for non-CC genotype, but this did not meet criteria for statistical significance (Table 
4-2). 
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Table 4-2 Multivariate regression analysis of genotypes non-CC vs. CC for CAV1 SNP rs4730751. 
Times to event endpoint for both cohorts were adjusted for age at diagnosis, gender, creatinine at 
presentation and type of ANCA 
 
Variable HR 95% Confidence Interval p value 
Birmingham Cohort    
Time to All-cause mortality 1.83 1.02-3.27 0.042 
Time to Death from Vascular cause 3.13 1.07-9.10 0.037 
Time to Death from Infection 3.71 1.28-10.77 0.016 
Time to Cancer Development from AAV diagnosis 5.55 1.59-19.31 0.007 
Time to Renal Replacement Therapy 1.79 0.86-3.73 0.119 
    
Northern European Cohort    
Time to All-cause mortality 0.90 0.44-1.84 0.764 
Time to Death from Vascular cause 1.33 0.27-6.67 0.729 
Time to Death from Infection 1.24 0.28-2.00 0.196 
Cancer 0.77* 0.28-2.17 0.625 
Time to Renal Replacement Therapy 1.37 0.63-2.96 0.427 
    
*Exact date of cancer onset during follow-up period not available, thus logistic regression analysis used, 
expressed as Odds Ratio 
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4.1.2.2 Northern European Cohort 
In the Northern European cohort, genomic DNA was successfully genotyped in 589 (>98%) 
patients. CAV1 SNP rs4730751 was within Hardy-Weinberg equilibrium bounds (p>0.05). As 
shown in Table 4-1, there was a significantly lower AA genotype and higher CC genotype 
prevalence in Northern Europe as compared to the Birmingham cohort: AA genotype in 5.1% 
(30/589); AC genotype in 39.2% (231/589), and CC genotype in 55.7% (328/589). The 
Northern European cohort had over 90% of patients diagnosed with GPA as compared to 
fewer than 60% Birmingham. The Northern European cohort also had significantly lower 
creatinine values (suggesting a better kidney function) at presentation. During a median 
follow-up of 89 months (interquartile range, 48-132 months), there were 33 deaths and 32 
patients who required RRT.  In all, there were 61 (10.4%) primary outcome events as 
compared to the 41.7% event rate in Birmingham described above. 
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No association was seen between genotype and Kaplan-Meier estimates of time to primary 
outcome measure (Figure 4-2; p=0.427). 
Figure 4-2 Kaplan-Meier analysis of time to all-cause mortality and renal replacement therapy in 
the Northern European cohort by genotype of CAV1 SNP rs4730751. The number of patients at risk 
at separate time points is shown by year of follow-up. Graphic data shown to the last surviving 
10% patients. p=0.427 
 
 
 
 
Year: 0 1 5 10     15 20 
AA 30 29 20 8      2 4 
AC 231 205 146 79       31 10 
CC 328 300 219 82       38 14 
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Overall primary outcome rates were 10.9% (2/30) for patients with AA genotype, 12.6% 
(29/231) for AC genotype, and 9.1% (30/328) for CC genotype. The Cox model showed no 
evidence of association between genotype and the primary outcome measure (non-CC 
genotype vs. CC genotype HR: 1.29; 95% CI, 0.78-2.13; p=0.319). As shown in Table 4-2, no 
evidence for an association between genotype and any of the secondary outcome measures 
was evident in the replication cohort. 
 
4.1.2.3 Interaction between CAV1 genotype and Clinical Diagnosis 
Due to current evidence of GPA and MPA being considered separate genetic disease entities, 
the influence of genotype for each diagnosis was next examined. The primary methodology 
for this was to examine a statistical interaction between CAV1 genotype and diagnosis. In 
addition a subgroup analysis for each secondary outcome was performed. This was 
performed with the assistance of Queen Elizabeth Hospital Birmingham statistician James 
Hodson. 
For all outcomes, the CC genotype was associated with lower risk. A significant interaction 
(last column of Table 4-3) between CAV1 genotype and diagnosis was observed only for the 
‘Renal Replacement Therapy’ outcome, whereby the influence of genotype was greater in 
patients with GPA. Although at first sight the results of the subgroup analyses seem to 
suggest a difference between diagnostic groups (second to last column of Table 4-3), this is 
likely a result of numbers in the study. The results of the interaction analyses (a more robust 
way of examining this issue) do not point to a differential effect of genotype between 
diagnoses. 
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Table 4-3 Cox regression analyses assessing the association of genotype upon the outcomes when 
the cohort is divided into diagnoses and then an assessment of the significance of interaction to 
address if the CAV1 SNP genotype effect varied between diagnoses 
 
Time to Event Diagnosis Hazard Ratio (95% CI) CC vs. non-
CC p-value 
Interaction 
p-value 
All-cause mortality or 
Renal Replacement 
Therapy 
GPA               
MPA 
0.56 (0.36, 0.86)    
0.67 (0.39, 1.15) 
 0.009       
0.15 
0.66 
     All-cause mortality GPA    
MPA 
0.74 (0.43, 1.29)    
0.47 (0.25, 0.90) 
0.29          
0.02 
0.25 
     Death from vascular 
cause 
GPA    
MPA 
0.33 (0.11, 1.04)    
0.33 (0.10, 1.06) 
0.06          
0.06 
0.95 
          Death from infection GPA    
MPA 
0.63 (0.24, 1.66)    
0.40 (0.15, 1.09) 
0.35          
0.07 
0.49 
     Cancer (*) GPA    
MPA 
0.18 (0.04, 0.82)    
0.11 (0.01, 0.87) 
0.03          
0.04 
0.62 
Renal Replacement 
Therapy 
GPA    
MPA 
0.39 (0.20, 0.76)    
1.16 (0.54, 2.51) 
0.006             
0.70 
0.04 
(*) Analysis performed on Birmingham data only, as time to cancer data was unavailable for the Northern 
European cohort. 
 
4.1.3 Discussion 
This is the first study to evaluate the role of CAV1 gene variation in determining clinical 
outcome in patients with AAV. In the Birmingham cohort, gene variation at the CAV1 SNP 
rs4730751 was associated with the chosen combined primary end-point of time to all-cause 
mortality or RRT. In addition, secondary analyses showed an association between this SNP 
and all-cause mortality, death from infection, death from cardiovascular disease, and the 
development of cancer from AAV diagnosis. These findings are plausible from previous 
studies in caveolin-1 biology, specifically with its role in vascular disease, sepsis, cancer and 
fibrosis.  
111 | P a g e  
 
The association between genotype and clinical outcome was not replicated in the Northern 
European cohort. There may be a number of reasons underlying this. The Northern 
European cohort appeared to have a lower expected event rate for an AAV cohort. 
Flossmann et al studied 535 patients with GPA or MPA as part of the European Vasculitis 
Study Group.  Over a median follow-up of 5.2 years, there was a 25% mortality rate, with 
32.3% of deaths from infection, 21.1% of deaths from cardiovascular cause, and a 9.3% 
cancer incidence (170). Outcomes in the Birmingham cohort were similar, as over a median 
follow-up of 9.2 years the respective rates were 31.0%, 11.8%, 10.2% and 11.8%. In contrast, 
in the Northern European cohort over a median follow-up of 7.4 years, the respective rates 
were only 5.6%, 1.2%, 1.0% and 2.9%. The Northern European cohort was younger than that 
of Birmingham, and in particular had better kidney function at presentation. This likely 
reflects the “rheumatological” nature of the Northern European cohort versus the 
“nephrological” nature of the Birmingham cohort. Certainly kidney function at presentation 
is an important determinant of outcome in AAV, and this may explain the discrepancy 
between the cohorts, and the lack of association in the replication study. In addition, a 
difference in proportions of patients with GPA versus MPA was seen between the cohorts. 
Interestingly, we found some evidence that the influence of genotype differed between 
diagnoses for the time to requirement of renal replacement therapy, with a more marked 
effect in patients with a clinical diagnosis of GPA. This preliminary observation is relevant in 
light of emerging evidence that MPA and GPA are genetically distinct condition (25). As well 
as a HLA association, this study found PR3 genetic variation to be associated with GPA. Other 
examples of an antigen-specific autoimmunity include PLA2R in membranous nephropathy 
with associated genetic variation of PLA2R associated with membranous nephropathy 
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variant. However caution is required in the case of α1-antitrypsin genetic variation in AAV. 
This protease inhibitor is known to be a major inhibitor of proteinase 3 activity (221). 
However, despite altered activity of the protease inhibitor with patients with the Z allele of 
the gene SERPINA1, the Z allele carriage was not associated with disease severity, survival or 
replapse (222). Thus the SNP rs7151526 of this gene is likely to be in linkage disequlibrium 
with a nearby gene that is more likely to be the causal variant (25). 
It should be acknowledged that the study design did not take in to account the varying 
immunosuppression protocols of the differing institutions, nor the severity of the disease 
activity. In addition, there is the possibility of ascertainment bias with regard to patient 
outcomes in this observational study. Finally, the issue of cryptic population stratification 
always exists in studies such as this, although the inclusion of only white patients goes some 
way to limit the confounding effect of this.  
In summary, this is the first study to describe the association between CAV1 variation and 
the outcomes of patients with ANCA associated vasculitis and renal involvement. This study 
suggests a relationship between the CAV1 SNP rs4730751 and complications of AAV and its 
treatment, although the effect may be context-specific. 
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CHAPTER 5:  
NEW-ONSET DIABETES AFTER     
TRANSPLANTATION 
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5.1 New-onset diabetes after transplantation – can genetics identify 
pathways to its development? 
This section is based on my first author publication (223) 
 
5.1.1 Introduction 
Despite excellent first year outcomes in kidney transplantation, there remain significant 
long-term complications of premature graft loss, morbidity and mortality related to infection 
and cardiovascular disease. New-onset diabetes after transplantation (NODAT) is the major 
form of post-transplant hyperglycaemia that is associated with such complications. Thus 
research has focussed on measures to prevent post-transplant hyperglycaemia 
development, identification of those at risk in a timely manner and investigating molecular 
pathways to its development. Investigation of single nucleotide polymorphism (SNP) variants 
offers such a strategy. A number of previous studies have investigated specific candidate 
gene variants, usually on the basis of prior evidence of association with type 2 diabetes in 
non-transplanted individuals. Whilst some such SNPs have shown an association with 
NODAT, little attempt has been made to replicate findings in independent cohorts. During 
the last few years the nomenclature has interchanged with NODAT and post-transplant 
hyperglycaemia, with the latter now preferred. However, NODAT has been used for the 
purpose of the following chapter as pre-transplant diabetic status has been excluded for the 
study population below. 
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More recently, the first genome-wide association study (GWAS) in the field has been 
reported from Ireland (73). In the GWAS study, NODAT was defined as the use of oral 
hypoglycaemics or insulin over a 12 year follow-up period, with the median time of NODAT 
onset of 100 months. However this approach potentially misses a number of cases of 
NODAT, hence recent research highlights the growing momentum to use biochemical testing 
when identifying post-transplant hyperglycaemia (224, 225). It is also worth noting that 25% 
of patients in this GWAS study were treated with a calcineurin inhibitor-free maintenance 
regimen. Calcineurin inhibitors are widely used and are a known risk for NODAT 
development (226). 
The purpose of this study was to validate the findings of the GWAS and other candidate 
NODAT SNPs investigated in the Belfast study (73), but in a prospective study of patients 
undergoing a protocolised, contemporary immunosuppression regimen, and using detailed 
serial biochemical testing to identify the development of NODAT. The insulin receptor has a 
CAV1 binding motif to the CAV1 scaffolding domain, with CAV1 peptides stimulating insulin 
receptor kinase activity especially seen in adipocytes (97). The CKO mouse, although not 
overtly diabetic itself, does show features consistent with insulin resistance, with the mouse 
developing postprandial hyperglycaemia after 9 months of a high-fat diet (150). Thus CAV1 
rs4730751 was included with the potential SNPs associated with NODAT. 
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5.1.2 Results 
Demographics of the cohort are shown in Table 5-1. The cohort was aged 45 years (±15), 
human leucocyte antigen (HLA) mismatched 2.41 (±1.43), body mass index increase of 1.0 
(±2.2) with 68% undergoing live kidney transplantation. Eighteen patients (26.5%) were 
diagnosed with NODAT, of whom 11 patients (61.1%) were diagnosed on the basis of the 
result of OGTT testing alone. Patients developing NODAT were older and displayed greater 
changes in BMI over the first year post-transplantation (p<0.05 for both). There were no 
significant differences between patients developing and not developing NODAT for HLA 
mismatch, rejection episodes, overall steroid dose used per day, tacrolimus levels or 
presence of adult polycystic kidney disease (p>0.05 for all). No patients had a prevalent or 
incident hepatitis C virus infection (this infection has been associated with NODAT). This is 
likely a reflection of the sample size and population investigated, as these are known risk 
factors for post-transplant hyperglycaemia. 
 
117 | P a g e  
 
Table 5-1 Demographics of renal transplant study cohort 
 
Characteristic NODAT Non-NODAT        All p value 
Number of patients (%)  18 (26) 50 (74) 68 
Age (years) 54 (±12) 41 (±15) 45 (±15) 0.002 
Female (%) 8 (44) 20 (40) 28 (41) 0.785 
Body Mass Index (Kg/m
2
) 27.5 (±4.9) 26.3 (±4.8) 26.6 (±4.8) 0.375 
Body Mass Index Change 
(Kg/m
2
) 
-0.5 (±2.5) 1.5 (±1.9) 1.0 (±2.2) 0.002 
Polycystic Kidney Disease (%) 3 (17) 7 (14) 10 (15) 0.717 
Transplant type, live (%) 13 (72.2) 33 (66) 46 (67.6) 0.775 
Human Leucocyte Antigen 
mismatch 
2.82 (±1.59) 2.45 (±1.36) 2.56 (±1.43) 0.371 
Total Rejection Episodes 0.39 (±0.61) 0.25 (±0.64) 0.29 (±0.63) 0.179 
1
st
 Month Rejection Episodes 0.11 (±0.32) 0.13 (±0.33) 0.12 (±0.33) 1.000 
Prednisolone dose (mg/day) 9.0 (6.3-9.7) 6.3 (6.3-9.3) 6.3 (6.3-9.7) 0.120 
FK Level (micrograms/l) 8.8 (±1.5) 8.1 (±1.3) 8.3 (±1.4) 0.107 
   
 
 
 
 
 
 
 
 
118 | P a g e  
 
Out of the remaining 50 candidate SNPs that were identified by literature review (73), 45 
were successfully genotyped (rs1800961 [HNFA], rs2069763 [IL-2], rs2265917 [SHPRH], 
rs6903252 [intergenic] and rs7903146 [TCF7L2] were unavailable as they were not amenable 
to the Sequenom iPLEX genotype bundle designs).  The genotype success rate for the 46 
SNPs (including rs4730751 [CAV1]) was >99%.  Seven SNPs (rs10117679 [GRIN3A], rs1016429 
[GRIN3A], rs12255372 [TCF7L2], rs17657199 [NDST1], rs2070874 [IL-4], rs2240747 [ZNRF4], 
rs4730751 [CAV1]) demonstrated deviation from Hardy-Weinberg equilibrium (p<0.05). 
In the adjusted logistic regression model, five SNPs were significantly associated with 
NODAT:  rs16936667 [PRDM14: OR 10.57; 95% CI 1.8-63.0; p=0.01], rs1801282 [PPARG: OR 
8.5; 95% CI 1.4-52.7; p=0.02], rs8192678 [PPARGC1A: OR 0.26; 95% CI 0.08-0.91; p=0.03], 
rs2144908 [HNF4A: OR 7.0; 95% CI 1.1-45.0; p=0.04] and rs2340721 [ATF6: OR 0.21; 95% CI 
0.04-1.0; p=0.05] (Table 5-2). 
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Table 5-2 Univariate (p value) and multivariate analysis (p value adj) of the candidate single 
nucleotide polymorphisms for the development of new-onset diabetes after transplantation 
 
SNP Gene Location  
Minor 
Allele 
MAF p value 
p value 
adj 
Odds ratio (95% CI) 
rs16936667 PRDM14 8:70975726 G 0.16 0.03 0.01 10.6 (1.8-63.0) 
rs1801282 PPARG 3:12393125 G 0.1 0.12 0.02 8.5 (1.4-52.7) 
rs8192678 PPARGC1A 4:23815662 A 0.34 0.17 0.03 0.26 (0.08-0.91) 
rs2144908 HNF4A 20:42985717 A 0.18 0.05 0.04 7.0 (1.1-45.0) 
rs2340721 ATF6 1:161849385 A 0.3 0.006 0.05 0.21 (0.04-1.0) 
rs198372 NPPA 1:11909514 A 0.12 0.14 0.08 0.11 (0.01-1.3) 
rs5219 KCNJ11 11:17409572 T 0.34 0.08 0.12 2.7 (0.77-9.8) 
rs10899444 SHANK2 11:70606500 G 0.15 0.77 0.15 0.32 (0.07-1.5) 
rs1025689 IL-17RB 3:53883722 G 0.44 0.14 0.15 0.45 (0.15-1.34) 
rs1124053 IL-17E  14:22914819 T 0.23 0.05 0.16 2.7 (0.68-10.3) 
rs2265477 SHPRH 6:146212338 C 0.46 0.54 0.17 0.45 (0.14-1.4) 
rs6793265 ITPR1 3:4735533 T 0.13 0.22 0.23 2.2 (0.60-8.4) 
rs7145618 PPP2R5C 14:102329098 C 0.07 0.64 0.25 3.1 (0.44-21.5) 
rs1783606 SHANK2 11:70576651 A 0.14 0.99 0.26 0.42 (0.09-1.9) 
rs2265919 SHPRH 6:146221753 G 0.44 0.74 0.29 0.54 (0.18-1.7) 
rs3212574 ITGA2 5:52366779 A 0.23 0.94 0.30 2.1 (0.50-9.2) 
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rs2107538 CCL5 17:34207780 T 0.18 0.07 0.34 2.1 (0.46-9.5) 
rs2240747 ZNRF4 19:5456930 C 0.21 0.86 0.37 2.0 (0.45-8.7) 
rs7533125 DNAJC16 1:15883744 C 0.23 0.43 0.40 0.61 (0.19-1.9) 
rs17657199 NDST1 5:149950246 T 0.03 0.37 0.41 2.5 (0.28-23.3) 
rs3817655 CCL5 17:34199641 A 0.18 0.12 0.48 1.8 (0.37-8.5) 
rs4819554 IL-17RA  22:17565035 G 0.12 0.62 0.49 1.7 (0.38-7.9) 
rs341497 DIAPH3 13:60429001 C 0.06 0.45 0.49 2.0 (0.28-14.1) 
rs2020902 CASP9 1:15834360 C 0.16 0.26 0.52 0.65 (0.17-2.4) 
rs1800795 IL-6 7:22766645 C 0.43 0.90 0.53 0.72 (0.26-2.0) 
rs1836882 NOX4 11:89232161 C 0.16 0.53 0.53 1.6 (0.36-7.2) 
rs1044498 ENPP1 6:132172368 C 0.14 0.21 0.55 0.58 (0.10-3.5) 
rs4394754 INPP5A 10:134343062 T 0.26 0.05 0.56 0.67 (0.17-2.6) 
rs11580170 AGMAT 1:15909744 T 0.28 0.40 0.58 0.72 (0.23-2.3) 
rs2280789 CCL5 17:34207003 C 0.13 0.14 0.59 1.7 (0.26-10.7) 
rs4730751 CAV1 7:116540796 A 0.26 0.16 0.60 0.70 (0.18-2.6) 
rs1799854 ABCC8 11:17448704 T 0.4 0.51 0.60 0.75 (0.25-2.2) 
rs1016429 GRIN3A 9:104402364 C 0.1 0.41 0.64 1.6 (0.24-10.0) 
rs2069762 IL-2 4:123377980 G 0.25 0.21 0.66 1.3 (0.39-4.4) 
rs1494558 IL-7R 5:35861068 A 0.35 0.79 0.70 1.2 (0.46-3.2) 
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rs2172749 IL-7R 5:35855264 C 0.35 0.79 0.70 1.2 (0.46-3.2) 
rs1043261 IL-17RB 3:53899276 T 0.11 0.23 0.71 0.73 (0.14-3.8) 
rs2861484 CELA2B 1:15812665 T 0.22 0.18 0.72 0.82 (0.28-2.4) 
rs10484821 ATP5F1P6 6:139868910 C 0.19 0.34 0.74 0.80 (0.21-3.1) 
rs2070874 IL-4 5:132009710 T 0.17 0.60 0.78 0.82 (0.21-3.3) 
rs10117679 GRIN3A 9:104378479 T 0.06 0.44 0.81 1.4 (0.1-18.3) 
rs1169288 HNF1A 12:121416650 G 0.36 0.96 0.82 1.1 (0.35-3.8) 
rs13266634 SLC30A8 8:118184783 T 0.38 0.53 0.84 0.89 (0.30-2.7) 
rs12255372 TCF7L2 10:114808902 T 0.28 0.94 0.91 1.1 (0.41-2.7) 
rs1871184 ITGA1 5:52234323 T 0.13 0.14 0.92 1.1 (0.16-7.4) 
rs17722392 KIDINS220 2:8940154 C 0.05 0.44 0.93 1.1 (0.09-13.8) 
   
    
Key: 
SNP: single nucleotide polymorphism, MAF: minor allele frequency, p value adj: p value adjusted for age, sex, 
body mass index at baseline and change after 12 months, CI: confidence interval. 
SNPs in red: 8 ‘glucotoxic’ SNPs from (73) 
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5.1.3 Discussion 
This study identifies SNP variants in common genes which are associated with the 
development of NODAT following kidney transplantation, thereby generating hypotheses to 
aid our understanding of mechanisms involved (discussed below) and the potential for risk-
stratifying patients pre-transplantation. 
Some of the features of the study are relevant and worth noting in the context of its 
findings. Firstly, all patients underwent screening for diabetes prior to transplantation, and 
so the episodes of diabetes following transplantation were truly “new onset” rather than 
pre-transplant diabetes which was picked up post-transplantation. Indeed for the live donor 
recipients in the study, OGTTs were also undertaken to exclude pre-transplant diabetes. For 
the diagnosis of diabetes following transplantation, OGTTs were undertaken at serial time-
points in a carefully phenotyped prospective cohort, and so this study in particular, is 
sensitive to the development of NODAT. Interestingly, the majority of patients were only 
diagnosed as a result of the OGTTs conducted specifically and additionally as part of this 
research study, and would have been missed (or the diagnosis delayed) in routine clinical 
practice. The original GWAS (73) reported 9.6% NODAT incidence over 12 years follow-up  
(57 patients with a median time of onset over 8 years), using a clinician-based diagnostic of 
NODAT, whilst in Birmingham after one year post-transplantation, over 25% (18 patients) 
developed NODAT in keeping with previous European cohorts. This may reflect two differing 
‘types’ of NODAT; Belfast appears to have a prolonged time to NODAT that could represent a 
‘wearing’ out of the pancreatic β cell, where the Birmingham cohort represents an 
‘inflammatory’ response to hyperglycaemia. This may explain why none of the top 8 SNPs 
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(Table 5-2, in red) identified in the Belfast GWAS, were significantly associated in this 
chapter. 
Secondly, although the inclusion of only white patients (self-reported) does limit 
generalisation to other ethnicities, it does nevertheless make the study’s findings more 
robust by limiting (albeit not fully excluding) the confounding effect of population 
stratification. Finally, the identified SNPs have been previously recognised as risk factors for 
diabetes and also for NODAT, and the current study therefore replicates these findings. As 
such, the p values have not been corrected for multiple comparisons. At 5% risk of false 
positives in the 46 SNPs would result in approximately 2 false positives assuming that the 
SNPs were independent of each other, yet, in view of the potential inter-relationship 
(discussed below) of the SNPs, the actual number of false positives is likely to be lower. 
The potential detrimental effects of hyperglycaemia on pancreatic human β cells resulting in 
reduced proliferation and increased apoptosis after 2 days and loss of secretory function 
after 4 days, have been shown in vitro which is reflected in the time to the potentially 
‘inflammatory’ NODAT onset in this study (227, 228). The five reported SNPs associated with 
NODAT in this study mirror the above mechanisms, and fall into three main interrelated 
categories, namely β cell apoptosis with reduction in cell mass, insulin sensitivity/release and 
mitochondrial dysfunction (Figure 5-1). The mammalian target of rapamycin (mTOR) is a 
member of the phospho-inositide 3-kinase (PI3K)-related kinase family and has a central role 
in the regulation of these SNPs. 
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Figure 5-1 Schematic of how the significant candidate genes may lead to new-onset diabetes after 
transplantation development, with mTOR being the central regulator to this  
 
 
mTOR regulates peroxisome proliferator-activated receptor gamma co-activator 1 alpha 
(PGC1α - PPARGC1α rs8192678) and peroxisome proliferator-activated receptor gamma 
(PPARy – PPARG rs1801282) signalling to promote cell growth, proliferation, metabolism and 
survival; both these SNPs have been associated with type II diabetes previously (229, 230). 
mTOR enhances the activity of these transcription factors PPARy and PGC1α by the 
regulation of lipid synthesis, thus acts as a key sensor for mitochondrial and B cell nutrient 
status via leucine and its regulation of AMP-activated protein kinase inhibiting secretion of 
insulin, controlling mitochondrial oxidative metabolism and biogenesis through transcription 
PGC1α physical interaction with yin-yang 1 (231, 232). mTOR regulates the transcription 
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regulator, PR domain zinc protein 14 (PRDM14 rs16936667) which interacts directly with the 
chromatin regulator polycomb repressive complex 2 to exert its effects via trimethylation of 
histone H3 lysine27 and enhancer of zeste homolog 2 to regulate β cell proliferation, cell 
mass and apoptosis (233-235). This SNP was associated with NODAT in the recent GWAS 
(73). 
Activated transcription factor 6 (ATF6 rs2340721) is present in pancreatic β cells, adipocytes 
and hepatocytes. It becomes activated during periods of tacrolimus induced endoplasmic 
reticulum stress in transplantation, to improve cell survival via mTOR in combating the 
unfolded protein response that leads to apoptosis, lipogenesis and gluconeogenesis (236, 
237). Although not previously associated with NODAT, this SNP has been associated with an 
increased BMI in a renal transplant cohort 15, pre-diabetes in a Chinese cohort (238) and has 
been found in tight linkage disequilibrium (in Caucasians) with rs2070150 which is associated 
with type II diabetes in Pima Indians (239). Mutations in the gene hepatocyte nuclear factor 
4 (HNF4 rs2144908) have been associated with NODAT (240) and reduced insulin secretion 
to glucose stimulation due to progressive β-cell dysfunction, with defects in the GLUT2 
transporter and mitochondrial dysfunction in the pathogenesis of maturity onset of diabetes 
in the young (241-243). mTOR has an indirect effect on HNF4α by its regulation of PPARGC1α 
which co-activates with HNF4α thus regulating downstream gluconeogenic targets (244, 
245). 
In vivo studies have shown chronic inhibition of mTOR by rapamycin leads to insulin 
resistance and lipid dysregulation associated with defective insulin, insulin growth factor 
signalling and β-cell toxicity (231, 246, 247). However, there remains controversy over the 
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use of sirolimus and the development of NODAT with some studies suggesting its use is an 
independent risk factor for NODAT (248) whilst in others, sirolimus has been used to 
improve the metabolic parameters in a small number of NODAT patients as a substitute for 
calcineurin inhibitors (249). Recent studies have also highlighted the dyslipidaemia, need for 
more anti-lipid medication (250) and the requirement for higher steroid dose in a sub-
analysis of the SYMPHONY trial with the use of sirolimus (251) and thus questions if 
conversion to sirolimus will improve the cardiovascular survival outcomes in patients with or 
at risk of NODAT. A recent meta-analysis of 21 randomised control trials has shown an 
increased risk of death with sirolimus conversion in kidney transplantation despite a 
significant decrease in malignancy (252).  
For the number of SNPs tested in this study compared to the 18 cases of NODAT and 50 non-
NODAT control patients, the power is 60% to identify OR of 2, with 20% minor allele 
frequency, thus the 5 identified SNPs in this study requires further validation in another 
cohort as the optimal way of confirming these findings (253). CAV1 rs4730751 was not 
associated with NODAT. This may have been due to the higher frequency of the minor allele 
at over 25% which meant the SNP demonstrated deviation from Hardy-Weinberg 
equilibrium and thus the interpretation is unreliable. 
In summary, this study represents a replication study of candidate SNPs in regard to the risk 
of developing NODAT following kidney transplantation. It is hypothesis generating into the 
prevailing mechanisms of this important complication of transplantation, and may even 
serve to stratify the risk for individual patients. Though previous attempts to use genetic 
variation in improving the risk for future type 2 diabetes development in addition to clinical 
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risk factors have only led to a net risk reclassification of 4% in the Framingham Offspring 
study risk (age, sex, parental history of type 2 diabetes, body mass index, high density 
lipoprotein cholesterol, triglycerides, fasting glucose) (254) and 5% to the Cambridge risk 
score (age, sex, drug treatment, family history of type 2 diabetes, body mass index, smoking 
status) (255). This chapter also highlights the importance of careful biochemical phenotyping 
with OGTTs to diagnose NODAT in reducing time to diagnosis and missed cases and how this 
can potentially change the genotype:phenotype associations found. 
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CHAPTER 6:  
RENAL EXPRESSION OF MURINE 
CAVEOLIN-1 
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6.1 Renal expression of murine caveolin-1 
6.1.1 Non-immune and stromal kidney cell staining 
By using confocal microscopy, it is possible to visualise where the expression of caveolin-1 
resides in the kidney. From the initial staining of wild-type frozen kidney tissue, Cav1 
appears to be expressed in the in the glomerulus, lining of tubules as well as the vasculature 
(Figure 6-1). 
 
Figure 6-1 Confocal microscopy showing caveolin-1 staining (green) in a x40 image of a wild-type 
mouse kidney frozen section. Nuclei appear as grey with DAPI staining 
 
 
Glomerulus 
Tubular 
lining 
Vessel 
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By staining with another antibody, it is possible to visualise how Cav1 expression resides 
near endothelial cells (CD31), vasculature (αSMA), tubular epithelial cells (E-cadherin) and 
podocytes (synaptopodin). For all confocal images, Cav1 staining is coloured green, other 
antibody staining red, nuclei staining grey and merged co-localisation yellow. 
As shown in Figure 6-2, caveolin-1 co-localises with CD31, especially in the glomerular 
endothelial cell and capillary loops. Cav1 is also aligned with the renal vasculature smooth 
muscle cells as represented by αSMA staining (Figure 6-3). αSMA is also a marker of 
myofibroblasts that were not present in the non-injured kidney. 
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Figure 6-2 CD31 (red) and caveolin-1 (green) confocal images. Caveolin-1 co-localisation with CD31 
especially in glomerular capillary loops and endothelium 
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Figure 6-3 αSMA (red) and caveolin-1 (green) confocal images highlighting the renal vasculature 
 
 
In Figure 6-4, Cav1 staining reveals a basolateral tubular distribution and does not co-localise 
with tubular epithelial cell marker E-cadherin in the mouse kidney that has not been injured. 
E-cadherin stains more abundantly in distal tubules, collecting ducts and medullary 
segments, but less so in proximal tubules (256, 257). It is an important molecule in tubular 
epithelial health by maintaining cell polarity (258). 
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Figure 6-4 E-cadherin (red) and caveolin-1 (green) confocal images 
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Podocytes reside within the glomerulus and are a common epithelial cell that becomes 
damaged in proteinuric diseases. The actin-based foot process of podocytes and interposed 
slit diaphragm are integral in preventing proteinuria. Synaptopodin is an actin-associated 
protein that is essential for the integrity of the podocyte cytoskeleton. In Figure 6-5, Cav1 is 
not associated with synaptopodin staining. 
Figure 6-5 Synaptopodin (red) and caveolin-1 (green) confocal images 
 
 
Wild-type mouse embryonic fibroblasts were isolated from day 13.5 embryos prior to the 
thesis by myself and stored in liquid nitrogen containers. These were thawed, and 2000 cells 
per well were cultured on a 6 well plate slide prior to being fixed in acetone and stained for 
caveolin-1 to confirm presence on this mouse strain fibroblasts (Figure 6-6). 
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Figure 6-6 Mouse embryonic fibroblasts stained with caveolin-1 (green) and DAPI for nuclei 
staining (grey) 
 
 
6.1.2 Immune cell and caveolin-1 staining 
Three antibodies were chosen to screen for immune cells in the kidney: CD45 (leucocytes), 
CD3e (T cells) and F4/80 (macrophages). However, it should be noted that CD3e may also 
stain for other T cells such as the Treg and Th17 cells as well as natural killer cells. CD3e 
stains for the 20kDa protein in the T cell receptor complex. F4/80 may also stain renal 
dendritic cells but these tend to express lower levels of F4/80 than renal macrophages (259). 
In Figure 6-7, CD45 staining revealed a small number of leucocytes are present in the non-
injured wild-type kidney with only one cell with co-localisation (yellow) with Cav1. 
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Figure 6-7 CD45 (red) and caveolin-1 (green) confocal images 
 
 
 
137 | P a g e  
 
Figure 6-8 shows only isolated CD3e positive cells in the kidney with Cav1 surrounding the 
same nuclei. 
Figure 6-8 CD3e (red) and caveolin-1 (green) confocal images 
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There are majority of leucocytes in the non-injured wild-type kidney were stained positively 
with F4/80 (Figure 6-9). 
Figure 6-9 F4/80 (red) and caveolin-1 (green) confocal images 
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6.2 Small animal models of renal fibrosis in the caveolin-1 knockout 
mouse 
In order to investigate the effects of caveolin-1 in renal fibrosis, two models of renal fibrosis 
were used in the wild-type and caveolin-1 knockout (CKO) mouse. The aim of these were to 
see what happens to caveolin-1 expression in renal fibrosis and if caveolin-1 knockout led to 
more renal fibrosis. 
 
6.2.1 Ciclosporin model of renal fibrosis 
As this model had not been trialled in Birmingham before, pilot studies were carried out 
using wild-type mice. For the first pilot, C57BL/6 mice were used as this was the major strain 
of the CKO mouse. Unfortunately, on the fourth day of the subcutaneous injections (and 
despite the mice from the vehicle group looking well) the CsA treated group displayed 
unhealthy toxic fur and facial features so the mice were culled. They were then investigated 
to see what had happened. It is likely the combination of CsA with Cremophor EL and 
ethanol induced an acutely toxic hepatic and acute kidney injury which was reflected in their 
weight (p=0.01 with reduction in weight in the CsA treated mice, Mann-Whitney U) and 
blood results with deteriorating kidney and liver function tests (Figure 6-10). 
Hepatic histology also revealed similar changes with H&E staining showing acute liver injury 
with vacuolation and loss of architecture. Renal histology showed features consistent with 
acute kidney injury with marked vacuolation of tubules Figure 6-11. 
140 | P a g e  
 
Figure 6-10 First ciclosporin model pilot results (n=4). Control group received vehicle and treatment 
group received ciclosporin in the vehicle 
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Figure 6-11 Representative H&E sections of liver and kidney tissue from the initial ciclosporin pilot 
 
 
 
 
   
 
The vehicle was changed to olive oil instead of Cremophor that allowed a marked reduction 
of 94% ethanol to be used to dissolve the ciclosporin (50mg ciclosporin in 0.35mls 94% 
ethanol and 4.65mls of olive oil = [10mg/ml]). This emulsion could now be drawn up into a 
1ml syringe easily. An initial 14 day toxicity trial (with preceding 7 day low salt diet) was 
conducted with one mouse in each 10mg/Kg, 15mg/Kg, 20mg/Kg and 30mg/Kg group and 
two mice receiving 3mls/Kg vehicle (to estimate similar volumes of the CsA receiving group). 
As there was no overt toxicity displayed, the 30mg/Kg and vehicle only mice continued to 
receive subcutaneous injections until day 28, with the addition of two 30mg/Kg CsA 
Control Treatment 
Liver 
Kidney 
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receiving mice, and a further vehicle only receiving mouse. All mice successfully reached the 
end of the pilot. 
Upon blood sampling, there was no significant difference in renal and liver function between 
the 30mg/Kg receiving CsA and the control vehicle receiving mice (n=3, Table 6-1).  There 
was no increased fibrosis staining seen on renal histology. 
 
Table 6-1 Blood sampling results from the second ciclosporin model pilot; treatment (Rx) group 
and vehicle (Control) group 
 
Mouse BUN Creatinine Total Billirubin 
Dosage of 
CsA 
 
(mg/dl) (µmol/l) (µmol/l) (mg/Kg) 
Rx1 17.60 14.4 4.6 10.0 
Rx2 16.31 15.6 4.1 15.0 
Rx3 28.05 13.2 3.7 20.0 
Rx4 22.77 17.2 4.3 30.0 
Rx5 38.57 20.0 3 30.0 
Rx6 76.07 72.0 4 30.0 
  
    Control 1 21.40 11.4 2.5 0.0 
Control 2 17.46 16.7 2.4 0.0 
Control 3 21.43 15 2.0 0.0 
 
 
A third pilot study was designed to use CD-1 mice instead of the C57BL/6 strain, as per 
Andoh et al in 1997 (189). Five CD-1 mice received the vehicle, whilst five mice received 
30mg/Kg/day of subcutaneous CsA treatment. There were no significant differences 
between renal function and weight changes of the groups. The ciclosporin levels were 
undetectable in the control group (reported as <20µg/l) and average of 450 µg/l (standard 
deviation: 101µg/l) in the treatment group (Figure 6-12).  
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Figure 6-12 Results from the third ciclosporin pilot model of renal fibrosis (n=5) 
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Upon blinded histopathologist review, the expected patchy fibrosis was quite minor for this 
model compared to control (Figure 6-13). 
Figure 6-13 Representative Masson Trichrome stain for control and post CsA treatment mice. Note 
the subtle patchy blue fibrosis highlighted by the blue rectangle 
 
 
 
 
There was no significant difference seen on RT-qPCR mRNA fold induction (Figure 6-14) for 
Cav1, TGFβ-1, collagen 1α1 and collagen 3α1 between vehicle receiving mice (control) and 
CsA receiving mice (treatment). 
Control Treatment 
145 | P a g e  
 
Figure 6-14 RT-qPCR mRNA fold induction in control and treatment groups in the third ciclosporin 
model pilot of renal fibrosis (n=5) 
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In light of these findings and in conjunction with the BMSU, it was decided not pursue this 
model. There have been a number of issues with the CsA model despite the success of the 
non-toxicity pilot. The strain switch from C57BL/6 to CD-1 was made as no overt fibrosis was 
seen and previous studies have shown a tubular necrotic rather than an interstitial fibrotic 
picture using this strain (260). However the third pilot using CD-1 mice was thought to be 
too much of a subtle fibrotic model and would require a large number of animals to continue 
the experiments themselves and the number/generations required to backcross the CKO 
mouse onto the pure CD-1 background, which as an outbred strain has inherent problems as 
well. Thus, this model was abandoned. 
As a result, an additional time-point was added to the UUO model at day 3 so the early 
inflammatory/fibrotic stage effects of Cav1 in the wild-type and the KO could be examined. 
The confocal/histology frozen snapped tissue had evidence of freeze burn in the CsA models 
so tissue storage was changed so kidneys were fixed in PFA 4% immediately for 2 hours at 
room temperature and then placed in 18% sucrose overnight at 4°C. The tissue quarters 
were then embedded in OCT that is frozen using liquid nitrogen vapour. 
 
6.2.2 Unilateral ureteric obstruction model of renal fibrosis 
6.2.2.1 Introduction 
Unilateral ureteric obstruction (UUO) causes a cascade of events that leads to marked 
interstitial fibrosis between day 7-14 after obstruction (261). The overall renal function is not 
affected due to the non-obstructed (contra-lateral) kidney undergoing hypertrophy to 
compensate for loss of renal filtration. Thus it is essential that separate sham operated mice 
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are used as control rather than using the contra-lateral kidney as control due to variations in 
compensation (262). The UUO animal model has been used to investigate renal fibrosis for 
over 50 years initially in rabbits (263), but lately in rats and mice due to their susceptibility to 
gene alterations allowing investigation of the respective gene deletion upon interstitial 
fibrosis. The development of interstitial fibrosis is the resultant effect from angiotensin type 
1 receptor stimulation and TGFβ-1 induction, due to reduction of renal blood flow with the 
first 24 hours of UUO. After several days, hydronephrosis occurs on the side of the UUO with 
interstitial inflammatory macrophages influx and tubular cell death from apoptosis and 
necrosis (262). Myofibroblasts are abundant from epithelial and endothelial mesenchymal 
transition (EMT and endo-MT respectively) and vascular rarefaction from destabilisation 
after pericyte transformation to myofibroblasts (264). This leads to collagen 1 and III 
interstitial deposition as well as collagen IV mainly in the tubular basement membrane. 
Initially a pilot model was performed to see if the model could be reproducible in my hands 
using C57BL/6 mice as wild-type controls and then in the CKO mouse. Vascular clips were 
used to obstruct the ureter initially but I noted that occasionally the clips could injure the 
ureter and if not closed sufficiently, urine would be allowed to pass through. To counter this, 
two sutures were placed around the ureter to cause obstruction and not allow urine to pass 
through. From the initial pilot, it was observed that the CKO group had a marked destruction 
of the renal architecture at day 14 of the UUO model as compared to its wild-type 
counterpart upon histological staining Figure 6-15. There was a non-significant reduction in 
the kidney:body weight Figure 6-16. 
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Figure 6-15 Haemtoxylin and eosin staining of day 14 UUO left kidneys in the wild-type and 
caveolin-1 knockout mouse. There is marked destruction of the renal architecture with volume loss 
and tubular atrophy. 
 
 
Figure 6-16 The kidney to body weight ratio of the left kidney was non-significantly reduced in 
knockout mouse (n=3, Mann-Whitney U) 
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6.2.2.2 Caveolin-1 expression in the UUO model of renal fibrosis 
 
Caveolin-1 expression is increased in the left obstructed kidney as compared to sham 
operated wild-type mice. RT-qPCR mRNA fold induction was increased significantly to sham 
in the day 14 model (p=0.022) and increased in the day 3 model, but this did not attain 
statistical significance (p=0.055). After calculating mRNA the fold induction using the sham 
operating mouse as control (see methods 2.1.2.6), there was a relative 6.9 (±2.5) fold 
increase in Cav1 mRNA in the day 14 as compared to the day 3 left obstructed kidney 
(p=0.033, Figure 6-17). 
 
Figure 6-17 Relative fold induction ratio caveolin-1 increase in day 14 compared to day 3 model of 
the left obstructed kidney 
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Cav1 protein expression was also increased as seen with Western blotting, the longer the 
model of fibrosis studied (Figure 6-18). Representative images using confocal microscopy 
also show an increase in Cav1 staining as the temporal length of fibrotic injury progresses 
compared to sham (Figure 6-19). 
 
Figure 6-18 Representative Western blot showing the caveolin-1 protein expression in relation to β 
actin in the left kidney: day 14 versus day 3 models of renal fibrosis 
 
 
 
 
 
Key: Cav1: caveolin-1; d14: day 14; d3: day 3, WT: wild-type, L: left 
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Figure 6-19 Confocal microscopy (x10) of caveolin-1 staining in the left UUO kidney 
 
 
 
 
When comparing the contralateral kidneys, there was over 3 fold induction significant 
increase in Cav1 mRNA corresponding to the physiological compensation of the right kidney 
in UUO injury, as well as increased Cav1 protein expression (Figure 6-20 and Figure 6-21 
respectively). This highlights that sham operated mice should be used as controls rather than 
the right kidney in the UUO model of injury. There was a non-significant rise in right kidney 
Cav1 mRNA between days 3 and 14 of the model (p=0.51, unpaired t-test). 
 
Sham Day 3 Day 14 
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Figure 6-20 Comparison of the caveolin-1 fold induction change of the right compensatory kidney 
in UUO wild-type mice to the left sham operated kidney. One-way ANOVA (top line) to compare 
difference between groups and post Dunnett’s multiple comparison test for day 3 and day 14 to 
right sham operated kidney 
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Figure 6-21 Western blot of the wild-type right kidney in UUO. Knockout left kidney included that 
shows no caveolin-1 protein expression present. 
 
 
 
 
 
 
 
 
 
Key: Cav1: caveolin-1; d14: day 14; d3: day 3, WT: wild-type, R: right, L: left, CKO: caveolin-1 
knockout 
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6.2.2.3 Other markers of fibrosis in UUO 
 
As the model advances with time, there are significant increases in TGFβ-1, collagen 1α1 and 
collagen 3α1 fold induction as well as a non-significant increase in Gomori staining of fibrosis 
(Figure 6-22). Wild-type mice of the day 3 model of UUO lose weight as compared to day 14. 
Figure 6-22 Relative fold induction ratio, weight change and Gomori staining of wild-type UUO 
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Confocal microscopy shows an increase in CD31, F4/80 and αSMA positive staining in day 3 
and day 14 models as compared to sham operated mice (Figure 6-23). 
Figure 6-23 CD31, F4/80 and αSMA confocal staining in wildtype mice in UUO models of fibrosis 
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6.2.2.4 Unilateral ureteric obstruction in caveolin-1 knockout mice 
 
Sham operated wild-type and CKO mice did not significantly differ in the fold induction of 
TGFβ-1, collagen 1α1 or collagen 3α1 (Figure 6-24). 
 
Figure 6-24 Wild-type (WT) and caveolin-1 knockout (KO) mice sham operated mice show non-
significant (ns) mRNA fold induction changes 
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The CKO mice show a similar pattern of progressive fibrosis as the UUO model temporally 
progresses. As the model advances with time, there are significant increases in TGFβ-1, 
collagen 1α1 and collagen 3α1 fold induction as well as a significant increase in Gomori 
staining of fibrosis. The CKO mice lose more weight at day 3 than at day 14 time points of the 
UUO model (Figure 6-25). 
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Figure 6-25 Relative fold induction ratio, weight change and Gomori staining of knockout left 
obstructed kidney at day 3 and day 14 of the UUO model 
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Whilst there are significant increases in the mRNA fold induction ratios of TGFβ-1, collagen 
1α1 and collagen 3α1, and more weight reduction in the CKO mouse group at day 3, there is 
an increase in the Gomori fibrosis percentage seen in the wild-type group (Figure 6-26). 
Figure 6-26 Relative fold induction ratio, weight change and Gomori staining of left obstructed 
kidney, comparing wild-type to caveolin-1 knockout at day 3 
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Whilst there are significant decreases in the mRNA fold induction ratios of TGFβ-1 and 
collagen 3α1, and weight reduction in the CKO mouse group at day 14, there is an increase in 
the Gomori fibrosis percentage seen in the CKO group, which is the opposite seen at day 3 
(Figure 6-27). 
Figure 6-27 Relative fold induction ratio, weight change and Gomori staining of left obstructed 
kidney, comparing wild-type to caveolin-1 knockout at day 14 
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The most striking difference with confocal microscopy between wild-type and CKO groups is 
the amount of F4/80 staining seen as the model progresses with time. This staining is more 
visible in the wild-type than CKO group (Figure 6-28). 
Figure 6-28 Confocal F4/80 staining in wild-type and caveolin-1 knockout mice 
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There were non-significant increases in the fold induction ratio changes in the right 
compensatory kidney between day 3 and day 14 models and wild-type and CKO groups. 
There were no changes in the Gomori staining of the right kidneys in UUO (Figure 6-29). 
Figure 6-29 Right compensatory kidneys relative fold induction ratios and Gomori staining at day 3 
and day 14 in wild-type and caveolin-1 knockout groups 
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6.2.3 Discussion 
 
From the staining seen on confocal microscopy, caveolin-1 is expressed in the renal 
endothelium including the glomerular endothelium, vasculature and basolateral aspects of 
tubules, F4/80 and CD3e staining positive cells. There was an increase in caveolin-1 
expression, whether at a protein or mRNA level, seen in the UUO model of renal fibrosis in 
the injured kidney in the wild-type mouse as compared to sham. This is consistent with the 
literature described in section 1.2.5.1 where there is an observed increase in caveolin-1 
expression upon injury to the human and murine kidney. Cav1 expression was more 
pronounced the later the UUO injury had occurred. 
After an initial increase in CD31 confocal staining at day 3 of the UUO model (as compared to 
sham operated mice), there was decrease in CD31 staining by day 14, whilst αSMA staining 
was increased at day 14 as compared to day 3. This phenomenon has been noted previously 
in murine UUO and represents a likely endothelial to mesenchymal transition to 
myofibroblasts (265). 
Align to this, at day 3 there was a decline in the murine weight. Although this could be due 
to the recent surgery, it could reflect an inflammatory systemic milieu that was more 
pronounced in the CKO group, hence less Gomori staining with increased TGFβ-1 and 
collagen I and III mRNA in the CKO group at day 3. There was also a failure of weight gain the 
CKO group at day 14 as compared to the day 14 wild-type mice, with a reduction in TGFβ-1 
and collagen I and III mRNA and increased Gomori collagen staining. The fibrotic matrix is 
rich in fibrillar collagen I and III (266). This is likely to reflect the established accelerated 
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fibrosis in the CKO day 14 group compared to wild-type. Wild-type Cav1 expression was also 
increased in the compensatory right non-obstructed kidney as compared to sham at day 3 
and day 14. This highlights that the contralateral kidney should not be used as control in the 
UUO model. 
The most striking difference between the wild-type and knockout groups is the F4/80 
positive staining cells, which was greater in the wild-type model. During the initial injury 
from UUO, tubular cell death and extracellular matrix remodelling lead to the release a 
hetergenous set of molecules called danger associated molecular pattern molecules (such as 
hylauronan, fibronectin and uromodulin) that trigger sterile inflammation via the innate 
immune system (267). They promote polarization of resident and infiltrating macrophages to 
either M1 (known as classical or pro-inflammatory) or M2 (alternative or regulatory/pro-
fibrotic) phenotypes. M1b macrophages predominate during the onset of sterile 
inflammation (268) and injury with pericyte detachment and vascular rarefaction (269), 
releasing pro-inflammatory cytokines and reactive oxygen species, exacerbating the initial 
injury promoting epithelial and endothelial mesenchymal transition via metalloproteinases 
and degrading the extracellular matrix.  M2 macrophages release TGFβ-1, IL-10, VEGF and 
phagocytose (270). With Cav1 deletion, macrophages have been shown to have a reduced 
phagocytic ability after lipopolysaccharide challenge and thus a potential reduced ability to 
clear apoptotic cells, releasing more inflammatory cytokines (271). In cardiac models of 
fibrosis, Cav1 deletion has led to a maladaptive repair process with increased inflammatory 
molecules as well as more M2 polarized macrophages at an earlier time-point as compared 
to wild-type (272). In the CKO UUO group at day 3, the mRNA of TGFβ-1, collagen I and III 
were all increased suggesting there is more M2 phenotype as well. However by day 14 in the 
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CKO versus wild-type group, the initial M2 ‘wound’ healing macrophage phenotype is 
maladaptive with substantial remodelling of the interstitium with collagen-based scar tissue 
as shown by Gomori staining. 
The worsening of fibrosis in the CKO day 14 group mirrors the findings of the only published 
literature of the UUO model of renal fibrosis in Cav1 knockout mice. Park et al showed that 
at day 10 of UUO, there was a reduced surge in mesenchymal stem cells with associated 
worse fibrosis in the CKO group (119). Cav1 is required for renal stem cell engraftment as 
CXCR4 dimerization induced by stromal cell-derived factor-1 occurs in caveolae. It should be 
noted however Park et al has used a different strain for the wild-type compared to the CKO 
group, thus with different mouse strains have varying susceptibility to fibrosis, this may have 
affected the changes seen. 
In conclusion, Cav1 mRNA and expression on Western blotting is increased at day 3 and 
further increased day 14 UUO, in line with published murine and human data in renal 
disease. However, upon its deletion, fibrosis worsens at day 14 of the UUO model compared 
to wild-type. 
 
 
 
 
 
165 | P a g e  
 
 
 
 
 
 
 
CHAPTER 7:  
     GENERAL DISCUSSION 
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7.1 General Discussion 
Patients with CKD suffer adverse effects as a result of their disease or side-effects of the 
treatment required to treat their underlying illness. It is paramount to be able to risk stratify 
these patients’ phenotype in regards to these adverse effects in order to introduce a 
personalised approach to future therapy. Patients with CKD suffer from increased morbidity 
and mortality related to cardiovascular disease, infection and malignancy as compared to 
the general population. This thesis has highlighted the use of CAV1 SNP rs4730751 in 
identifying those patients with increased morbidity and mortality, not only within a systemic 
disease such as AAV that encompasses cardiovascular, infection and malignancy related 
death but also progression of renal disease to ESRD. Arterial stiffness has also been 
associated with an increased risk of cardiovascular disease as CKD progresses, and as shown 
in chapter 3.1.1, the expressed SNP is associated with differing arterial stiffness. The 
common finding in the thesis is that the CC genotype is associated with a protective 
phenotype in the adverse effects of CKD. However, the question remains as to whether this 
SNP’s association relates to direct mechanistic causality, as the SNP is found on the non-
coding intron of the CAV1 gene (Figure 7-1). In general, intronic SNP could be in linkage 
disequilibrium with another gene, however, rs4730751 is not in linkage disequilibrium with 
genetic variants in exons that may truncate or alter CAV1 protein (158). Thus its effect may 
be by influencing resulting transcripts or splicing (273). In mice, intronic variance in the Cav1 
gene has shown changes in the predominance of the isoform of caveolin-1 expressed (274). 
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Figure 7-1 Caveolin-1 single nucleotide polymorphism rs4730751 location on chromosome 7 
 
 
Key: Red rectangle showing location of CAV1 SNP rs4730751 
 
As eNOS is bound to CAV1, eNOS SNP rs1799983 was also found to risk stratify patients with 
evidence of left ventricular wall remodelling in early stage CKD. Although CAV1 rs4730751 
SNP was not shown to be associated with NODAT, the use of SNP variants in common genes 
which are associated with the development of NODAT following kidney transplantation, 
offered a hypothesis generating method to our understanding of mechanisms involved in 
NODAT development and the potential for risk-stratifying patients pre-transplantation. As 
shown in this thesis, patients' phenotype could be differentiated in kidney disease by CAV1 
and related candidate gene SNPs. 
The murine models of renal fibrosis did show that lack of Cav1 led to an increased fibrotic 
phenotype. Although this has been shown in non-renal organ fibrotic diseases, it was 
important to show this in the kidney, as the fibrotic response is dependent on the local 
tissue microenvironment of specialised structures, resident organ cells and response to 
infiltrating cells in the target organ. The majority of the existing renal in vivo CAV1 research 
has shown an increased expression with a worse renal phenotype in children with congenital 
ureteric obstruction (131) and in adult based glomerular disease (132), with authors 
indicating that CAV1 expression was detrimental. Use of the CKO mouse has shown a 
protective phenotype in a largely glomerular disease model of diabetic nephropathy using 
steptozotocin (133), and similar protection in mesangial matrix expansion using pathological 
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light chains (134). These latter studies serve to highlight that glomerulus is a specialised 
microenvironment within the kidney where CAV1 expression leads to a worse phenotype, 
whilst in models of interstitial fibrosis, this thesis and Park et al (119) have shown that CAV1 
expression is protective. The exact mechanism is likely multifactorial with Park et al showing 
the surge of mesenchymal stem cell is curtailed with no CXCR4 dimerization without 
caveolae as well as observed differences in F4/80 positive staining cells in this thesis. Park et 
al did show that overexpression of caveolin-1 was associated with an increased neointimal 
formation suggesting the interplay between inflammation, matrix turnover, wound 
fibrogenesis/healing and scar formation is key in forming an adaptive or maladaptive repair 
process, with CAV1 expression central to this process. Luminex could be used to examine the 
cytokine profile in the differing time-points of the UUO model in the CKO and wild-type 
groups. Flow cytometry could also be used to identify the types of macrophages seen in the 
UUO model between the groups. 
The exact timing of increased CAV1 protein or gene expression in a renal disease process 
either acutely, glomerular based or in reversing a scarring process remains to be elucidated 
as does its role in influencing improved renal outcome. Future studies would look to use a 
conditional knockout to investigate models of renal fibrosis at different time-points to find 
the optimal timing of any negative effects of Cav1 expression. It would also be preferable to 
use a more chronic model of renal fibrosis such as the folic acid model of nephropathy with 
resulting reduced eGFR and use other models that mimic immune mediated and heavily 
proteinuric diseases to reflect the diversity seen in human disease. To answer the question 
of the effects of infiltrating leucocytes into the kidney, bone marrow chimeras of the wild-
type and knockout animal can be used in the renal models of fibrosis. It is also exciting to see 
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that the non-phosphorylatable CAV1 Y14 prevented VEGF-induced RhoA activation and 
fibronectin upregulation in mesangial cells (127) and future studies should consider the use 
of this non-phosphorylatable CAV1 Y14 in potentially reducing renal interstitial fibrosis. 
By using a patient’s CAV1 rs4730751 genotype, future studies could look to tailor treatment 
balancing the risk and intensity of therapy such as immunosuppression in cardiovascular, 
infective and malignant associated related mortality to likely progression of the renal disease 
itself. Renal biopsies could be used from these patients to examine the degree of interstitial 
fibrosis and caveolin-1 expression including the dominant isoform expressed to see if there is 
an overt functional difference between the genotypes. From the Lancet in July 2016, 
thirteen fibrotic genes predicting future fibrosis in renal allografts was found from examining 
the renal transplant biopsy transcriptome (275). A similar approach could be extended to 
see if any genetic differences can be found in biopsy tissue depending on patient’s genotype 
in renal allografts as previously donor CAV1 SNP rs4730751 genotype predicted renal 
allograft survival and fibrosis (82, 158). This could assist understanding of how variation with 
this SNP could lead to fibrotic change. Future potential therapy could include delivering 
CAV1 to donor kidneys whilst being machine perfused prior to transplantation. 
In conclusion, the CAV1 rs4730751 SNP could be used as a marker of disease risk either in 
isolation or as part of a clinical risk score to counsel patients on the likely prognosis of their 
condition.  The pleiotropic effects of CAV1 can differentiate patients' phenotype in CKD. 
Manipulation of CAV1 expression has the potential in manipulating the renal fibrotic process 
by altering macrophage number and potentially phenotype, and altering TGFβ-1 expression 
and the endothelial to mesenchymal transitional process. 
170 | P a g e  
 
 
 
 
 
 
 
CHAPTER 8:  
                      REFERENCES 
 
 
 
 
 
 
 
 
 
 
 
 
 
171 | P a g e  
 
8.1 References 
1. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, et al. Prevalence of chronic kidney 
disease in the United States. Jama. 2007;298(17):2038-47. 
2. Kerr M, Bray B, Medcalf J, O'Donoghue DJ, Matthews B. Estimating the financial cost of 
chronic kidney disease to the NHS in England. Nephrol Dial Transplant. 2012;27 Suppl 3:iii73-80. 
3. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to 
estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of 
Diet in Renal Disease Study Group. Ann Intern Med. 1999;130(6):461-70. 
4. Levey AS, Coresh J, Greene T, Marsh J, Stevens LA, Kusek JW, et al. Expressing the 
Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with 
standardized serum creatinine values. Clin Chem. 2007;53(4):766-72. 
5. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Ford CE, et al. Blood pressure and 
end-stage renal disease in men. N Engl J Med. 1996;334(1):13-8. 
6. Ruilope LM, Campo C, Rodriguez-Artalejo F, Lahera V, Garcia-Robles R, Rodicio JL. Blood 
pressure and renal function: therapeutic implications. J Hypertens. 1996;14(11):1259-63. 
7. Fraser SD, Roderick PJ, Aitken G, Roth M, Mindell JS, Moon G, et al. Chronic kidney disease, 
albuminuria and socioeconomic status in the Health Surveys for England 2009 and 2010. J Public 
Health (Oxf). 2014;36(4):577-86. 
8. Aitken GR, Roderick PJ, Fraser S, Mindell JS, O'Donoghue D, Day J, et al. Change in prevalence 
of chronic kidney disease in England over time: comparison of nationally representative cross-
sectional surveys from 2003 to 2010. BMJ Open. 2014;4(9):e005480. 
9. Weiner DE, Tighiouart H, Amin MG, Stark PC, MacLeod B, Griffith JL, et al. Chronic kidney 
disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of 
community-based studies. J Am Soc Nephrol. 2004;15(5):1307-15. 
10. Chapter 1: Definition and classification of CKD. Kidney Int Suppl (2011). 2013;3(1):19-62. 
11. Scott RP, Quaggin SE. Review series: The cell biology of renal filtration. J Cell Biol. 
2015;209(2):199-210. 
12. Tampe B, Zeisberg M. Contribution of genetics and epigenetics to progression of kidney 
fibrosis. Nephrol Dial Transplant. 2014;29 Suppl 4:iv72-9. 
13. Reese PP, Cappola AR, Shults J, Townsend RR, Gadegbeku CA, Anderson C, et al. Physical 
performance and frailty in chronic kidney disease. Am J Nephrol. 2013;38(4):307-15. 
14. Tonelli M, Wiebe N, Guthrie B, James MT, Quan H, Fortin M, et al. Comorbidity as a driver of 
adverse outcomes in people with chronic kidney disease. Kidney Int. 2015;88(4):859-66. 
15. Smyth LJ, Duffy S, Maxwell AP, McKnight AJ. Genetic and epigenetic factors influencing 
chronic kidney disease. Am J Physiol Renal Physiol. 2014;307(7):F757-76. 
16. Igarashi P, Somlo S. Genetics and pathogenesis of polycystic kidney disease. J Am Soc 
Nephrol. 2002;13(9):2384-98. 
17. Genomes Project C, Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, et al. A global 
reference for human genetic variation. Nature. 2015;526(7571):68-74. 
18. Thomas PD. Single Nucleotide Polymorphisms in Human Disease and Evolution: Phylogenies 
and Genealogies.  eLS: John Wiley & Sons, Ltd; 2001. 
19. Keller BJ, Martini S, Sedor JR, Kretzler M. A systems view of genetics in chronic kidney 
disease. Kidney Int. 2012;81(1):14-21. 
20. Renkema KY, Stokman MF, Giles RH, Knoers NV. Next-generation sequencing for research 
and diagnostics in kidney disease. Nat Rev Nephrol. 2014;10(8):433-44. 
21. Kottgen A, Pattaro C, Boger CA, Fuchsberger C, Olden M, Glazer NL, et al. New loci associated 
with kidney function and chronic kidney disease. Nat Genet. 2010;42(5):376-84. 
172 | P a g e  
 
22. Stanescu HC, Arcos-Burgos M, Medlar A, Bockenhauer D, Kottgen A, Dragomirescu L, et al. 
Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy. N Engl J Med. 
2011;364(7):616-26. 
23. Beck LH, Jr., Bonegio RG, Lambeau G, Beck DM, Powell DW, Cummins TD, et al. M-type 
phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 
2009;361(1):11-21. 
24. Bullich G, Ballarin J, Oliver A, Ayasreh N, Silva I, Santin S, et al. HLA-DQA1 and PLA2R1 
polymorphisms and risk of idiopathic membranous nephropathy. Clin J Am Soc Nephrol. 
2014;9(2):335-43. 
25. Lyons PA, Rayner TF, Trivedi S, Holle JU, Watts RA, Jayne DR, et al. Genetically distinct 
subsets within ANCA-Associated Vasculitis. N Engl J Med. 2012;367(3):214-23. 
26. Fraga MF, Ballestar E, Paz MF, Ropero S, Setien F, Ballestar ML, et al. Epigenetic differences 
arise during the lifetime of monozygotic twins. Proc Natl Acad Sci U S A. 2005;102(30):10604-9. 
27. Simmonds MJ, Benavente D, Brand OJ, Moore J, Ball S, Ferro CJ, et al. Skewing of female X-
chromosome inactivation: an epigenetic risk factor for kidney transplantation outcome. 
Transplantation. 2013;95(5):e25-8. 
28. Chand S, McKnight AJ, Borrows R. Genetic polymorphisms and kidney transplant outcomes. 
Curr Opin Nephrol Hypertens. 2014;23(6):605-10. 
29. Israni A, Leduc R, Holmes J, Jacobson PA, Lamba V, Guan W, et al. Single-nucleotide 
polymorphisms, acute rejection, and severity of tubulitis in kidney transplantation, accounting for 
center-to-center variation. Transplantation. 2010;90(12):1401-8. 
30. O'Brien RP, Phelan PJ, Conroy J, O'Kelly P, Green A, Keogan M, et al. A genome-wide 
association study of recipient genotype and medium-term kidney allograft function. Clin Transplant. 
2013;27(3):379-87. 
31. Hou W, Huang Z, Ji Z, Zhou J. Human leukocyte antigen-G-14-base-pair-insertion/deletion 
polymorphism and graft survival in kidney transplant recipients. Exp Clin Transplant. 2014;12(2):89-
94. 
32. Littera R, Piredda G, Pani A, Frongia M, Onano B, Michittu MB, et al. Role of human leukocyte 
antigen-G 14-base pair polymorphism in kidney transplantation outcomes. J Nephrol. 
2013;26(6):1170-8. 
33. Israni AK, Leduc R, Jacobson PA, Wildebush W, Guan W, Schladt D, et al. Inflammation in the 
setting of chronic allograft dysfunction post-kidney transplant: phenotype and genotype. Clin 
Transplant. 2013;27(3):348-58. 
34. Bay JT, Schejbel L, Madsen HO, Sorensen SS, Hansen JM, Garred P. Low C4 gene copy 
numbers are associated with superior graft survival in patients transplanted with a deceased donor 
kidney. Kidney Int. 2013;84(3):562-9. 
35. Engela AU, Boer K, Roodnat JI, Peeters AM, Eilers PH, Kal-van Gestel JA, et al. Genetic 
variants of FOXP3 influence graft survival in kidney transplant patients. Hum Immunol. 
2013;74(6):751-7. 
36. Karimi MH, Hejr S, Geramizadeh B, Yaghobi R, Sagheb MM, Kamali-Sarvestani E. Combined 
analysis of cytokine gene polymorphism and the level of expression with allograft function in kidney 
transplant recipients. Transpl Immunol. 2014;30(1):46-51. 
37. Hejr S, Karimi MH, Yaghobi R, Kamali-Sarvestani E, Geramizadeh B, Roozbeh J. Association of 
IL-17, IL-21, and IL-23R gene polymorphisms with HBV infection in kidney transplant patients. Viral 
Immunol. 2013;26(3):201-6. 
38. El-Gezawy EM, Eldin EN, Mohamed WS, Mahmoud MS, Saied SA, Abd El-Latif HH, et al. 
Tumor necrosis factor-alfa and monocyte chemoattractant protein-1 gene polymorphisms in kidney 
transplant recipients. Saudi J Kidney Dis Transpl. 2013;24(4):688-95. 
173 | P a g e  
 
39. Lee JP, Kim do H, Yang SH, Hwang JH, An JN, Min SI, et al. Serum bilirubin affects graft 
outcomes through UDP-glucuronosyltransferase sequence variation in kidney transplantation. PLoS 
One. 2014;9(4):e93633. 
40. Kim TH, Jeong KH, Kim SK, Lee SH, Ihm CG, Lee TW, et al. TLR9 gene polymorphism 
(rs187084, rs352140): association with acute rejection and estimated glomerular filtration rate in 
renal transplant recipients. Int J Immunogenet. 2013;40(6):502-8. 
41. Vu D, Tellez-Corrales E, Shah T, Hutchinson I, Min DI. Influence of Cyclooxygenase-2 (COX-2) 
gene promoter-1195 and allograft inflammatory factor-1 (AIF-1) polymorphisms on allograft 
outcome in Hispanic kidney transplant recipients. Hum Immunol. 2013;74(10):1386-91. 
42. Wu X, Wan Q, Ye Q, Zhou J. Mannose-binding lectin-2 and ficolin-2 gene polymorphisms and 
clinical risk factors for acute rejection in kidney transplantation. Transpl Immunol. 2014;30(2-3):71-5. 
43. Ge YZ, Wu R, Jia RP, Liu H, Yu P, Zhao Y, et al. Association between interferon gamma +874 
T>A polymorphism and acute renal allograft rejection: evidence from published studies. Mol Biol 
Rep. 2013;40(10):6043-51. 
44. Gaafar A, Iqniebi A, Sheereen A, Eldali A, Turpeinen H, Adra C, et al. Study of the cytokine 
polymorphisms in correlation to rejection and graft survival in renal allograft donors and recipients 
from a homogenous Saudi population. Transpl Immunol. 2014;30(1):34-9. 
45. Dhaouadi T, Sfar I, Bardi R, Jendoubi-Ayed S, Abdallah TB, Ayed K, et al. Cytokine gene 
polymorphisms in kidney transplantation. Transplant Proc. 2013;45(6):2152-7. 
46. Kloda K, Domanski L, Pawlik A, Safranow K, Ciechanowski K. The impact of ICAM1 and VCAM1 
gene polymorphisms on long-term renal transplant function and recipient outcomes. Ann Transplant. 
2013;18:231-7. 
47. Pawlik A, Dabrowska-Zamojcin E, Dziedziejko V, Safranow K, Domanski L. Association 
between IVS3 +17T/C CD28 gene polymorphism and the acute kidney allograft rejection. Transpl 
Immunol. 2014;30(2-3):84-7. 
48. La Manna G, Cappuccilli ML, Capelli I, Baraldi O, Cuna V, Battaglino G, et al. The impact of 
apoptosis and inflammation gene polymorphisms on transplanted kidney function. Ann Transplant. 
2013;18:256-64. 
49. Wan QQ, Li JL, Ye QF, Zhou JD. Genetic association of tumor necrosis factor-beta, interleukin-
10, and interleukin-1 gene cluster polymorphism with susceptibility to pneumonia in kidney 
transplant recipients. Transplant Proc. 2013;45(6):2211-4. 
50. Chen Z, Bouamar R, Van Schaik RH, De Fijter JW, Hartmann A, Zeier M, et al. Genetic 
polymorphisms in IL-2, IL-10, TGF-beta1, and IL-2RB and acute rejection in renal transplant patients. 
Clin Transplant. 2014. 
51. Krichen H, Gorgi Y, Dhaouadi T, Mecheri Y, Sfar I, Bardi R, et al. Toll-like receptor 4 and CD14 
gene polymorphisms in Tunisian kidney transplantation. Transplant Proc. 2013;45(10):3472-7. 
52. Kloda K, Domanski L, Bobrek-Lesiakowska K, Pawlik A, Safranow K, Kwiatkowska E, et al. The 
impact of CTLA4 and PTPN22 genes polymorphisms on long-term renal allograft function and 
transplant outcomes. Ren Fail. 2013;35(9):1223-7. 
53. Suzuki Y, Itoh H, Fujioka T, Sato F, Kawasaki K, Sato Y, et al. Association of plasma 
concentration of 4beta-hydroxycholesterol with CYP3A5 polymorphism and plasma concentration of 
indoxyl sulfate in stable kidney transplant recipients. Drug Metab Dispos. 2014;42(1):105-10. 
54. Stifft F, Stolk LM, Undre N, van Hooff JP, Christiaans MH. Lower variability in 24-hour 
exposure during once-daily compared to twice-daily tacrolimus formulation in kidney 
transplantation. Transplantation. 2014;97(7):775-80. 
55. Wu MJ, Chang CH, Cheng CY, Shu KH, Chen CH, Cheng CH, et al. Reduced variability of 
tacrolimus trough level in once-daily tacrolimus-based Taiwanese kidney transplant recipients with 
high-expressive genotype of cytochrome P450 3A5. Transplant Proc. 2014;46(2):403-5. 
174 | P a g e  
 
56. Vannaprasaht S, Reungjui S, Supanya D, Sirivongs D, Pongskul C, Avihingsanon Y, et al. 
Personalized tacrolimus doses determined by CYP3A5 genotype for induction and maintenance 
phases of kidney transplantation. Clin Ther. 2013;35(11):1762-9. 
57. Niioka T, Kagaya H, Miura M, Numakura K, Saito M, Inoue T, et al. Pharmaceutical and 
genetic determinants for interindividual differences of tacrolimus bioavailability in renal transplant 
recipients. Eur J Clin Pharmacol. 2013;69(9):1659-65. 
58. Passey C, Birnbaum AK, Brundage RC, Oetting WS, Israni AK, Jacobson PA. Dosing equation 
for tacrolimus using genetic variants and clinical factors. Br J Clin Pharmacol. 2011;72(6):948-57. 
59. Boughton O, Borgulya G, Cecconi M, Fredericks S, Moreton-Clack M, MacPhee IA. A 
published pharmacogenetic algorithm was poorly predictive of tacrolimus clearance in an 
independent cohort of renal transplant recipients. Br J Clin Pharmacol. 2013;76(3):425-31. 
60. Shuker N, Bouamar R, van Schaik RH, Clahsen-van Groningen MC, Damman J, Baan CC, et al. 
A Randomized Controlled Trial Comparing the Efficacy of Cyp3a5 Genotype-Based With Body-Weight-
Based Tacrolimus Dosing After Living Donor Kidney Transplantation. Am J Transplant. 
2016;16(7):2085-96. 
61. Spierings N, Holt DW, MacPhee IA. CYP3A5 genotype had no impact on intrapatient 
variability of tacrolimus clearance in renal transplant recipients. Ther Drug Monit. 2013;35(3):328-31. 
62. Li DY, Teng RC, Zhu HJ, Fang Y. CYP3A4/5 polymorphisms affect the blood level of 
cyclosporine and tacrolimus in Chinese renal transplant recipients. Int J Clin Pharmacol Ther. 
2013;51(6):466-74. 
63. Tavira B, Coto E, Diaz-Corte C, Alvarez V, Lopez-Larrea C, Ortega F. A search for new CYP3A4 
variants as determinants of tacrolimus dose requirements in renal-transplanted patients. 
Pharmacogenet Genomics. 2013;23(8):445-8. 
64. Chitnis SD, Ogasawara K, Schniedewind B, Gohh RY, Christians U, Akhlaghi F. Concentration 
of tacrolimus and major metabolites in kidney transplant recipients as a function of diabetes mellitus 
and cytochrome P450 3A gene polymorphism. Xenobiotica. 2013;43(7):641-9. 
65. Elens L, Capron A, van Schaik RH, De Meyer M, De Pauw L, Eddour DC, et al. Impact of 
CYP3A4*22 allele on tacrolimus pharmacokinetics in early period after renal transplantation: toward 
updated genotype-based dosage guidelines. Ther Drug Monit. 2013;35(5):608-16. 
66. Shilbayeh S. The impact of genetic polymorphisms on time required to attain the target 
tacrolimus levels and subsequent pharmacodynamic outcomes in pediatric kidney transplant 
patients. Saudi J Kidney Dis Transpl. 2014;25(2):266-77. 
67. Mostafa-Hedeab G, Saber-Ayad MM, Latif IA, Elkashab SO, Elshaboney TH, Mostafa MI, et al. 
Functional G1199A ABCB1 polymorphism may have an effect on cyclosporine blood concentration in 
renal transplanted patients. J Clin Pharmacol. 2013;53(8):827-33. 
68. Ogasawara K, Chitnis SD, Gohh RY, Christians U, Akhlaghi F. Multidrug resistance-associated 
protein 2 (MRP2/ABCC2) haplotypes significantly affect the pharmacokinetics of tacrolimus in kidney 
transplant recipients. Clin Pharmacokinet. 2013;52(9):751-62. 
69. Vafadari R, Bouamar R, Hesselink DA, Kraaijeveld R, van Schaik RH, Weimar W, et al. Genetic 
polymorphisms in ABCB1 influence the pharmacodynamics of tacrolimus. Ther Drug Monit. 
2013;35(4):459-65. 
70. Kazancioglu HO, Ak G, Turkmen A, Ozbek U, Tuncer FN, Karabulut A. The role of MDR1 
C3435T gene polymorphism on gingival hyperplasia in Turkish renal transplant patients treated with 
cyclosporine in the absence of calcium channel blockers. Transplant Proc. 2013;45(6):2233-7. 
71. Quaglia M, Terrazzino S, Boldorini R, Stratta P, Genazzani AA. Severe acute nephrotoxicity in 
a kidney transplant patient despite low tacrolimus levels: a possible interaction between donor and 
recipient genetic polymorphisms. J Clin Pharm Ther. 2013;38(4):333-6. 
72. Valderhaug TG, Hjelmesaeth J, Hartmann A, Roislien J, Bergrem HA, Leivestad T, et al. The 
association of early post-transplant glucose levels with long-term mortality. Diabetologia. 
2011;54(6):1341-9. 
175 | P a g e  
 
73. McCaughan JA, McKnight AJ, Maxwell AP. Genetics of new-onset diabetes after 
transplantation. J Am Soc Nephrol. 2014;25(5):1037-49. 
74. Tavira B, Gomez J, Diaz-Corte C, Llobet L, Ruiz-Pesini E, Ortega F, et al. Mitochondrial DNA 
haplogroups and risk of new-onset diabetes among tacrolimus-treated renal transplanted patients. 
Gene. 2014;538(1):195-8. 
75. Nicoletto BB, Souza GC, Fonseca NK, Centenaro A, Manfro RC, Canani LH, et al. Association 
between 276G/T adiponectin gene polymorphism and new-onset diabetes after kidney 
transplantation. Transplantation. 2013;96(12):1059-64. 
76. Chudek J, Szotowska M, Karkoszka H, Verbeke F, Trautsolt W, Gumprecht J, et al. Genotypes 
of renin-angiotensin system and plasma adiponectin concentration in kidney transplant patients. Ann 
Transplant. 2013;18:593-603. 
77. Reeves-Daniel AM, DePalma JA, Bleyer AJ, Rocco MV, Murea M, Adams PL, et al. The APOL1 
gene and allograft survival after kidney transplantation. Am J Transplant. 2011;11(5):1025-30. 
78. Kofman T, Audard V, Narjoz C, Gribouval O, Matignon M, Leibler C, et al. APOL1 
polymorphisms and development of CKD in an identical twin donor and recipient pair. Am J Kidney 
Dis. 2014;63(5):816-9. 
79. Han SS, Lee H, Oh YJ, Lee JP, Kim S, Ha J, et al. Identification of the effects of aging-related 
gene-matrix metalloproteinase on allograft outcomes in kidney transplantation. Transplant Proc. 
2013;45(6):2158-64. 
80. Moore J, McKnight AJ, Dohler B, Simmonds MJ, Courtney AE, Brand OJ, et al. Donor ABCB1 
variant associates with increased risk for kidney allograft failure. J Am Soc Nephrol. 
2012;23(11):1891-9. 
81. Naesens M, Lerut E, de Jonge H, Van Damme B, Vanrenterghem Y, Kuypers DR. Donor age 
and renal P-glycoprotein expression associate with chronic histological damage in renal allografts. J 
Am Soc Nephrol. 2009;20(11):2468-80. 
82. Moore J, McKnight AJ, Simmonds MJ, Courtney AE, Hanvesakul R, Brand OJ, et al. Association 
of caveolin-1 gene polymorphism with kidney transplant fibrosis and allograft failure. Jama. 
2010;303(13):1282-7. 
83. Palade GE. Fine Structure of Blood Capillaries. J Appl Phys. 1953;24(11):1424-. 
84. Yamada E. The fine structure of the renal glomerulus of the mouse. J Biophys Biochem Cytol. 
1955;1(6):551-66. 
85. Cohen AW, Hnasko R, Schubert W, Lisanti MP. Role of caveolae and caveolins in health and 
disease. Physiol Rev. 2004;84(4):1341-79. 
86. Fan JY, Carpentier JL, van Obberghen E, Grunfeld C, Gorden P, Orci L. Morphological changes 
of the 3T3-L1 fibroblast plasma membrane upon differentiation to the adipocyte form. J Cell Sci. 
1983;61:219-30. 
87. Glenney JR, Jr., Zokas L. Novel tyrosine kinase substrates from Rous sarcoma virus-
transformed cells are present in the membrane skeleton. J Cell Biol. 1989;108(6):2401-8. 
88. Glenney JR, Jr. Tyrosine phosphorylation of a 22-kDa protein is correlated with 
transformation by Rous sarcoma virus. J Biol Chem. 1989;264(34):20163-6. 
89. Rothberg KG, Heuser JE, Donzell WC, Ying YS, Glenney JR, Anderson RG. Caveolin, a protein 
component of caveolae membrane coats. Cell. 1992;68(4):673-82. 
90. Scherer PE, Lewis RY, Volonte D, Engelman JA, Galbiati F, Couet J, et al. Cell-type and tissue-
specific expression of caveolin-2. Caveolins 1 and 2 co-localize and form a stable hetero-oligomeric 
complex in vivo. J Biol Chem. 1997;272(46):29337-46. 
91. Scheiffele P, Verkade P, Fra AM, Virta H, Simons K, Ikonen E. Caveolin-1 and -2 in the exocytic 
pathway of MDCK cells. J Cell Biol. 1998;140(4):795-806. 
92. Tang Z, Scherer PE, Okamoto T, Song K, Chu C, Kohtz DS, et al. Molecular cloning of caveolin-
3, a novel member of the caveolin gene family expressed predominantly in muscle. J Biol Chem. 
1996;271(4):2255-61. 
176 | P a g e  
 
93. Chidlow JH, Jr., Sessa WC. Caveolae, caveolins, and cavins: complex control of cellular 
signalling and inflammation. Cardiovasc Res. 2010;86(2):219-25. 
94. Parton RG, Simons K. The multiple faces of caveolae. Nat Rev Mol Cell Biol. 2007;8(3):185-94. 
95. Tanase C. CAV1 (caveolin 1, caveolae protein, 22kDA). Atlas Genet Cytogenet Oncol 
Haematol. 2009;13(11):788-92. 
96. Engelman JA, Zhang XL, Lisanti MP. Sequence and detailed organization of the human 
caveolin-1 and -2 genes located near the D7S522 locus (7q31.1). Methylation of a CpG island in the 5' 
promoter region of the caveolin-1 gene in human breast cancer cell lines. FEBS Lett. 1999;448(2-
3):221-30. 
97. Engelman JA, Zhang X, Galbiati F, Volonte D, Sotgia F, Pestell RG, et al. Molecular genetics of 
the caveolin gene family: implications for human cancers, diabetes, Alzheimer disease, and muscular 
dystrophy. Am J Hum Genet. 1998;63(6):1578-87. 
98. Schubert W, Frank PG, Razani B, Park DS, Chow CW, Lisanti MP. Caveolae-deficient 
endothelial cells show defects in the uptake and transport of albumin in vivo. J Biol Chem. 
2001;276(52):48619-22. 
99. Norkin LC, Anderson HA, Wolfrom SA, Oppenheim A. Caveolar endocytosis of simian virus 40 
is followed by brefeldin A-sensitive transport to the endoplasmic reticulum, where the virus 
disassembles. J Virol. 2002;76(10):5156-66. 
100. del Pozo MA, Balasubramanian N, Alderson NB, Kiosses WB, Grande-Garcia A, Anderson RG, 
et al. Phospho-caveolin-1 mediates integrin-regulated membrane domain internalization. Nat Cell 
Biol. 2005;7(9):901-8. 
101. Sharma DK, Brown JC, Choudhury A, Peterson TE, Holicky E, Marks DL, et al. Selective 
stimulation of caveolar endocytosis by glycosphingolipids and cholesterol. Mol Biol Cell. 
2004;15(7):3114-22. 
102. Goligorsky MS, Li H, Brodsky S, Chen J. Relationships between caveolae and eNOS: everything 
in proximity and the proximity of everything. Am J Physiol Renal Physiol. 2002;283(1):F1-10. 
103. Meng XM, Tang PM, Li J, Lan HY. TGF-beta/Smad signaling in renal fibrosis. Front Physiol. 
2015;6:82. 
104. Razani B, Zhang XL, Bitzer M, von Gersdorff G, Bottinger EP, Lisanti MP. Caveolin-1 regulates 
transforming growth factor (TGF)-beta/SMAD signaling through an interaction with the TGF-beta 
type I receptor. J Biol Chem. 2001;276(9):6727-38. 
105. Sigismund S, Argenzio E, Tosoni D, Cavallaro E, Polo S, Di Fiore PP. Clathrin-mediated 
internalization is essential for sustained EGFR signaling but dispensable for degradation. Dev Cell. 
2008;15(2):209-19. 
106. Shi F, Sottile J. Caveolin-1-dependent beta1 integrin endocytosis is a critical regulator of 
fibronectin turnover. J Cell Sci. 2008;121(Pt 14):2360-71. 
107. Rizzo V, Morton C, DePaola N, Schnitzer JE, Davies PF. Recruitment of endothelial caveolae 
into mechanotransduction pathways by flow conditioning in vitro. Am J Physiol Heart Circ Physiol. 
2003;285(4):H1720-9. 
108. Yu J, Bergaya S, Murata T, Alp IF, Bauer MP, Lin MI, et al. Direct evidence for the role of 
caveolin-1 and caveolae in mechanotransduction and remodeling of blood vessels. J Clin Invest. 
2006;116(5):1284-91. 
109. Sedding DG, Hermsen J, Seay U, Eickelberg O, Kummer W, Schwencke C, et al. Caveolin-1 
facilitates mechanosensitive protein kinase B (Akt) signaling in vitro and in vivo. Circ Res. 
2005;96(6):635-42. 
110. Di Guglielmo GM, Le Roy C, Goodfellow AF, Wrana JL. Distinct endocytic pathways regulate 
TGF-beta receptor signalling and turnover. Nat Cell Biol. 2003;5(5):410-21. 
111. Li Z, Wermuth PJ, Benn BS, Lisanti MP, Jimenez SA. Caveolin-1 deficiency induces 
spontaneous endothelial-to-mesenchymal transition in murine pulmonary endothelial cells in vitro. 
Am J Pathol. 2013;182(2):325-31. 
177 | P a g e  
 
112. Ito T, Williams JD, Fraser DJ, Phillips AO. Hyaluronan regulates transforming growth factor-
beta1 receptor compartmentalization. J Biol Chem. 2004;279(24):25326-32. 
113. Zhang XL, Topley N, Ito T, Phillips A. Interleukin-6 regulation of transforming growth factor 
(TGF)-beta receptor compartmentalization and turnover enhances TGF-beta1 signaling. J Biol Chem. 
2005;280(13):12239-45. 
114. Peng F, Wu D, Ingram AJ, Zhang B, Gao B, Krepinsky JC. RhoA activation in mesangial cells by 
mechanical strain depends on caveolae and caveolin-1 interaction. J Am Soc Nephrol. 
2007;18(1):189-98. 
115. Zhang Y, Peng F, Gao B, Ingram AJ, Krepinsky JC. Mechanical strain-induced RhoA activation 
requires NADPH oxidase-mediated ROS generation in caveolae. Antioxid Redox Signal. 
2010;13(7):959-73. 
116. Bocanegra V, Manucha W, Pena MR, Cacciamani V, Valles PG. Caveolin-1 and Hsp70 
interaction in microdissected proximal tubules from spontaneously hypertensive rats as an effect of 
Losartan. J Hypertens. 2010;28(1):143-55. 
117. Wei Y, Yang X, Liu Q, Wilkins JA, Chapman HA. A role for caveolin and the urokinase receptor 
in integrin-mediated adhesion and signaling. J Cell Biol. 1999;144(6):1285-94. 
118. Pontrelli P, Ursi M, Ranieri E, Capobianco C, Schena FP, Gesualdo L, et al. CD40L 
proinflammatory and profibrotic effects on proximal tubular epithelial cells: role of NF-kappaB and 
lyn. J Am Soc Nephrol. 2006;17(3):627-36. 
119. Park HC, Yasuda K, Ratliff B, Stoessel A, Sharkovska Y, Yamamoto I, et al. Postobstructive 
regeneration of kidney is derailed when surge in renal stem cells during course of unilateral ureteral 
obstruction is halted. Am J Physiol Renal Physiol. 2010;298(2):F357-64. 
120. Yamaguchi T, Murata Y, Fujiyoshi Y, Doi T. Regulated interaction of endothelin B receptor 
with caveolin-1. Eur J Biochem. 2003;270(8):1816-27. 
121. Percy C, Waters MJ, Gobe G. Caveolins in the repair phase of acute renal failure after 
oxidative stress. Nephrology (Carlton). 2004;9(6):374-80. 
122. Ren Z, Liang W, Chen C, Yang H, Singhal PC, Ding G. Angiotensin II induces nephrin 
dephosphorylation and podocyte injury: role of caveolin-1. Cell Signal. 2012;24(2):443-50. 
123. Couet J, Li S, Okamoto T, Ikezu T, Lisanti MP. Identification of peptide and protein ligands for 
the caveolin-scaffolding domain. Implications for the interaction of caveolin with caveolae-associated 
proteins. J Biol Chem. 1997;272(10):6525-33. 
124. Liu P, Ying Y, Ko YG, Anderson RG. Localization of platelet-derived growth factor-stimulated 
phosphorylation cascade to caveolae. J Biol Chem. 1996;271(17):10299-303. 
125. Torres VA, Tapia JC, Rodriguez DA, Lladser A, Arredondo C, Leyton L, et al. E-cadherin is 
required for caveolin-1-mediated down-regulation of the inhibitor of apoptosis protein survivin via 
reduced beta-catenin-Tcf/Lef-dependent transcription. Mol Cell Biol. 2007;27(21):7703-17. 
126. Ko YG, Lee JS, Kang YS, Ahn JH, Seo JS. TNF-alpha-mediated apoptosis is initiated in caveolae-
like domains. J Immunol. 1999;162(12):7217-23. 
127. Wu T, Zhang B, Ye F, Xiao Z. A potential role for caveolin-1 in VEGF-induced fibronectin 
upregulation in mesangial cells: involvement of VEGFR2 and Src. Am J Physiol Renal Physiol. 
2013;304(6):F820-30. 
128. Lin MI, Yu J, Murata T, Sessa WC. Caveolin-1-deficient mice have increased tumor 
microvascular permeability, angiogenesis, and growth. Cancer Res. 2007;67(6):2849-56. 
129. Nishiyama A, Hitomi H. Role of caveolin and heat shock protein 70 interaction in the 
antioxidative effects of an angiotensin II type 1 receptor blocker in spontaneously hypertensive rats 
proximal tubules. J Hypertens. 2010;28(1):9-12. 
130. Trujillo J, Ramirez V, Perez J, Torre-Villalvazo I, Torres N, Tovar AR, et al. Renal protection by a 
soy diet in obese Zucker rats is associated with restoration of nitric oxide generation. Am J Physiol 
Renal Physiol. 2005;288(1):F108-16. 
178 | P a g e  
 
131. Valles PG, Manucha W, Carrizo L, Vega Perugorria J, Seltzer A, Ruete C. Renal caveolin-1 
expression in children with unilateral ureteropelvic junction obstruction. Pediatr Nephrol. 
2007;22(2):237-48. 
132. Moriyama T, Tsuruta Y, Shimizu A, Itabashi M, Takei T, Horita S, et al. The significance of 
caveolae in the glomeruli in glomerular disease. J Clin Pathol. 2011;64(6):504-9. 
133. Guan TH, Chen G, Gao B, Janssen MR, Uttarwar L, Ingram AJ, et al. Caveolin-1 deficiency 
protects against mesangial matrix expansion in a mouse model of type 1 diabetic nephropathy. 
Diabetologia. 2013;56(9):2068-77. 
134. Herrera GA, Turbat-Herrera EA, Teng J. Animal Models of Light Chain Deposition Disease 
Provide a Better Understanding of Nodular Glomerulosclerosis. Nephron. 2016. 
135. Yamamoto I, Horita S, Takahashi T, Kobayashi A, Toki D, Tanabe K, et al. Caveolin-1 
expression is a distinct feature of chronic rejection-induced transplant capillaropathy. Am J 
Transplant. 2008;8(12):2627-35. 
136. Tourkina E, Richard M, Oates J, Hofbauer A, Bonner M, Gooz P, et al. Caveolin-1 regulates 
leucocyte behaviour in fibrotic lung disease. Ann Rheum Dis. 2010;69(6):1220-6. 
137. Wang XM, Zhang Y, Kim HP, Zhou Z, Feghali-Bostwick CA, Liu F, et al. Caveolin-1: a critical 
regulator of lung fibrosis in idiopathic pulmonary fibrosis. J Exp Med. 2006;203(13):2895-906. 
138. Del Galdo F, Sotgia F, de Almeida CJ, Jasmin JF, Musick M, Lisanti MP, et al. Decreased 
expression of caveolin 1 in patients with systemic sclerosis: crucial role in the pathogenesis of tissue 
fibrosis. Arthritis Rheum. 2008;58(9):2854-65. 
139. Miyasato SK, Loeffler J, Shohet R, Zhang J, Lindsey M, Le Saux CJ. Caveolin-1 modulates TGF-
beta1 signaling in cardiac remodeling. Matrix Biol. 2011;30(5-6):318-29. 
140. Zhang GY, Yu Q, Cheng T, Liao T, Nie CL, Wang AY, et al. Role of caveolin-1 in the 
pathogenesis of tissue fibrosis by keloid-derived fibroblasts in vitro. Br J Dermatol. 2011;164(3):623-
7. 
141. Tsai TH, Chen SF, Huang TY, Tzeng CF, Chiang AS, Kou YR, et al. Impaired Cd14 and Cd36 
expression, bacterial clearance, and Toll-like receptor 4-Myd88 signaling in caveolin-1-deleted 
macrophages and mice. Shock. 2011;35(1):92-9. 
142. Gadjeva M, Paradis-Bleau C, Priebe GP, Fichorova R, Pier GB. Caveolin-1 modifies the 
immunity to Pseudomonas aeruginosa. J Immunol. 2010;184(1):296-302. 
143. Guo Q, Shen N, Yuan K, Li J, Wu H, Zeng Y, et al. Caveolin-1 plays a critical role in host 
immunity against Klebsiella pneumoniae by regulating STAT5 and Akt activity. Eur J Immunol. 
2012;42(6):1500-11. 
144. Zeitlin PL. Pseudomonas aeruginosa: can studies in engineered cells tell us why is it such a 
problem in people with cystic fibrosis? Focus on "Cystic fibrosis transmembrane conductance 
regulator and caveolin-1 regulate epithelial cell internalization of Pseudomonas aeruginosa". Am J 
Physiol Cell Physiol. 2009;297(2):C235-7. 
145. Sharon-Friling R, Shenk T. Human cytomegalovirus pUL37x1-induced calcium flux activates 
PKCalpha, inducing altered cell shape and accumulation of cytoplasmic vesicles. Proc Natl Acad Sci U 
S A. 2014;111(12):E1140-8. 
146. Moriyama T, Marquez JP, Wakatsuki T, Sorokin A. Caveolar endocytosis is critical for BK virus 
infection of human renal proximal tubular epithelial cells. J Virol. 2007;81(16):8552-62. 
147. Fu Y, Moore XL, Lee MK, Fernandez-Rojo MA, Parat MO, Parton RG, et al. Caveolin-1 Plays a 
Critical Role in the Differentiation of Monocytes into Macrophages. Arterioscler Thromb Vasc Biol. 
2012. 
148. Schwencke C, Schmeisser A, Walter C, Wachter R, Pannach S, Weck B, et al. Decreased 
caveolin-1 in atheroma: loss of antiproliferative control of vascular smooth muscle cells in 
atherosclerosis. Cardiovasc Res. 2005;68(1):128-35. 
149. Zhou X, He P. Endothelial [Ca2+]i and caveolin-1 antagonistically regulate eNOS activity and 
microvessel permeability in rat venules. Cardiovasc Res. 2010;87(2):340-7. 
179 | P a g e  
 
150. Schwencke C, Braun-Dullaeus RC, Wunderlich C, Strasser RH. Caveolae and caveolin in 
transmembrane signaling: Implications for human disease. Cardiovasc Res. 2006;70(1):42-9. 
151. Williams TM, Lisanti MP. Caveolin-1 in oncogenic transformation, cancer, and metastasis. Am 
J Physiol Cell Physiol. 2005;288(3):C494-506. 
152. Sotgia F, Martinez-Outschoorn UE, Howell A, Pestell RG, Pavlides S, Lisanti MP. Caveolin-1 
and cancer metabolism in the tumor microenvironment: markers, models, and mechanisms. Annu 
Rev Pathol. 2012;7:423-67. 
153. Mathieu R, Klatte T, Lucca I, Mbeutcha A, Seitz C, Karakiewicz PI, et al. Prognostic value of 
Caveolin-1 in patients treated with radical prostatectomy: a multicentric validation study. BJU Int. 
2015. 
154. Karlsson M, Thorn H, Parpal S, Stralfors P, Gustavsson J. Insulin induces translocation of 
glucose transporter GLUT4 to plasma membrane caveolae in adipocytes. FASEB journal : official 
publication of the Federation of American Societies for Experimental Biology. 2002;16(2):249-51. 
155. Pojoga LH, Yao TM, Opsasnick LA, Garza AE, Reslan OM, Adler GK, et al. Dissociation of 
hyperglycemia from altered vascular contraction and relaxation mechanisms in caveolin-1 null mice. J 
Pharmacol Exp Ther. 2014;348(2):260-70. 
156. Asterholm IW, Mundy DI, Weng J, Anderson RG, Scherer PE. Altered mitochondrial function 
and metabolic inflexibility associated with loss of caveolin-1. Cell Metab. 2012;15(2):171-85. 
157. Yang Y, Tong Y, Gong M, Lu Y, Wang C, Zhou M, et al. Activation of PPARbeta/delta protects 
pancreatic beta cells from palmitate-induced apoptosis by upregulating the expression of GLP-1 
receptor. Cell Signal. 2014;26(2):268-78. 
158. Van der Hauwaert C, Savary G, Pincon C, Gnemmi V, Noel C, Broly F, et al. Donor caveolin 1 
(CAV1) genetic polymorphism influences graft function after renal transplantation. Fibrogenesis 
Tissue Repair. 2015;8:8. 
159. Testa A, Spoto B, Sanguedolce MC, Parlongo RM, Pisano A, Tripepi G, et al. eNOS and 
caveolin-1 gene polymorphisms interaction and intima media thickness: a proof of concept study in 
ESRD patients. Am J Hypertens. 2012;25(1):103-8. 
160. Tampe B, Zeisberg M. Contribution of genetics and epigenetics to progression of kidney 
fibrosis. Nephrology, dialysis, transplantation : official publication of the European Dialysis and 
Transplant Association - European Renal Association. 2013. 
161. Chue CD, Townend JN, Steeds RP, Ferro CJ. Arterial stiffness in chronic kidney disease: causes 
and consequences. Heart. 2010;96(11):817-23. 
162. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of 
death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296-305. 
163. Odudu A, Eldehni MT, Fakis A, McIntyre CW. Rationale and design of a multi-centre 
randomised controlled trial of individualised cooled dialysate to prevent left ventricular systolic 
dysfunction in haemodialysis patients. BMC Nephrol. 2012;13:45. 
164. Breidthardt T, McIntyre CW. Dialysis-induced myocardial stunning: the other side of the 
cardiorenal syndrome. Rev Cardiovasc Med. 2011;12(1):13-20. 
165. Ferguson JF, Matthews GJ, Townsend RR, Raj DS, Kanetsky PA, Budoff M, et al. Candidate 
gene association study of coronary artery calcification in chronic kidney disease: findings from the 
CRIC study (Chronic Renal Insufficiency Cohort). Journal of the American College of Cardiology. 
2013;62(9):789-98. 
166. McNamara DM, Holubkov R, Postava L, Ramani R, Janosko K, Mathier M, et al. Effect of the 
Asp298 variant of endothelial nitric oxide synthase on survival for patients with congestive heart 
failure. Circulation. 2003;107(12):1598-602. 
167. Velloso MW, Pereira SB, Gouveia L, Chermont S, Tardin OM, Goncalves R, et al. Endothelial 
nitric oxide synthase Glu298Asp gene polymorphism in a multi-ethnical population with heart failure 
and controls. Nitric Oxide. 2010;22(3):220-5. 
180 | P a g e  
 
168. Page A, Reich H, Zhou J, Lai V, Cattran DC, Scholey JW, et al. Endothelial nitric oxide synthase 
gene/gender interactions and the renal hemodynamic response to angiotensin II. J Am Soc Nephrol. 
2005;16(10):3053-60. 
169. Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause 
mortality with arterial stiffness: a systematic review and meta-analysis. Journal of the American 
College of Cardiology. 2010;55(13):1318-27. 
170. Flossmann O, Berden A, de Groot K, Hagen C, Harper L, Heijl C, et al. Long-term patient 
survival in ANCA-associated vasculitis. Ann Rheum Dis. 2011;70(3):488-94. 
171. Sharif A, Baboolal K. Risk factors for new-onset diabetes after kidney transplantation. Nat 
Rev Nephrol. 2010;6(7):415-23. 
172. Kim YG, Ihm CG, Lee TW, Lee SH, Jeong KH, Moon JY, et al. Association of genetic 
polymorphisms of interleukins with new-onset diabetes after transplantation in renal 
transplantation. Transplantation. 2012;93(9):900-7. 
173. Tavira B, Coto E, Torres A, Diaz-Corte C, Diaz-Molina B, Ortega F, et al. Association between a 
common KCNJ11 polymorphism (rs5219) and new-onset posttransplant diabetes in patients treated 
with Tacrolimus. Mol Genet Metab. 2012;105(3):525-7. 
174. Anders HJ, Schlondorff DO. Innate immune receptors and autophagy: implications for 
autoimmune kidney injury. Kidney Int. 2010;78(1):29-37. 
175. Eddy AA. Progression in chronic kidney disease. Adv Chronic Kidney Dis. 2005;12(4):353-65. 
176. Fujita Y, Maruyama S, Kogo H, Matsuo S, Fujimoto T. Caveolin-1 in mesangial cells suppresses 
MAP kinase activation and cell proliferation induced by bFGF and PDGF. Kidney Int. 2004;66(5):1794-
804. 
177. Park DS, Cohen AW, Frank PG, Razani B, Lee H, Williams TM, et al. Caveolin-1 null (-/-) mice 
show dramatic reductions in life span. Biochemistry. 2003;42(51):15124-31. 
178. Insel PA, Patel HH. Do studies in caveolin-knockouts teach us about physiology and 
pharmacology or instead, the ways mice compensate for 'lost proteins'? Br J Pharmacol. 
2007;150(3):251-4. 
179. Gabriel S, Ziaugra L, Tabbaa D. SNP genotyping using the Sequenom MassARRAY iPLEX 
platform. Curr Protoc Hum Genet. 2009;Chapter 2:Unit 2 12. 
180. Edwards NC, Ferro CJ, Kirkwood H, Chue CD, Young AA, Stewart PM, et al. Effect of 
spironolactone on left ventricular systolic and diastolic function in patients with early stage chronic 
kidney disease. Am J Cardiol. 2010;106(10):1505-11. 
181. Chue CD, Townend JN, Moody WE, Zehnder D, Wall NA, Harper L, et al. Cardiovascular 
effects of sevelamer in stage 3 CKD. J Am Soc Nephrol. 2013;24(5):842-52. 
182. Stringer S, Sharma P, Dutton M, Jesky M, Ng K, Kaur O, et al. The natural history of, and risk 
factors for, progressive chronic kidney disease (CKD): the Renal Impairment in Secondary care (RIISC) 
study; rationale and protocol. BMC Nephrol. 2013;14:95. 
183. Graffelman J, Weir BS. Testing for Hardy-Weinberg equilibrium at biallelic genetic markers on 
the X chromosome. Heredity (Edinb). 2016;116(6):558-68. 
184. Maceira AM, Prasad SK, Khan M, Pennell DJ. Normalized left ventricular systolic and diastolic 
function by steady state free precession cardiovascular magnetic resonance. J Cardiovasc Magn 
Reson. 2006;8(3):417-26. 
185. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. 
Recommendations for chamber quantification: a report from the American Society of 
Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing 
Group, developed in conjunction with the European Association of Echocardiography, a branch of the 
European Society of Cardiology. J Am Soc Echocardiogr. 2005;18(12):1440-63. 
186. Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA, et al. 
Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am 
Soc Echocardiogr. 2009;22(2):107-33. 
181 | P a g e  
 
187. Chapman CB, Ewer SM, Kelly AF, Jacobson KM, Leal MA, Rahko PS. Classification of left 
ventricular diastolic function using American Society of Echocardiography Guidelines: agreement 
among echocardiographers. Echocardiography. 2013;30(9):1022-31. 
188. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al. PLINK: a tool set 
for whole-genome association and population-based linkage analyses. Am J Hum Genet. 
2007;81(3):559-75. 
189. Andoh TF, Lam TT, Lindsley J, Alpers CE, Bennett WM. Enhancement of chronic cyclosporine 
nephrotoxicity by sodium depletion in an experimental mouse model. Nephrology. 1997;3(5):471-8. 
190. Eddy AA, Lopez-Guisa JM, Okamura DM, Yamaguchi I. Investigating mechanisms of chronic 
kidney disease in mouse models. Pediatr Nephrol. 2012;27(8):1233-47. 
191. Chand S, Edwards NC, Chue CD, Jesky M, Stringer S, Simmonds MJ, et al. Caveolin-1 single-
nucleotide polymorphism and arterial stiffness in non-dialysis chronic kidney disease. Nephrol Dial 
Transplant. 2015. 
192. Sarnak MJ, Levey AS. Cardiovascular disease and chronic renal disease: a new paradigm. Am J 
Kidney Dis. 2000;35(4 Suppl 1):S117-31. 
193. Kranzhofer R, Schmidt J, Pfeiffer CA, Hagl S, Libby P, Kubler W. Angiotensin induces 
inflammatory activation of human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 
1999;19(7):1623-9. 
194. Takagishi T, Murahashi N, Azagami S, Morimatsu M, Sasaguri Y. Effect of angiotensin II and 
thromboxane A2 on the production of matrix metalloproteinase by human aortic smooth muscle 
cells. Biochem Mol Biol Int. 1995;35(2):265-73. 
195. Moody WE, Edwards NC, Chue CD, Ferro CJ, Townend JN. Arterial disease in chronic kidney 
disease. Heart. 2013;99(6):365-72. 
196. Baumann M, Wassertheurer S, Suttmann Y, Burkhardt K, Heemann U. Aortic pulse wave 
velocity predicts mortality in chronic kidney disease stages 2-4. J Hypertens. 2014;32(4):899-903. 
197. Hickson SS, Butlin M, Broad J, Avolio AP, Wilkinson IB, McEniery CM. Validity and 
repeatability of the Vicorder apparatus: a comparison with the SphygmoCor device. Hypertens Res. 
2009;32(12):1079-85. 
198. Tang L, Wang H, Ziolo MT. Targeting NOS as a therapeutic approach for heart failure. 
Pharmacol Ther. 2013. 
199. Massy ZA, Stenvinkel P, Drueke TB. The role of oxidative stress in chronic kidney disease. 
Semin Dial. 2009;22(4):405-8. 
200. Hassan GS, Williams TM, Frank PG, Lisanti MP. Caveolin-1-deficient aortic smooth muscle 
cells show cell autonomous abnormalities in proliferation, migration, and endothelin-based signal 
transduction. Am J Physiol Heart Circ Physiol. 2006;290(6):H2393-401. 
201. Matsushita K, Sang Y, Ballew SH, Shlipak M, Katz R, Rosas SE, et al. Subclinical atherosclerosis 
measures for cardiovascular prediction in CKD. J Am Soc Nephrol. 2015;26(2):439-47. 
202. Ortiz A, Covic A, Fliser D, Fouque D, Goldsmith D, Kanbay M, et al. Epidemiology, contributors 
to, and clinical trials of mortality risk in chronic kidney failure. Lancet. 2014;383(9931):1831-43. 
203. Baigent C, Landray M. Which cardiovascular risk factors matter in chronic kidney disease? 
Nephrol Dial Transplant. 2007;22(1):9-11. 
204. Zoccali C, Benedetto FA, Maas R, Mallamaci F, Tripepi G, Malatino LS, et al. Asymmetric 
dimethylarginine, C-reactive protein, and carotid intima-media thickness in end-stage renal disease. J 
Am Soc Nephrol. 2002;13(2):490-6. 
205. Chand S, Chue CD, Edwards NC, Hodson J, Simmonds MJ, Hamilton A, et al. Endothelial nitric 
oxide synthase single nucleotide polymorphism and left ventricular function in early chronic kidney 
disease. PLoS One. 2015;10(1):e0116160. 
206. Tesauro M, Thompson WC, Rogliani P, Qi L, Chaudhary PP, Moss J. Intracellular processing of 
endothelial nitric oxide synthase isoforms associated with differences in severity of cardiopulmonary 
182 | P a g e  
 
diseases: cleavage of proteins with aspartate vs. glutamate at position 298. Proc Natl Acad Sci U S A. 
2000;97(6):2832-5. 
207. Veldman BA, Spiering W, Doevendans PA, Vervoort G, Kroon AA, de Leeuw PW, et al. The 
Glu298Asp polymorphism of the NOS 3 gene as a determinant of the baseline production of nitric 
oxide. J Hypertens. 2002;20(10):2023-7. 
208. Joshi MS, Mineo C, Shaul PW, Bauer JA. Biochemical consequences of the NOS3 Glu298Asp 
variation in human endothelium: altered caveolar localization and impaired response to shear. FASEB 
J. 2007;21(11):2655-63. 
209. Joshi MS, Bauer JA. Preliminary computational modeling of nitric oxide synthase 3 
interactions with caveolin-1: influence of exon 7 Glu298Asp polymorphism. Acta Biochim Biophys Sin 
(Shanghai). 2008;40(1):47-54. 
210. Tardin OM, Pereira SB, Velloso MW, Balieiro HM, Costa B, Alves TO, et al. Genetic 
polymorphism G894T and the prognosis of heart failure outpatients. Arq Bras Cardiol. 
2013;101(4):352-8. 
211. Zhang X, Lynch AI, Davis BR, Ford CE, Boerwinkle E, Eckfeldt JH, et al. Pharmacogenetic 
association of NOS3 variants with cardiovascular disease in patients with hypertension: the GenHAT 
study. PLoS One. 2012;7(3):e34217. 
212. Massion PB, Dessy C, Desjardins F, Pelat M, Havaux X, Belge C, et al. Cardiomyocyte-
restricted overexpression of endothelial nitric oxide synthase (NOS3) attenuates beta-adrenergic 
stimulation and reinforces vagal inhibition of cardiac contraction. Circulation. 2004;110(17):2666-72. 
213. Philip I, Plantefeve G, Vuillaumier-Barrot S, Vicaut E, LeMarie C, Henrion D, et al. G894T 
polymorphism in the endothelial nitric oxide synthase gene is associated with an enhanced vascular 
responsiveness to phenylephrine. Circulation. 1999;99(24):3096-8. 
214. Brunner F, Andrew P, Wolkart G, Zechner R, Mayer B. Myocardial contractile function and 
heart rate in mice with myocyte-specific overexpression of endothelial nitric oxide synthase. 
Circulation. 2001;104(25):3097-102. 
215. Chand S, Holle JU, Hilhorst M, Simmonds MJ, Smith S, Kamesh L, et al. Caveolin-1 single 
nucleotide polymorphism in antineutrophil cytoplasmic antibody associated vasculitis. PLoS One. 
2013;8(7):e69022. 
216. Ntatsaki E, Watts RA, Scott DG. Epidemiology of ANCA-associated vasculitis. Rheum Dis Clin 
North Am. 2010;36(3):447-61. 
217. Rahmattulla C, Mooyaart AL, van Hooven D, Schoones JW, Bruijn JA, Dekkers OM, et al. 
Genetic variants in ANCA-associated vasculitis: a meta-analysis. Ann Rheum Dis. 2015. 
218. McGeoch L, Twilt M, Famorca L, Bakowsky V, Barra L, Benseler SM, et al. CanVasc 
Recommendations for the Management of Antineutrophil Cytoplasm Antibody-associated 
Vasculitides. J Rheumatol. 2016;43(1):97-120. 
219. Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, et al. Wegener 
granulomatosis: an analysis of 158 patients. Ann Intern Med. 1992;116(6):488-98. 
220. Fauci AS, Haynes BF, Katz P, Wolff SM. Wegener's granulomatosis: prospective clinical and 
therapeutic experience with 85 patients for 21 years. Ann Intern Med. 1983;98(1):76-85. 
221. Willcocks LC, Lyons PA, Rees AJ, Smith KG. The contribution of genetic variation and infection 
to the pathogenesis of ANCA-associated systemic vasculitis. Arthritis Res Ther. 2010;12(1):202. 
222. Morris H, Morgan MD, Wood AM, Smith SW, Ekeowa UI, Herrmann K, et al. ANCA-associated 
vasculitis is linked to carriage of the Z allele of alpha(1) antitrypsin and its polymers. Ann Rheum Dis. 
2011;70(10):1851-6. 
223. Chand S, McKnight AJ, Shabir S, Chan W, McCaughan JA, Maxwell AP, et al. Analysis of single 
nucleotide polymorphisms implicate mTOR signalling in the development of new-onset diabetes after 
transplantation. BBA Clin. 2016;5:41-5. 
183 | P a g e  
 
224. Sharif A, Moore RH, Baboolal K. The use of oral glucose tolerance tests to risk stratify for 
new-onset diabetes after transplantation: An underdiagnosed phenomenon. Transplantation. 
2006;82(12):1667-72. 
225. Bergrem HA, Valderhaug TG, Hartmann A, Hjelmesaeth J, Leivestad T, Bergrem H, et al. 
Undiagnosed diabetes in kidney transplant candidates: a case-finding strategy. Clin J Am Soc Nephrol. 
2010;5(4):616-22. 
226. Kurzawski M, Dziewanowski K, Lapczuk J, Wajda A, Drozdzik M. Analysis of common type 2 
diabetes mellitus genetic risk factors in new-onset diabetes after transplantation in kidney transplant 
patients medicated with tacrolimus. Eur J Clin Pharmacol. 2012;68(12):1587-94. 
227. Donath MY, Ehses JA, Maedler K, Schumann DM, Ellingsgaard H, Eppler E, et al. Mechanisms 
of beta-cell death in type 2 diabetes. Diabetes. 2005;54 Suppl 2:S108-13. 
228. Favaro E, Miceli I, Bussolati B, Schmitt-Ney M, Cavallo Perin P, Camussi G, et al. 
Hyperglycemia induces apoptosis of human pancreatic islet endothelial cells: effects of pravastatin 
on the Akt survival pathway. Am J Pathol. 2008;173(2):442-50. 
229. Hara K, Tobe K, Okada T, Kadowaki H, Akanuma Y, Ito C, et al. A genetic variation in the PGC-
1 gene could confer insulin resistance and susceptibility to Type II diabetes. Diabetologia. 
2002;45(5):740-3. 
230. Moon MK, Cho YM, Jung HS, Park YJ, Yoon KH, Sung YA, et al. Genetic polymorphisms in 
peroxisome proliferator-activated receptor gamma are associated with Type 2 diabetes mellitus and 
obesity in the Korean population. Diabet Med. 2005;22(9):1161-6. 
231. Blattler SM, Cunningham JT, Verdeguer F, Chim H, Haas W, Liu H, et al. Yin Yang 1 deficiency 
in skeletal muscle protects against rapamycin-induced diabetic-like symptoms through activation of 
insulin/IGF signaling. Cell Metab. 2012;15(4):505-17. 
232. Laplante M, Sabatini DM. mTOR signaling at a glance. J Cell Sci. 2009;122(Pt 20):3589-94. 
233. Chan YS, Goke J, Lu X, Venkatesan N, Feng B, Su IH, et al. A PRC2-dependent repressive role 
of PRDM14 in human embryonic stem cells and induced pluripotent stem cell reprogramming. Stem 
Cells. 2013;31(4):682-92. 
234. Chen H, Gu X, Su IH, Bottino R, Contreras JL, Tarakhovsky A, et al. Polycomb protein Ezh2 
regulates pancreatic beta-cell Ink4a/Arf expression and regeneration in diabetes mellitus. Genes & 
Development. 2009;23(8):975-85. 
235. Zhou JX, Dhawan S, Fu H, Snyder E, Bottino R, Kundu S, et al. Combined modulation of 
polycomb and trithorax genes rejuvenates beta cell replication. The Journal of clinical investigation. 
2013;123(11):4849-58. 
236. Fougeray S, Loriot MA, Nicaud V, Legendre C, Thervet E, Pallet N. Increased body mass index 
after kidney transplantation in activating transcription factor 6 single polymorphism gene carriers. 
Transplant Proc. 2011;43(9):3418-22. 
237. Odisho T, Zhang L, Volchuk A. ATF6beta regulates the Wfs1 gene and has a cell survival role 
in the ER stress response in pancreatic beta-cells. Experimental cell research. 2015;330(1):111-22. 
238. Gu N, Ma X, Zhang J, Dong A, Jin M, Feng N, et al. Obesity has an interactive effect with 
genetic variation in the activating transcription factor 6 gene on the risk of pre-diabetes in individuals 
of Chinese Han descent. PLoS One. 2014;9(10):e109805. 
239. Thameem F, Farook VS, Bogardus C, Prochazka M. Association of amino acid variants in the 
activating transcription factor 6 gene (ATF6) on 1q21-q23 with type 2 diabetes in Pima Indians. 
Diabetes. 2006;55(3):839-42. 
240. Yang J, Hutchinson, II, Shah T, Min DI. Genetic and clinical risk factors of new-onset diabetes 
after transplantation in Hispanic kidney transplant recipients. Transplantation. 2011;91(10):1114-9. 
241. Byrne MM, Sturis J, Menzel S, Yamagata K, Fajans SS, Dronsfield MJ, et al. Altered insulin 
secretory responses to glucose in diabetic and nondiabetic subjects with mutations in the diabetes 
susceptibility gene MODY3 on chromosome 12. Diabetes. 1996;45(11):1503-10. 
184 | P a g e  
 
242. Mohlke KL, Boehnke M. The role of HNF4A variants in the risk of type 2 diabetes. Curr Diab 
Rep. 2005;5(2):149-56. 
243. Wang H, Maechler P, Antinozzi PA, Hagenfeldt KA, Wollheim CB. Hepatocyte nuclear factor 
4alpha regulates the expression of pancreatic beta -cell genes implicated in glucose metabolism and 
nutrient-induced insulin secretion. J Biol Chem. 2000;275(46):35953-9. 
244. Charos AE, Reed BD, Raha D, Szekely AM, Weissman SM, Snyder M. A highly integrated and 
complex PPARGC1A transcription factor binding network in HepG2 cells. Genome Res. 
2012;22(9):1668-79. 
245. Schmidt SF, Mandrup S. Gene program-specific regulation of PGC-1{alpha} activity. Genes & 
Development. 2011;25(14):1453-8. 
246. Lopes PC, Fuhrmann A, Carvalho F, Sereno J, Santos MR, Pereira MJ, et al. Cyclosporine A 
enhances gluconeogenesis while sirolimus impairs insulin signaling in peripheral tissues after 3 weeks 
of treatment. Biochem Pharmacol. 2014;91(1):61-73. 
247. Barlow AD, Nicholson ML, Herbert TP. Evidence for rapamycin toxicity in pancreatic beta-
cells and a review of the underlying molecular mechanisms. Diabetes. 2013;62(8):2674-82. 
248. Gyurus E, Kaposztas Z, Kahan BD. Sirolimus therapy predisposes to new-onset diabetes 
mellitus after renal transplantation: a long-term analysis of various treatment regimens. Transplant 
Proc. 2011;43(5):1583-92. 
249. Veroux M, Tallarita T, Corona D, Sinagra N, Giaquinta A, Zerbo D, et al. Conversion to 
sirolimus therapy in kidney transplant recipients with new onset diabetes mellitus after 
transplantation. Clin Dev Immunol. 2013;2013:496974. 
250. Guerra G, Ciancio G, Gaynor JJ, Zarak A, Brown R, Hanson L, et al. Randomized trial of 
immunosuppressive regimens in renal transplantation. J Am Soc Nephrol. 2011;22(9):1758-68. 
251. Claes K, Meier-Kriesche HU, Schold JD, Vanrenterghem Y, Halloran PF, Ekberg H. Effect of 
different immunosuppressive regimens on the evolution of distinct metabolic parameters: evidence 
from the Symphony study. Nephrol Dial Transplant. 2012;27(2):850-7. 
252. Knoll GA, Kokolo MB, Mallick R, Beck A, Buenaventura CD, Ducharme R, et al. Effect of 
sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-
analysis of individual patient data. BMJ. 2014;349:g6679. 
253. Lieberman MD, Cunningham WA. Type I and Type II error concerns in fMRI research: re-
balancing the scale. Soc Cogn Affect Neurosci. 2009;4(4):423-8. 
254. Meigs JB, Shrader P, Sullivan LM, McAteer JB, Fox CS, Dupuis J, et al. Genotype score in 
addition to common risk factors for prediction of type 2 diabetes. N Engl J Med. 2008;359(21):2208-
19. 
255. Talmud PJ, Hingorani AD, Cooper JA, Marmot MG, Brunner EJ, Kumari M, et al. Utility of 
genetic and non-genetic risk factors in prediction of type 2 diabetes: Whitehall II prospective cohort 
study. BMJ. 2010;340:b4838. 
256. Piepenhagen PA, Peters LL, Lux SE, Nelson WJ. Differential expression of Na(+)-K(+)-ATPase, 
ankyrin, fodrin, and E-cadherin along the kidney nephron. Am J Physiol. 1995;269(6 Pt 1):C1417-32. 
257. Lee SY, Han SM, Kim JE, Chung KY, Han KH. Expression of E-cadherin in pig kidney. J Vet Sci. 
2013;14(4):381-6. 
258. Prozialeck WC, Lamar PC, Appelt DM. Differential expression of E-cadherin, N-cadherin and 
beta-catenin in proximal and distal segments of the rat nephron. BMC Physiol. 2004;4:10. 
259. Kruger T, Benke D, Eitner F, Lang A, Wirtz M, Hamilton-Williams EE, et al. Identification and 
functional characterization of dendritic cells in the healthy murine kidney and in experimental 
glomerulonephritis. J Am Soc Nephrol. 2004;15(3):613-21. 
260. LaSpina M, Tripathi S, Gatto LA, Bruch D, Maier KG, Kittur DS. An interleukin-6-neutralizing 
antibody prevents cyclosporine-induced nephrotoxicity in mice. J Surg Res. 2008;148(2):121-5. 
261. Nagle RB, Bulger RE. Unilateral obstructive nephropathy in the rabbit. II. Late morphologic 
changes. Lab Invest. 1978;38(3):270-8. 
185 | P a g e  
 
262. Chevalier RL, Forbes MS, Thornhill BA. Ureteral obstruction as a model of renal interstitial 
fibrosis and obstructive nephropathy. Kidney Int. 2009;75(11):1145-52. 
263. Nagle RB, Bulger RE, Cutler RE, Jervis HR, Benditt EP. Unilateral obstructive nephropathy in 
the rabbit. I. Early morphologic, physiologic, and histochemical changes. Lab Invest. 1973;28(4):456-
67. 
264. Smith SW, Chand S, Savage CO. Biology of the renal pericyte. Nephrol Dial Transplant. 
2012;27(6):2149-55. 
265. Maciel TT, Coutinho EL, Soares D, Achar E, Schor N, Bellini MH. Endostatin, an antiangiogenic 
protein, is expressed in the unilateral ureteral obstruction mice model. J Nephrol. 2008;21(5):753-60. 
266. Duffield JS. Cellular and molecular mechanisms in kidney fibrosis. J Clin Invest. 
2014;124(6):2299-306. 
267. Anders HJ, Schaefer L. Beyond tissue injury-damage-associated molecular patterns, toll-like 
receptors, and inflammasomes also drive regeneration and fibrosis. J Am Soc Nephrol. 
2014;25(7):1387-400. 
268. Lech M, Anders HJ. Macrophages and fibrosis: How resident and infiltrating mononuclear 
phagocytes orchestrate all phases of tissue injury and repair. Biochim Biophys Acta. 
2013;1832(7):989-97. 
269. Fligny C, Duffield JS. Activation of pericytes: recent insights into kidney fibrosis and 
microvascular rarefaction. Curr Opin Rheumatol. 2013;25(1):78-86. 
270. Braga TT, Agudelo JS, Camara NO. Macrophages During the Fibrotic Process: M2 as Friend 
and Foe. Front Immunol. 2015;6:602. 
271. Li J, Scherl A, Medina F, Frank PG, Kitsis RN, Tanowitz HB, et al. Impaired phagocytosis in 
caveolin-1 deficient macrophages. Cell Cycle. 2005;4(11):1599-607. 
272. Shivshankar P, Halade GV, Calhoun C, Escobar GP, Mehr AJ, Jimenez F, et al. Caveolin-1 
deletion exacerbates cardiac interstitial fibrosis by promoting M2 macrophage activation in mice 
after myocardial infarction. J Mol Cell Cardiol. 2014;76:84-93. 
273. Freedman ML, Monteiro AN, Gayther SA, Coetzee GA, Risch A, Plass C, et al. Principles for the 
post-GWAS functional characterization of cancer risk loci. Nat Genet. 2011;43(6):513-8. 
274. Kogo H, Fujimoto T. Caveolin-1 isoforms are encoded by distinct mRNAs. Identification Of 
mouse caveolin-1 mRNA variants caused by alternative transcription initiation and splicing. FEBS Lett. 
2000;465(2-3):119-23. 
275. O'Connell PJ, Zhang W, Menon MC, Yi Z, Schroppel B, Gallon L, et al. Biopsy transcriptome 
expression profiling to identify kidney transplants at risk of chronic injury: a multicentre, prospective 
study. Lancet. 2016. 
 
 
 
 
 
 
 
186 | P a g e  
 
APPENDIX I: Primary papers published from the completion of this 
MD 
 
Analysis of single nucleotide polymorphisms implicate mTOR signalling in the development 
of new-onset diabetes after transplantation. Chand S, McKnight AJ, Shabir S, Chan W, 
McCaughan J, Maxwell AP, Borrows R. BBA Clinical. 2016 Jun; 5(2):41-45 
 
Caveolin-1 single nucleotide polymorphism and arterial stiffness in non-dialysis chronic 
kidney disease. Chand S, Edwards N, Chue C, Jesky M, Stringer S, Simmonds MJ, Duffy CE, 
Cockwell P, Harper L, Steeds RP, Townend JN, Ferro CJ, Borrows R. Nephrol Dial Transplant. 
2015 Oct 3 
 
eNOS Glu298Asp gene variation and left ventricular function in early chronic kidney disease. 
Chand S, Chue CD, Edwards NC, Simmonds MJ, Hamilton A, Gough SCL, Steeds RP, Townend 
JN, Ferro CJ, Borrows R. PLoS One. 2015 Jan 22;10(1):e0116160 
 
Genetic polymorphisms and kidney transplant outcomes. Chand S, McKnight AJ, Borrows R. 
Curr Opin Nephrol Hypertens. 2014 Nov;23(6):605-10 
 
Caveolin-1 single nucleotide polymorphism in antineutrophil cytoplasmic antibody 
associated vasculitis. Chand S, Holle J, Hilhorst M, Simmonds M, Smith S, Kamesh L, Hewins 
P, McKnight AJ, Maxwell AP, Cohen Tervaert JW, Wieczorek S, Harper L, Borrows R. PLoS 
One. 2013 Jul;8(7):e69022 
